International Society for Heart and Lung Transplantation

BOARD OF DIRECTORS

President
Robert C. Robbins, MD, Stanford, CA

Past President
Mark L. Barr, MD, Los Angeles, CA

President-Elect
Paul A. Corris, MB, FRCP, Newcastle, UK

Secretary-Treasurer
Mandeep R. Mehra, MD, Baltimore, MD

DIRECTORS
Nicholas R. Banner, FRCP, Harefield, UK
Fabienne Dobbels, PhD, Leuven, Belgium
Mariell Jessup, MD, Philadelphia, PA
Ronald H. Kerman, PhD, Houston TX
Shaf Keshavjee, MD, FRCSC, FACS, Toronto, Canada
Walter Klepetko, MD, Vienna, Austria
Stephen R. Large, FRCS, Cambridge, UK
Joren C. Madsen, MD, Dphil, Boston, MA
Bruno M. Meiser, MD, Munich, Germany
Randall C. Starling, MD, MPH, Cleveland, OH
Steven A. Webber, MB ChB, Pittsburgh PA

EX OFFICIO BOARD MEMBERS

JHLT Editor
James K. Kirklin, MD, Birmingham AL

Transplant Registry Medical Director
Marshall I. Hertz, MD, Minneapolis, MN

Scientific Program Chair
Duane Davis, MD, Durham, NC

Development Committee Co-Chair
Leslie W. Miller, MD, Washington, DC

Staff
Amanda W. Rowe
Executive Director

Phyllis Glenn
Assistant Executive Director
Director of Membership Services

Lisa A. Edwards
Director of Meetings

Lee Ann Mills
Director of Operations

14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org
ishlt@ishlt.org
Note: A name preceded by an asterisk indicates that the individual has indicated a relationship which, in the context of this CME activity, could be perceived as a potential conflict of interest. Please refer to the disclosure information provided in this booklet for additional information about specific individuals’ disclosure information.

SCIENTIFIC PROGRAM COMMITTEE

*Duane Davis, MD, Durham, NC, Program Chair
Robert C. Robbins, MD, Stanford, CA, President
*Barbara D. Alexander, MD, Durham, NC
Carla C. Baan, PhD, Rotterdam, The Netherlands
Nancy P. Blumenthal, MSN, CRNP, Ardmore, PA
*Paul A. Corris, MB, FRCP, Newcastle Upon Tyne, United Kingdom
John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom
Thomas J. Dengler, MD, Heidelberg, Germany
*Fabienne Dobbels, MSc, PhD, Leuven, Belgium
*Thomas M. Egan, MD, Chapel Hill, NC
Michael C. Fishbein, MD, Los Angeles, CA
Joshua M. Hare, MD, Miami, FL
Axel Haverich, MD, Hannover, Germany
Michael J. Jurmann, MD, Berlin, Germany
*Shaf Keshavjee, MD, Toronto, ON, Canada
James K. Kirklin, MD, Birmingham, AL
Joren C. Madsen, MD, D.Phil., Boston, MA
*Cynthia M. Magro, MD, New York, NY
*Mandeep R. Mehra, MD, Baltimore, MD
*Bryan F. Meyers, MD, St. Louis, MO
*Carmelo A. Milano, MD, Durham, NC
Michael S. Mulligan, MD, Seattle, WA
*Scott M. Palmer, MD, Durham, NC
Jean B. Rea, RN, MS, CCTC, Durham, NC
*Joseph G. Rogers, MD, Durham, NC
*Bruce R. Rosengard, MD, FRCS, FACS, Boston, MA
*Stuart D. Russell, MD, Baltimore, MD
*Gregory I. Snell, FRACP, MBBS, Prahran, VIC, Australia
*Stuart C. Sweet, MD, PhD, St. Louis, MO
Jeffrey A. Towbin, MD, Houston, TX
Thomas K. Waddell, MD, PhD, Toronto, ON, Canada
*Lori J. West, MD, D.Phil, Edmonton, AB, Canada
*Martin R. Zamora, MD, Denver, CO
*Andreas O. Zuckermann, MD, Vienna, Austria

ABSTRACT REVIEWERS

Vivek N. Ahya, MD, Philadelphia, PA
James S. Allan, MD, Marblehead, MA
Abbas Ardehali, MD, Los Angeles, CA
*Nicholas R. Banner, FRCP, Harefield, Middlesex, United Kingdom
*Maher A. Baz, MD, Gainesville, FL
Christian Benden, MD, Zurich, Switzerland
*Gerald J. Berry, MD, Stanford, CA,
*Sanjeeta M. Bhorade, MD, Chicago, IL
*Emily A. Blumberg, MD, Philadelphia, PA
*Annette Boehler, MD, Zurich, Switzerland
*Steven F. Bolling, MD, Ann Arbor, MI
*Susan C. Brozena, MD, North Wales, PA
*Michael Burch, MD, London, United Kingdom
Margaret Burke, FRCPath, Harefield, Middlesex, United Kingdom
*Marcelo Cantarovich, MD, Montreal, PQ, Canada
*Charles E. Canter, MD, St. Louis, MO
*Leway Chen, MD, MPH, Rochester, NY
Susan M. Chernenko, MN, Toronto, ON, Canada
Cliff K. C. Chooong, FRACS, Cambridge, United Kingdom
John V. Conte, MD, Baltimore, MD
Andrea M. D’Armini, MD, Pavia, Italy
Hiroshi Date, MD, Okayama, Japan
*Nicolaas De Jonge, MD, Utrecht, The Netherlands
DEVELOPMENT COMMITTEE
Mandeep R. Mehra, MD, Co-Chair
Leslie W. Miller, MD, Co-Chair
Mark L. Barr, MD
Paul A. Corris, MB, FRCP
Robert C. Robbins, MD

EDUCATION COMMITTEE
Mandeep R. Mehra, MD, Chair
Mark L. Barr, MD
John Dark, MD, FRCS
Duane Davis, MD
Robert C. Robbins, MD
Lori J. West, MD, D.Phil

FINANCE COMMITTEE
Mandeep R. Mehra, MD, Treasurer and Chair
Mark L. Barr, MD
Robert Robbins, MD
James K. Kirklin, MD
Leslie W. Miller, MD

GRANTS AND AWARDS COMMITTEE
Mark L. Barr, MD, Chair
John Dark, MB, FRCS, Co-Chair
Susan Stewart, FRCPath, Co-Chair

HISTORY AND ARCHIVES COMMITTEE
Hector Ventura, MD, Co-Chair
Stephan Schueler, MD, Co-Chair
Mandeep Mehra, MD, Board Liaison

NOMINATING COMMITTEE
Mark L. Barr, MD, Chair
Jon Kobashigawa, MD
Alec Patterson, MD
Robert C. Robbins, MD
Stephan Schueler, MD

REGISTRY EXECUTIVE COMMITTEE
Marshall I. Hertz, MD, Medical Director
Mark M. Boucek, MD, Associate Director for Pediatric Heart Transplantation
Paul Aurora, MD, Associate Director for Pediatric Lung Transplantation
Leah B. Edwards, PhD, Associate Director for Data Analysis
Berkeley M. Keck, RN, MPH, Associate Director for Database Management
David O. Taylor, MD, Associate Director for Heart Transplantation
Elbert P. Trulock, MD, Associate Director for Lung Transplantation
Jason Christie, MD, Associate Co-Director for Lung Transplantation
Fabienne Dobbels, PhD, Associate Director for Outcomes Analysis

SCIENTIFIC COUNCIL CHAIRS
Cell Transplantation/Tissue Engineering
Joshua M. Hare, Chair
Robert C. Robbins, MD, Board Liaison
Heart Failure, Transplant Medicine and Mechanical Support
Maria Rosa Costanzo, MD, Co-Chair
Edoardo Gronda, MD, Co-Chair
Mariell Jessup, MD, Board Liaison

Infectious Diseases
F. Kate Gould, MBBS, Chair
Mariell Jessup, MD, Board Liaison

Nursing and Social Sciences
Jane MacIver, RN, MSN, Co-Chair
Catherine M. Murks, RN, MS, CS, ANP, Co-Chair
Fabienne Dobbels, MSc, PhD, Board Liaison

Pathology and Basic Science
Susan Stewart, FRCPath, Co-Chair
James George, PhD, Co-Chair
Ronald H. Kerman, PhD, Board Liaison

Pediatric Transplantation
Michael Burch, MD, Co-Chair
Maryanne Chrisant, MD, Co-Chair
Francesco Parisi, MD, Co-Chair
Stuart Sweet, MD, PhD, Co-Chair
Lori West, MD, DPhil, Co-Chair
Steven Webber, MB, ChB, Board Liaison

Pulmonary Arterial Hypertension
Raymond Benza, MD, Co-Chair
Reda Girgis, MB BCh, Co-Chair
John Scott, MD, Co-Chair
Paul Corris, MB, FRCP, Board Liaison

Pulmonary Transplantation
Allan Glanville, MD, FRACP, Co-Chair
Marc Estenne, MD, Co-Chair
Paul Corris, MB, FRCP, Board Liaison
ISHLT PAST PRESIDENTS

1981-1982 Michael Hess, MD
1982-1984 Jack Copeland, MD
1984-1986 Terence English, FRCS
1986-1988 Stuart Jamieson, MD
1988-1990 Bruno Reichart, MD
1990-1991 Margaret Billingham, MD
1991-1992 Christian Cabrol, MD
1992-1993 John O’Connell, MD
1993-1994 Eric Rose, MD
1994-1995 John Wallwork, FRCS
1995-1996 Sharon Hunt, MD
1996-1997 William Baumgartner, MD
1997-1998 Leslie Miller, MD
1998-1999 Alan Menkis, MD, FRCS(C)
1999-2000 Robert L. Kormos, MD
2000-2001 Anne Keogh, MBBS, MD
2001-2002 James B. Young, MD
2002-2003 Stephan Schuler, MD
2003-2004 Jon Kobashigawa, MD
2004-2005 Alec Patterson, MD
2005-2006 Mark L. Barr, MD
PAST PROGRAM CHAIRS

1988 Los Angeles, CA
John C. Baldwin, MD

1989 Munich, Germany
Bruno Reichart, MD
D. Glenn Pennington, MD

1990 San Diego, CA
D. Glenn Pennington, MD

1991 Paris, France
John B. O’Connell, MD

1992 San Diego, CA
Eric A. Rose, MD

1993 Boca Raton, FL
Maria Rosa Costanzo, MD

1994 Venice, Italy
John Wallwork, MBChB, FRCS

1995 San Francisco, CA
Leslie W. Miller, MD

1996 New York, NY
William A. Baumgartner, MD

1997 London, England
Stephan Schueler, MD

1998 Chicago, IL
James B. Young, MD

1999 San Francisco, CA
Mark L. Barr, MD

2000 Osaka, Japan
Jon Kobashigawa, MD

2001 Vancouver, Canada
David O. Taylor, MD

2002 Washington, DC
Robert C. Robbins, MD

2003 Vienna, Austria
Bruce R. Rosengard, MD

2004 San Francisco, CA
Mandeep Mehra, MD

2005 Philadelphia, PA
Shaf Keshavjee, MD

2006 Madrid, Spain
John Dark, MB, FRCS
ISHLT AWARD RECIPIENTS

Lifetime Achievement Award

2004  Sir Magdi Yacoub, MD  
1999  Keith Reemtsma, MD  
1996  Norman Shumway, MD  

Lifetime Service Award

1997  Jacques Losman  
1996  Michael Kaye  

ISHLT/Astellas Transplant Career Development Award

2006  Dennis A. Wigle, MD, PhD  

ISHLT/Roche Transplant Career Development Award

2000  Gordon D. Wu, MD  

ISHLT Transplant Career Development Award

2002  Anthony Azakie, MD  

ISHLT/Novartis Transplant Career Development Award

2004  Allan M. Ramirez, MD  

ISHLT/Roche Transplant Research Fellowship Grant

2006  Rachel L. Anderson, MBBS  
2005  Ahmad Saad, MD  
2004  Kendra N. Taylor, PhD  
2003  Felix Fernandez, MD  
2002  Ruediger Hoebelt, MD  
2001  Matteo Vatta, PhD  
2001  Arnar Geirsson, MD  
2000  Christopher H. Wigfield, FRCS  
1999  Donald Wong, PhD  
       Sivasai Krovvidi, PhD  
1998  Kelly S.A. Blair, MD  
       A.M. El Gamel, MD  
1997  Jonathen Chen, MD  
       Anne K. Raisanen-Sokolowski, MD  
1996  Tuija S. Ikonen, MD  

ISHLT/Novartis Transplant Research Fellowship Grant

2006  Matthew J. Weiss, MD  
2000  Richard S. Lee, MD  
1999  George Juang, MD  
1999  Satoshi Saito, MD  
1998  Margaret L. Schwarze, MD  

ISHLT/Astellas (Fujisawa) Transplant Research Fellowship Grant

2005  Arne Neyrinck, MD  
2004  Christian A. Gleissner, MD  
2003  Ewout J. van den Bos, MD  
1997  Alyssa M. Krasinskas, MD  

ISHLT/Actelion Transplant Research Fellowship Grant

2004  Tsuyoshi Shoji, MD, PhD  

ISHLT/XDx Transplant Research Fellowship Grant

2006  Edward N. Seung, PhD
2004  Monica Zwierzchonieuska, MD

ISHLT/Encysive Transplant Research Fellowship Grant

2006  Heather E. Merry, MD

ISHLT/Transmedics Transplant Research Fellowship Grant

2006  Zhaohui Li, PhD

ISHLT/Chiron Transplant Research Fellowship Grant

2005  Ryan C. Fields, MD

ISHLT/Wyeth-Ayerst Transplant Research Fellowship Grant

1998  Christine L. Lau, MD

ISHLT/Ortho Biotech Transplant Research Fellowship Grant

1997  Owen T. Lawrence, MD
1996  Andrew F. Pierre, MD
1995  Frances L. Johnson, MD

ISHLT Transplant Research Fellowship Grant

1998  Scott D. Ross, MD

ISHLT Nursing Research Grant

2006  Thierry Troosters, PhD
2005  Annemarie F. Kaan, MCN
2004  Deidre E. Logan, PhD
2003  Diane H. Leloudis, RN, MSN
2003  Janet E. Madill, PhD
2002  Annette J. De Vito Dabbs, RN, MN, PhD
2001  Lynn Doering, RN, DNSc
2000  Nancy M. Albert, MSN, RN
1999  Jeanne Salyer, PhD
1998  Katherine St. Clair, RN, MSN
1997  Eileen Collins, RN, PhD

Caves Award

2006  Gregor Warnecke, MD
2005  Sigrid Sandner, MD
2005  Frank D'Ovidio, MD
2004  M.D. Peterson, MD
2003  Sigrid Sandner, MD
2002  Peter Blaha, MD
2001  Alexander S. Krupnick, MD
2000  Michael P. Fischbein, MD
1999  Joerg Koglin, MD
1998  Carla C. Baan, MD
1997  Simon D. Eiref, MD
1996  Moninder S. Bhabra, MD
1995  Elizabeth A. Davis, MD
1994  Jobst Winter, MD
1994  Alain Chapelier, MD
1993    David Marshman, MD
1992    David P. Kapelanski, MD
1991    A. Jiminez, MD
1990    Andres J. Duncan, MD
1989    A.M. Wood, MD
1988    Charles D. Fraser, Jr., MD
1987    Wim Van Der Bij, MD
1986    Stuart J. Knechtle, MD
1985    Michael A. Breda, MD
1984    Hermann Reichenspurner, MD
1983    Robbin G. Cohen, MD

Nursing Excellence Research Award

2006    Kathleen L. Grady, PhD, RN
2005    Mary Amanda Dew, PhD
About ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2300 members from over 45 countries, representing over 10 different disciplines involved in the management and treatment of end-stage heart and lung disease.

This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, and transplant coordinators. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The mission of the Society is:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
5. To establish and maintain an international registry for heart and lung transplantation.
6. To award research grants and establish endowments for the study of these disciplines.

About San Francisco

ISHLT is returning to San Francisco for our 4th time in 12 years. Why? Because San Francisco is a great city that our members love to visit – our meeting attendance is consistently the highest when we meet in San Francisco. San Francisco in April has so much to offer: some of the best weather of the year, miles of shoreline that bustles with activity, cable cars, world-famous international cuisine, unparalleled shopping, world-class museums, acres of parkland and recreation areas, to name just a few. San Francisco is so familiar to so many, but here are a few tidbits you may not have already known:

- You can walk the entire 7 mile shoreline from the Golden Gate Bridge to the San Francisco-Oakland Bay Bridge, along beautiful promenades and pathways.
- Historic trolleys from all over the world travel along the tracks from the Ferry Building to Fisherman’s Wharf.
- San Francisco’s famous Piers are numbered, beginning at the Ferry Building. The even numbers are to the East, the odd numbers are to the West, and some piers no longer exist.
- In the winter months, as many as 900 wild sea lions live at Pier 39.
- The following were invented in San Francisco: the martini, chop suey, the fortune cookie, the mai tai, cioppino, Crab Louis, and Irish coffee.
- The water temperature of San Francisco Bay is around 48 degrees Fahrenheit.
- At the Hyde Street Pier, you can see vessels that sailed the bay 600 years ago.
- The giant coastal redwoods in the Muir Woods National Monument can reach a height of 250 feet.
- Sonoma and Napa counties are home to over 300 wineries that produce nearly 2 billion bottles of wine each year.
- The steepest street in San Francisco is Filbert, at 31.5 degrees in parts.
- San Francisco’s cable cars travel at a speed of 9 miles per hour.
- The Palace of the Legion of Honor holds one of the world’s most significant collections of Rodin sculpture.
- There are 14,000 Victorian homes in San Francisco.
- Alcatraz means Pelican in Spanish.
- San Francisco is approximately 7 miles long and 7 miles wide.
- Denim jeans were invented in San Francisco for the Gold Rush miners who needed tough, comfortable clothing.
- The statue in the middle of Washington Square Park is of Ben Franklin, not George Washington.

New for 2007

This year, the meeting schedule has been revised to better conform with the attendance practices of our delegates. We hope that you will find the schedule changes to be advantageous and we are interested in your feedback.
The most important schedule changes apply to the first and last days of the meeting, Wednesday and Saturday. On Wednesday, we have moved the meeting up to begin at 8 am. We will conduct 11 satellite symposia from 8 am – Noon, followed by a luncheon symposium from 12:30-2:00 pm. The Opening Plenary Session will begin at 2:30 pm, followed by concurrent sessions.

On Saturday, we will end the meeting at Noon to enable you to enjoy the many advantages of free time in San Francisco. Saturday morning will open with concurrent sessions at 8:00 am and will close with a thought-provoking and entertaining Plenary Session at 9:45 am.

Also new this year is the expansion of the meeting from 4 concurrent sessions to 6 concurrent sessions. We are fortunate to be using a facility with the flexibility to expand our meeting, and the number of excellent abstract submissions prompted the Program Committee to take advantage of this. With six concurrent sessions, we have been able to accept all of the abstracts that were considered worthy of oral presentation, and we were also able to incorporate several invited lectures into the abstract sessions. We hope that you find this expanded format to be valuable, and we would appreciate your feedback.

Back on the program again this year are the Sunrise Symposia. These early morning sessions are designed to provide a more in-depth review of a focused topic. There are eight symposia total, scheduled four each day on Thursday and Friday from 7 am – 8 am.

Topics include:
- Immunobiology for Clinicians: Basic Biology
- State of the Art Management Options for Bronchiolitis Obiterans
- Fungal Disease: Shifting Trends/New Treatments
- Management Issues with Continuous Flow Devices
- Immunobiology for Clinicians: Principles of Therapy
- Novel Insights in Mechanisms of Bronchiolitis Obliterans
- From Observation to Research in Nursing and Social Sciences: Acting on Your Ideas
- When Palliation Fails: Transplantation for the Adult with Congenital Heart Disease

HIGHLIGHTS OF THE SCIENTIFIC PROGRAM

While this year’s program offers a greater breadth and depth of information related to thoracic transplantation than previously possible, it also spotlights the role that the newest technologic advances will have in medicine and transplantation.

Wednesday morning’s satellite symposia cover a broad range of topics. These include sessions exploring the latest advances and the future directions in circulatory support, advances in our understanding and treatment of pulmonary hypertension, the role of cellular immune therapy in transplantation, the interactions between innate immunity and the adaptive immune response, and strategies to minimize nephrotoxicity in transplant recipients.

Additional areas of major focus in this meeting are the changes in organ allocation, particularly the rationale, the implications and the future directions of heart and lung allocation, and the role of antibody mediated organ injury. Advances in our understanding of immunobiology, diagnostic testing, and current and future treatment strategies will be highlighted.

This year we have re-introduced the sunrise symposia highlighted by sessions covering basic immunobiology and immune therapies for the clinician, enabling clinical research, advances in the understanding and treatment of BOS, new and improved diagnosis and treatment of fungal infections, and the state of the art using continuous flow devices.

We will have the opportunity to revisit the origins or our society and profession through the insights of Donald McRae, author of *Every Second Counts: The Race to Perform the First Human Heart Transplant*, and to explore the future of our society in Robert Robbins’s presidential address.

One of the most exciting components of this year’s meeting will be a series of lectures covering the hottest areas of scientific advances and their application in medicine and transplantation. These include the roles that nanotechnology, genomics and proteomics, RNA interference and cell therapy will play in the future management of our patients. We look forward to your attendance and active participation in this year’s meeting.

PHILLIP K. CAVES AWARD SESSION

The 8 finalists for the Philip K. Caves Award will present their original research work in a dedicated session. This prestigious Award is named for the pioneer of the technique of transvenous endomyocardial biopsy. The $1000 prize is awarded to the best presentation by a resident/fellow/student who is first author of the abstract. Come and support the best and brightest residents, fellows and graduate students – the future of our society - as they present their research findings and are judged for the winner of this prestigious award.

PRESIDENT’S GALA RECEPTION

The President’s Gala Reception will be held Wednesday, April 25, from 8:00 pm – 10:00 pm at San Francisco’s beautiful and ornate City Hall, which is just a few blocks from the Hilton. The talented Marginal Donors, starring our own Heather Ross, MD, will be performing for the crowd. Please be sure to join us for this wonderful event on the opening day of the meeting.

One ticket to the Gala Reception is included with each paid registration. Additional tickets may be purchased for $75 each.
CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 32.25 hours in Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Continuing Education Point/Contact Hours have been applied for with the American Board of Transplant Coordinators (ABTC) and Critical Care Nurses (AACN).

Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker’s presentation. Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair. These disclosures will be printed in the Final Program and made available at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

Goals

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease: and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives

At the conclusion of this meeting, participants should be able to:
1. evaluate different approaches to and ethical issues surrounding organ allocation
2. identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
3. compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
4. understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
5. compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
6. describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
7. understand current animal models of basic science immunology and their application to the transplant setting
8. evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
9. understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
10. identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
11. evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies: and compare the value of these therapies as alternatives and/or bridges to transplantation
12. evaluate and implement the use of alternative methods of monitoring and treating rejection
13. identify, prevent, and treat donor-transmitted diseases
14. understand how psychosocial and behavioral issues impact clinical post-transplant outcomes
Disclosure

Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker’s presentation or a chair or program planner’s involvement in the activity.

Every speaker, chair, and program committee member has been required to complete a disclosure statement. The names of the individuals that have indicated a relationship which, in the context of their presentation(s) or involvement in the program, could be perceived as a potential conflict of interest (e.g. ownership of stock, significant honoraria/consulting fees, or direct research support from a commercial organization, etc.) are indicated in the program with an asterisk and are listed below. The program committee has taken steps to ensure that any potential conflicts of interest have been resolve to their satisfaction. Individuals whose names are not marked with an asterisk and who are not listed below have indicated to ISHLT that they have no relationships to disclosure. Additionally, all speakers and chairs have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

<table>
<thead>
<tr>
<th>Name</th>
<th>Presentations/Sessions</th>
<th>Company Affiliation(s)</th>
<th>Nature of Affiliation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbara Alexander</td>
<td>Roche Symposium, Concurrent 11, Prog Comm</td>
<td>Roche Enzon Pfizer Schering Plough</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Grant/Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consultant/Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speakers Bureau/Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advisory Board/Consultant</td>
</tr>
<tr>
<td>Selim Arcasoy</td>
<td>Sunrise 2</td>
<td>Astellas</td>
<td>Research Grant (significant)</td>
</tr>
<tr>
<td>Nicholas Banner</td>
<td>XDx Lunch, #37, Abstract Review</td>
<td>Roche</td>
<td>Speaker/Investigator (modest)</td>
</tr>
<tr>
<td>David Baran</td>
<td>Sunrise 5</td>
<td>Astellas</td>
<td>Honorarium (modest)</td>
</tr>
<tr>
<td>Maher Baz</td>
<td>Abstract Reviewer</td>
<td>Astellas</td>
<td>Investigator</td>
</tr>
<tr>
<td>Raymond Benza</td>
<td>Satellite 8</td>
<td>Actelion Pfizer United Therapeutics Lung Rx Myogen</td>
<td>Speaker/Grants (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker/Grants (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker/Grants (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker/Grants (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker/Grants (modest)</td>
</tr>
<tr>
<td>Gerald Berry</td>
<td>Concurrent 22, Abs Review</td>
<td>XDx</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Sangeeta Bhorade</td>
<td>Abstract Reviewer</td>
<td>Astellas</td>
<td>Grant Research Support</td>
</tr>
<tr>
<td>Emily Blumberg</td>
<td>Abstract Reviewer</td>
<td>Roche</td>
<td>Consultant/Speakers Bureau</td>
</tr>
<tr>
<td>Annette Boehler</td>
<td>Sunrise 6, Abstract Review, Mini Oral 1</td>
<td>Roche Novartis</td>
<td>Research Support (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support (modest)</td>
</tr>
<tr>
<td>Stephen Bolling</td>
<td>Abstract Reviewer</td>
<td>Edwards Orgis</td>
<td></td>
</tr>
<tr>
<td>Robert Boucek</td>
<td># 509</td>
<td>Astellas</td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td>Susan Brozena</td>
<td>Abstract Reviewer</td>
<td>GSK Medtronic Wyeth</td>
<td>Advisory Board/Speaker</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td>Michael Burch</td>
<td>#176, Concurrent 18, Satellite 3, Abstract Review</td>
<td>Roche Astellas</td>
<td>Travel Grant (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support (modest)</td>
</tr>
<tr>
<td>Martin Cadeiras</td>
<td># 215</td>
<td>XDx</td>
<td>Research Support (significant)</td>
</tr>
<tr>
<td>Marcelo Cantarovich</td>
<td>Abstract Reviewer</td>
<td>Novartis Roche Astellas</td>
<td>Travel Grant (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advisory Board/Honorarium (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Honorarium (modest)</td>
</tr>
<tr>
<td>Charles Canter</td>
<td>Satellite 3, Abstract Review</td>
<td>Blue Cross Blue Shield</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Hunter Champion</td>
<td>Satellite 2</td>
<td>Pfizer Encysive Cotherix</td>
<td>Speaker (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker (modest)</td>
</tr>
<tr>
<td>Leway Chen</td>
<td>Concurrent 36, Abstract Review</td>
<td>Johnson&amp;Johnson Ariomed Inc Thoratec</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speakers Bureau (modest)</td>
</tr>
<tr>
<td>Kenneth Chien</td>
<td>Opening Plenary</td>
<td>Cytori Progenetor</td>
<td>Consultant/Advisor (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Founder (modest)</td>
</tr>
<tr>
<td>Name</td>
<td>Concurrent/Abstract</td>
<td>Organization/Role</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Paul Corris</td>
<td>Concurrent 13, #524, 530, Program Committee, Closing Plenary, Satellite 8</td>
<td>Encysive Speaker/Scientific Advisor (modest) Actelion Speaker/Advisory Board GSK Research Support Pfizer Speaker/Advisory Board</td>
<td></td>
</tr>
<tr>
<td>Duane Davis</td>
<td>Program Committee, Opening Plenary, Satellite 5</td>
<td>XDX Grant Support (significant) St Jude Grant Support/ Speaker (modest) INO Consultant (modest) DOMPE Grant Support (significant) Roche Grant Support (significant)</td>
<td></td>
</tr>
<tr>
<td>Sabine DeGeest</td>
<td>Abstract Reviewer</td>
<td>BMS Consultant Novartis Consultant Sanofi-Aventis Consultant</td>
<td></td>
</tr>
<tr>
<td>Nicholas De Jonge</td>
<td>Concurrent 36, # 478, Abstract Reviewer</td>
<td>Novartis Advisory Board (modest)</td>
<td></td>
</tr>
<tr>
<td>Mario Deng</td>
<td># 58, Abstract Reviewer</td>
<td>XDx Research Support (significant)</td>
<td></td>
</tr>
<tr>
<td>Mary Amanda Dew</td>
<td># 368, Sunrise 7</td>
<td>Astellas Research Support (modest)</td>
<td></td>
</tr>
<tr>
<td>Anne Dipchand</td>
<td>Satellite 3, #512, 567</td>
<td>Novartis Research Support (modest) Astellas Research Support (modest) Roche Research Support (modest)</td>
<td></td>
</tr>
<tr>
<td>Fabienne Dobbels</td>
<td>Satellite 6, Program Committee</td>
<td>BMS Research Support/Speaker (modest) Novartis Speaker (modest)</td>
<td></td>
</tr>
<tr>
<td>Robert Dowling</td>
<td>Satellite 1</td>
<td>Abiomed Honorarium (modest)</td>
<td></td>
</tr>
<tr>
<td>Stephen Dummer</td>
<td>Abstract Reviewer</td>
<td>Pfizer Honorarium (modest)</td>
<td></td>
</tr>
<tr>
<td>Tom Egan</td>
<td>Program Committee</td>
<td>Medtronic Research Support Ethicon Research Support Terumo Research Support Cryolife Research Support Vitrolife Research Support</td>
<td></td>
</tr>
<tr>
<td>Howard Eisen</td>
<td>Satellite 12, # 46, Abstract Reviewer</td>
<td>Novartis Grants/Research/Consultant/Advisor (significant) Wyeth Grants/Research/Consultant/Advisor (modest) XDx Consultant/Advisor (modest)</td>
<td></td>
</tr>
<tr>
<td>Donald Esmore</td>
<td># 121, Abstract Reviewer</td>
<td>Ventracor Consultant (significant)</td>
<td></td>
</tr>
<tr>
<td>Gregory Ewald</td>
<td>Abstract Reviewer</td>
<td>Boston Scientific Consultant/Advisory Board GSK Speakers Bureau Scios Speakers Bureau</td>
<td></td>
</tr>
<tr>
<td>David Farrar</td>
<td># 94</td>
<td>Thoratec Employee (significant)</td>
<td></td>
</tr>
<tr>
<td>Roberto Favaloro</td>
<td>Concurrent 41</td>
<td>Novartis Clinical Trial PI</td>
<td></td>
</tr>
<tr>
<td>David Feldman</td>
<td>Concurrent 38, Abstract Reviewer</td>
<td>GSK Consultant/Advisor (significant) Medtronic Consultant/Advisor (significant) Scios Consultant/Advisor (modest) Thoratec Consultant (modest) Abbot Consultant (modest)</td>
<td></td>
</tr>
<tr>
<td>Michael Felker</td>
<td>Abstract Reviewer</td>
<td>Amgen Grant/Consulting/Honoraria Guidant Consulting Abott Advisory Board Roche Diagnostics Grant Support</td>
<td></td>
</tr>
<tr>
<td>Matthew Fenton</td>
<td># 176</td>
<td>Astellas Research Funding (modest) Roche Research Funding (modest)</td>
<td></td>
</tr>
<tr>
<td>Andrew Fisher</td>
<td>Abstract Reviewer</td>
<td>Actelion Travel Grant (modest)</td>
<td></td>
</tr>
<tr>
<td>Maureen Flattery</td>
<td>Sunrise 7</td>
<td>XDx Speakers Bureau (modest)</td>
<td></td>
</tr>
<tr>
<td>F. Jay Fricker</td>
<td>Sunrise 8</td>
<td>Encysive Consultant (modest)</td>
<td></td>
</tr>
<tr>
<td>Eli Gabbay</td>
<td>Abstract Reviewer</td>
<td>Actelion Advisory Board/Grants/Research Support Schering Grant/Research Support Encysive Advisory Board Myogen Research Support</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Event/Meeting</td>
<td>Company/Institution</td>
<td>Role/Support</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>Howard Gebel</td>
<td>Thursday Plenary</td>
<td>One Lambda</td>
<td>Research Support/Consultant (significant)</td>
</tr>
<tr>
<td>H. Ardeschir Ghofrani</td>
<td>Satellite 8</td>
<td>Encysive</td>
<td>Advisory Board/Speaker (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novartis</td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td>Advisory Board/Speaker (modest)</td>
</tr>
<tr>
<td>Reda Girgis</td>
<td>Satellite 2, #159, Concurrent 28</td>
<td>Encysive</td>
<td>Speaker/Research Support/Consultant (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Actelion</td>
<td>Speaker/Research Support/Consultant (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td>Research Support (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>United Therapeutics</td>
<td>Consultant/Research Support (modest)</td>
</tr>
<tr>
<td>Allan Glanville</td>
<td>Abstract Reviewer</td>
<td>Novartis</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janssen-Cilag</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Jeffrey Golden</td>
<td># 154</td>
<td>XDx</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cotherix</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td>Julian Gooi</td>
<td># 8</td>
<td>Transmedics</td>
<td>sponsored workshop (modest)</td>
</tr>
<tr>
<td>Kate Gould</td>
<td>Concurrent 39, Abstract Reviewer</td>
<td>Novartis</td>
<td>Speaker/Clinical Advisor (modest)</td>
</tr>
<tr>
<td>Bartley Griffith</td>
<td>Satellite 1, Concurrent 40</td>
<td>Circulite</td>
<td>Surgical Advisory Board (none)</td>
</tr>
<tr>
<td></td>
<td>#91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan Groetzner</td>
<td># 469, Concurrent 14</td>
<td>Roche</td>
<td>Travel Grant (modest)</td>
</tr>
<tr>
<td>Paolo Grossi</td>
<td>Abstract Reviewer</td>
<td>MSD</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Schering Plough</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bayer</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Ramsey Hachem</td>
<td># 14, 138</td>
<td>Astellas</td>
<td>Speaker (modest)</td>
</tr>
<tr>
<td>Ari Halldorsson</td>
<td># 303</td>
<td>Organ Transport Systems</td>
<td>Grant (matching funds)</td>
</tr>
<tr>
<td>John Herre</td>
<td># 339</td>
<td>Medtronic</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>St Jude</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guidant</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td>Marshall Hertz</td>
<td>Opening Plenary</td>
<td>Astellas</td>
<td>Study Monitor (modest)</td>
</tr>
<tr>
<td>Roland Hetzer</td>
<td>Abstract Reviewer</td>
<td>Berlin Heart</td>
<td>Consultant</td>
</tr>
<tr>
<td>Nicola Hiemann</td>
<td># 220, 234, 261</td>
<td>Roche</td>
<td>Grant Support (modest)</td>
</tr>
<tr>
<td>William Holman</td>
<td>Satellite 7</td>
<td>Thoratec</td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heartware</td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myoetech</td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evaheart</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Sally Houston</td>
<td>Abstract Reviewer</td>
<td>Merck</td>
<td>Stock</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td>Stock</td>
</tr>
<tr>
<td>Atul Humar</td>
<td>Concurrent 11</td>
<td>Roche</td>
<td>Grant/Research Support/Speaker (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Astellas</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td>Judson Hunt</td>
<td>Novartis Symposium, #398</td>
<td>Roche</td>
<td>PI/Grants/Research Support (modest)</td>
</tr>
<tr>
<td>Shahid Husain</td>
<td>Sunrise 3, Concurrent 11</td>
<td>Astellas</td>
<td>Grants (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biorad</td>
<td>Grants (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td>Speaker (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enzon</td>
<td>Grants (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Schering-Plough</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Martin Iversen</td>
<td># 449</td>
<td>Novartis</td>
<td>Research Grant (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
<td>Research Grant (significant)</td>
</tr>
<tr>
<td>Maryl Johnson</td>
<td>Satellite 9</td>
<td>Astellas</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Anne Keogh</td>
<td>Satellite 2, Novartis Satellite,</td>
<td>Roche</td>
<td>Investigator/Speaker/Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novartis</td>
<td>Investigator/Speaker/Advisory Board (modest)</td>
</tr>
</tbody>
</table>
Encysive Investigator/Speaker/Advisory Board (modest)
Myogen Investigator (modest)
Pfizer Investigator (modest)
Ventracor Investigator (modest)
Wyeth Investigator/Consultant (modest)

Shaf Keshavjee Abstract Reviewer
Program Committee
X Dx Scientific Advisor/Study PI (modest)
Astellas Research Support

Michelle Kittleson # 461, 542
Novartis Research Grants (significant)

Walter Klepetko Friday Plenary,
Novartis Symposium,
Abstract Reviewer
Astellas Research Support
Genzyme Research Support

Jon Kobashigawa Satellite 5, #466
Novartis Speaker/Advisory Board/Grant/Honoraria (modest)
Astellas Speaker/Advisory Board/Grant/Honoraria (modest)
Roche Speaker/Advisory Board/Grant/Honoraria (modest)
X Dx Grants/Advisory Board/ Honorarium (modest)

Daniel Kreisel Concurrent 21
Roche Grant (significant)

Bernard Kubak Sunrise 3
Pfizer Speakers Bureau (modest)
Merck Speakers Bureau (modest)
Enzon Speakers Bureau (modest)

Stephen Large Satellite 1,
Abstract Reviewer
Levitonix Travel Grant (modest)
Thoratec Travel Grant (modest)
St. Jude Travel Grant (modest)

Angeline Leet # 465, Concurrent 41
Roche Grant/Research Support/Speaker (modest)
Novartis Grant Support (modest)

Antonio Legorreta # 468
Novartis Grant/Research Support (significant)

Hans Lehmkuhl #397, 341, 397,
Concurrent 17,
Abstract Reviewer
Astellas Consultant (modest)
Roche Consultant (modest)
Novartis Consultant (modest)
Genzyme Consultant (modest)

Bronwyn Levvey # 416
Novartis Grant/Research Support (modest)

Matthias Loebe # 103
Micromed Consultant (significant)

James Long Satellite 7,
Abstract Reviewer
WorldHeart Consultant/Stockholder/Scientific Advisor (significant)
Thoratec Speaker (modest)

Peter MacDonald Abstract Reviewer
Roche Advisory Board (modest)
Actelion Advisory Board (modest)

Balikrisynan Mahesh # 378
Imperial College Intellectual Property Rights (modest)

Charles Marboe Abstract Reviewer
X Dx Consultant
Novartis Consultant

David Markham # 125
Novartis Speaker (modest)

Paul Mather Abstract Reviewer
Orgis Advisory Board
Astra-Zeneca Speakers Bureau

Frauke Mattner # 450
Pfizer Research Support (modest)

Simon Maybaum # 414
Columbia University Patent/Inventor (modest)

Kenneth McCurry Concurrent 27,
Mini Oral 3
X Dx Consultant/Speaker (modest)

Mandeep Mehra #131, 171,
Satellite 12,
Opening Plenary,
Program Committee,
XDx Symposium
Astellas Consultant/Research Grants (modest)
Novartis Consultant (modest)
Roche Consultant (modest)
Scios Consultant (modest)
Medtronic Consultant (modest)

Bruno Meiser # 29
Roche Research Grant/Consultant (significant)
Novartis Research Grant/Consultant (significant)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role or Committee</th>
<th>Company or Institution</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan Meyers</td>
<td>Program Committee</td>
<td>DOMPE</td>
<td>Consultant</td>
</tr>
<tr>
<td>Carmelo Milano</td>
<td>Program Committee</td>
<td>Thoratec</td>
<td>Consultant/Speaker</td>
</tr>
<tr>
<td>Nick Morrell</td>
<td>Satellite 2</td>
<td>Actelion</td>
<td>Speaker (modest)</td>
</tr>
<tr>
<td>Johannes Mueller</td>
<td># 338</td>
<td>Berlin Heart</td>
<td>Employee/Officer (significant)</td>
</tr>
<tr>
<td>Yoshifumi Naka</td>
<td>Sunrise 4, Concurrent 25, Abstract Reviewer</td>
<td>Terumo Heart Inc, Ventrarcor, Thoratec</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Devin Nelson</td>
<td># 335, 389</td>
<td>WorldHeart</td>
<td>Stockholder (modest)</td>
</tr>
<tr>
<td>Duc Nguyen</td>
<td># 82, 388</td>
<td>Thoratec</td>
<td>Fellowship Support (significant)</td>
</tr>
<tr>
<td>Jonathan Orens</td>
<td>Sunrise 2, Abstract Review</td>
<td>Astellas</td>
<td>Advisory Board (significant)</td>
</tr>
<tr>
<td>Scott Palmer</td>
<td>Program Committee</td>
<td>Roche</td>
<td>Investigator</td>
</tr>
<tr>
<td>Francesco Parisi</td>
<td>Satellite 3</td>
<td>Novartis</td>
<td>Medical Advisor (modest)</td>
</tr>
<tr>
<td>Myung Park</td>
<td>Satellite 2</td>
<td>Actelion, United Therapeutics, Encysive</td>
<td>Consultant/Speaker/Research Support (significant)</td>
</tr>
<tr>
<td>Gareth Parry</td>
<td>Mini Oral 2</td>
<td>Roche</td>
<td>Travel Grant (modest)</td>
</tr>
<tr>
<td>Jignesh Patel</td>
<td># 27, 490</td>
<td>Astellas, Novartis, Medtronic</td>
<td>Research Grant/ Advisory BoD/Honoraria (significant)</td>
</tr>
<tr>
<td>David Pauly</td>
<td># 477</td>
<td>National Institute of Health, Florida Dept of Health, Novartis, Astellas, Expression Diagnostics</td>
<td>Grant/Research Support (modest)</td>
</tr>
<tr>
<td>Si Pham</td>
<td># 59</td>
<td>Astellas, XDx</td>
<td>Research Support (significant)</td>
</tr>
<tr>
<td>Luciana Potena</td>
<td># 238, 501</td>
<td>Novartis</td>
<td>Speaker Bureau (modest)</td>
</tr>
<tr>
<td>Gregorio Rabago</td>
<td>Abstract Reviewer</td>
<td>Roche, Wyeth</td>
<td>Grant/Research/Advisory Board</td>
</tr>
<tr>
<td>Barry Rayburn</td>
<td>Concurrent 31, Prog Comm</td>
<td>Encysive</td>
<td>Speaker Bureau (modest)</td>
</tr>
<tr>
<td>Hermann Reichenspurner</td>
<td>Roche Symposium, #420</td>
<td>Astellas</td>
<td>Study Sponsor</td>
</tr>
<tr>
<td>Andrew Rivard</td>
<td># 304</td>
<td>Hibernicor</td>
<td>Board Member (modest)</td>
</tr>
<tr>
<td>Joe Rogers</td>
<td>Program Committee</td>
<td>GSK, Medtronic</td>
<td>Speakers Bureau</td>
</tr>
<tr>
<td>Marlene Rose</td>
<td>Abstract Reviewer</td>
<td>Imperial Innovations</td>
<td>Patent Inventor</td>
</tr>
<tr>
<td>David Rosenbaum</td>
<td># 12</td>
<td>Organ Transport Systems</td>
<td>Research Grant (significant)</td>
</tr>
<tr>
<td>Bruce Rosengard</td>
<td>Sunrise 5, Program Comm</td>
<td>Transmedics</td>
<td>PI (none)</td>
</tr>
<tr>
<td>Heather Ross</td>
<td>Novartis Symposium, #42, 474, Abstract Reviewer</td>
<td>Novartis, Wyeth, Astellas</td>
<td>Consultant/ Grants/ Research (modest)</td>
</tr>
<tr>
<td>Joseph Rossano</td>
<td># 429, 507</td>
<td>Scios</td>
<td>Grant/Research Support (significant)</td>
</tr>
<tr>
<td>Theresa Rowe</td>
<td># 128</td>
<td>XDx</td>
<td>Speakers Bureau (modest)</td>
</tr>
<tr>
<td>Stuart Russell</td>
<td>Sunrise 4, Concurrent 17, Program Committee</td>
<td>Thoratec</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Hani Sabbah</td>
<td># 385</td>
<td>Orqis Medical Inc</td>
<td>Research Grant/Speakers Bureau (significant)</td>
</tr>
<tr>
<td>Daniel Salomon</td>
<td>Friday Plenary</td>
<td>Appimetrix</td>
<td>Grant Research Support (significant)</td>
</tr>
<tr>
<td>Name</td>
<td>Title/Committee</td>
<td>Company/Position</td>
<td>Relationship</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Michael Schmoeckel</td>
<td># 498</td>
<td>Medtronic</td>
<td>Travel Grant (modest)</td>
</tr>
<tr>
<td>Mark Schnitzler</td>
<td># 7, 9</td>
<td>Roche, Novartis, Astellas</td>
<td>Grants/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transmedics</td>
<td>Grants/Research Support (significant)</td>
</tr>
<tr>
<td>Sebastian Schulte-Eistrup</td>
<td># 300</td>
<td>Transmedics</td>
<td>Travel Grant (modest)</td>
</tr>
<tr>
<td>Lianne Singer</td>
<td>Concurrent 13, # 280, Abstract Review</td>
<td>Roche, Astellas</td>
<td>Grants/Research Support (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Syncardia</td>
<td>Scientific Advisor (modest)</td>
</tr>
<tr>
<td>Nick Smedira</td>
<td>Abstract Review</td>
<td>Syncardia, Vital Sensors</td>
<td>Proctor (modest)</td>
</tr>
<tr>
<td>Greg Snell</td>
<td># 147, 481, 285, Mini Oral 1,</td>
<td>Actelion, Roche, Novartis</td>
<td>Research Support/Grant (significant)</td>
</tr>
<tr>
<td></td>
<td>Program Committee</td>
<td></td>
<td>Medical Advisor (modest)</td>
</tr>
<tr>
<td>Randall Starling</td>
<td>XDx Symposium, Session 8, Abstract Review</td>
<td>XDx, Novartis, Astellas, Thoratec, WorldHeart, WorldHeart, ADVISORY BOARD, Roche</td>
<td>Investigator/Contractor/Advisory Board (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advisor, Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support/Honorarium (modest)</td>
</tr>
<tr>
<td>Duncan Stewart</td>
<td>Satellite 8</td>
<td>Northern Therapeutics</td>
<td>CSO/Founding Scientist (significant)</td>
</tr>
<tr>
<td>Samuel Strober</td>
<td>Satellite 4</td>
<td>Genzyme</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Martin Strueber</td>
<td>Concurrent 2, Satellite 1, # 470, 331</td>
<td>Novartis, Thoratec, Roche</td>
<td>Grants/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grants/Research Support (significant)</td>
</tr>
<tr>
<td>Sean Studer</td>
<td>#153, 331</td>
<td>Novartis, Encysive</td>
<td>Grants/Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Benjamin Sun</td>
<td># 540</td>
<td>Thoratec</td>
<td>Research Support (modest)</td>
</tr>
<tr>
<td>Stuart Sweet</td>
<td>Mini Oral 2, Program Comm</td>
<td>XDx, Chiron</td>
<td>Research Support (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speakers Bureau (modest)</td>
</tr>
<tr>
<td>Jacqueline Szmuszkovicz</td>
<td>Concurrent 45</td>
<td>Encysive</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td>Henry Tazelaar</td>
<td>Abstract Review</td>
<td>XDx, MedImmune, Angelica Therapeutics</td>
<td>Consultant/Advisory Board (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consultant/Stockholder (significant)</td>
</tr>
<tr>
<td>Thomas Tedder</td>
<td>Satellite 5</td>
<td>MedImmune, Angelica Therapeutics</td>
<td>Consultant/Advisory Board (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consultant/Stockholder (significant)</td>
</tr>
<tr>
<td>Bert Trulock</td>
<td>Abstract Review</td>
<td>XDx, Nabi Pharma, Astellas, Chiron</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td>Steven Tsui</td>
<td>Concurrent 40, Abstract Review</td>
<td>Ventracor, ALung Ltd</td>
<td>Research Grant/Consultant/Advisor (significant)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Grant/Research Support</td>
</tr>
<tr>
<td>Patricia Uber</td>
<td>Concurrent 17, Abs. Review</td>
<td>Astellas</td>
<td>Speakers Bureau (modest)</td>
</tr>
<tr>
<td>Jean-Luc Vachiery</td>
<td>Concurrent 28</td>
<td>Encysive, GSK</td>
<td>Consultant (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consultant/Medical Advisor (modest)</td>
</tr>
<tr>
<td>Miriam Van Albada</td>
<td># 354</td>
<td>Astellas, Actelion</td>
<td>Support printing thesis (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Support printing thesis (modest)</td>
</tr>
<tr>
<td>Adrian Van Bakel</td>
<td>Abstract Review</td>
<td>Scios, Orgis Medical, Novartis, Medtronic</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support</td>
</tr>
<tr>
<td>Johan Van Haecke</td>
<td>Concurrent 5</td>
<td>Roche, Novartis, Astellas, XDx</td>
<td>Speaker/Research Support (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advisory Board (modest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Research Support (modest)</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation/Sponsor</td>
<td>Position</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| Erik Verschuuren      | #136, Concurrent 42  
Astellas   
Travel Grant (modest) |
| Lynne Wagoner         | Abstract Reviewer  
Astellas   
Consultant |
| Steven Webber         | Satellite 12, Abs Review  
Genetech   
Research Grant (significant) |
| Willem Weimar         | Abstract Reviewer  
Novartis   
Astellas   
Roche   
Wyeth   
Research Grant |
| Lori West             | Satellite 5, #36,  
Opening Plenary, Closing Plenary, Program Committee  
Astellas   
Novartis   
Grant/Research Support (modest) |
| Glen Westall          | Abstract Reviewer  
Cellestis   
Roche   
Research Grant (significant) |
| George Wieselthaler   | Program Committee, Satellite 1, Concurrent 7  
HeartWare   
Advisory Board (modest) |
| James Young           | Concurrent 1  
Acorn   
Guidant   
Medtronic   
WorldHeart   
Consultant (modest) |
| Aimee Zaas            | Sunrise 3  
Pfizer   
Pfizer   
Speaker (modest) |
| Marty Zamora          | Program Committee  
Roche   
Biogenesis   
DOMPE   
Grant/Research Support |
| Michael Zakliczynski  | # 23, 267  
Astellas   
Consultant (modest) |
| Mark Zucker           | Concurrent 19, Abstract Reviewer  
Encysive   
Nitromed   
Paracor   
CVT   
Speakers Bureau (modest) |
| Rachelle Zomack       | Sunrise 7  
XDx   
Advisory Board (modest) |
| Andreas Zuckermann    | Program Committee  
Genzyme   
Astellas   
Novartis   
Roche   
Wyeth   
Speaker |
|                        |                                   | Speaker/Study Committee |
|                        |                                   | Speaker/Study Member |
|                        |                                   | Speaker/investigator |
The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of

Gold Partners

Astellas Pharma US
Novartis
Roche

Silver Partners

Actelion
Encysive
TransMedics
XDx

toward this

Twenty Seventh Annual Meeting and Scientific Sessions
ADD TEMPLATE HERE – becky, since we have 6 concurrent sessions this year, you may want to do the template as a fold-out page
SCIENTIFIC PROGRAM

All meetings and activities will take place at the Hilton San Francisco unless otherwise specified. All papers will be presented in English. Abstract presenter names are underlined. A presentation title or name preceded by an asterisk indicates that the presenter/chair has indicated a relationship which, in the context of this CME activity, could be perceived as a potential conflict of interest. Please refer to the disclosure information provided in this booklet for additional information about specific presenter and chair disclosure information.

MONDAY, APRIL 23, 2007

3:00 PM – 10:00 PM
Exhibit Hall Build (Continental Ballroom)

TUESDAY, APRIL 24, 2007

8:00 AM – NOON
Registration Build (West Lounge Foyer)

8:00 AM – 8:00 PM
Exhibit Hall Build (Continental Ballroom)
Internet Café Set-up (Continental Ballroom Foyer)
Poster Board Set-up (Continental Ballroom and Yosemite Ballroom)

6:00 PM – 10:00 PM
ISHL Board of Directors Meeting (Union Square 19-20)

6:00 PM – 9:00 PM
Registration Desk Open (West Lounge Foyer)

6:00 PM – 9:00 PM
Slide Ready Room Open (Green Room)

WEDNESDAY, APRIL 25, 2007

6:00 AM – 6:00 PM
Registration Desk Open (West Lounge Foyer)

6:00 AM – 6:00 PM
Slide Ready Room Open (Green Room)

7:00 AM – NOON
Exhibitor Move-In (Continental Ballroom)
General Poster Session 1 Mounting (Continental Ballroom)

7:00 AM – 6:00 PM
Press Office Open (Executive Boardroom)

7:00 AM – 24 Hours
Internet Café Open (Continental Ballroom Foyer)

8:00 AM – 10:00 AM
SATELLITE SYMPOSIUM 1
New Mechanical Circulatory Support (MCS) Technology (Grand Ballroom B)
*Chairs: O. Howard Frazier, MD and *Stephen R. Large, MD

Continuous Flow Devices
*8:00 AM MicroMed, George M. Wieselthaler, MD, University of Vienna, Vienna, Austria
8:10 AM INCOR, Michael J. Jurmann, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
*8:20 AM HeartMate II, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

Total Artificial Heart
*8:30 AM Abiocor, Robert D. Dowling, MD, University of Louisville / Jewish Hospital, Louisville, KY
8:45 AM Cardiowest, Jack G. Copeland, MD, University of Arizona Health Science Center, Tucson, AZ

Percutaneous Devices
9:00 AM Tandem Heart, Reynolds M. Delgado, MD, Texas Heart Institute, Houston, TX
*9:15 AM Impella, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD
9:30 AM Bioengineering Perspective, Greg Burtle, PhD, Mississippi State University, Mississippi State, MS
9:50 AM Discussion

8:00 AM – 10:00 AM
SATELLITE SYMPOSIUM 2
Pulmonary Hypertension: A Tale of the Lungs and Two Ventricles (Grand Ballroom A)
Supported by an Unrestricted Educational Grant from Actelion

*Chairs: *Reda Girgis, MB, BCh and *Anne Keogh, MBBS, MD

8:00 AM Pathobiology of Pulmonary Hypertension, Nick W. Morrell, MD, FRCP, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom

8:20 AM Discussion

8:30 AM The Role of Rho Kinase Pathway in Right Heart Failure, Hunter C. Champion, MD, PhD, FAHA, Johns Hopkins Hospital, Baltimore, MD

8:50 AM Discussion

9:00 AM Pulmonary Hypertension in the Cardiac Transplant Setting, Leslie W. Miller, MD, Georgetown University Hospital, Washington, DC

9:20 AM Discussion

9:30 AM Pulmonary Hypertension in the Perioperative Setting, Myung H. Park, MD, University of Maryland School of Medicine, Baltimore, MD

9:50 AM Discussion

8:00 AM – 10:00 AM
SATellite Symposium 3
Protecting the Kidney in Pediatric Thoracic Transplant (Imperial Ballroom A)

*Chairs: *Charles E. Canter, MD and Glen P. Westall, FRACP

8:00 AM Renal Complications Following Solid Organ Transplant - Risk Factors and Management Strategies, Kathleen M. Campbell, MD, Cincinnati Children’s Hospital, Cincinnati, OH

8:20 AM Discussion

8:25 AM Minimizing Immunosuppression in Pediatric Recipients, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

8:45 AM Discussion

8:50 AM Debate: TOR Inhibitors – Time to Switch?

*8:50 AM Pro: Francisco Parisi, MD, Ospedale Pediatrico "Bambino Gesù", Rome, Italy
*9:05 AM Con: Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

9:20 AM Pro Rebuttal

9:25 AM Con Rebuttal

Update on the NHLBI's Pediatric Circulatory Support Program

9:30 AM Program Officer's Perspective, Timothy Baldwin, PhD, National Institutes of Health, Bethesda, MD

9:45 AM Investigator's Perspective, Brian W. Duncan, MD, Cleveland Clinic Foundation, Cleveland, OH

8:00 AM – 10:00 AM
SATellite Symposium 4
Cellular Immune Therapy (Imperial Ballroom B)

Chairs: Carla C. Baan, PhD and Thomas K. Waddell, MD, PhD

8:00 AM Mesenchymal Stem Cell Regulation of Alloresponses, TBA

8:30 AM The Role of Hematopoietic Stem Cells in Tolerance, Samuel Strober, MD, Stanford University, Palo Alto, CA

9:00 AM Regulatory Cells: Ready for the Clinic? TBA

9:30 AM Dendritic Cell Therapy, Angus Thomson, PhD, DSc, FRCPath, University of Pittsburgh School of Medicine, Pittsburgh, PA

8:00 AM – 10:00 AM
SATellite Symposium 5
The Evolving Problem of Antibodies in Thoracic Transplantation (Plaza Ballroom A)

*Chairs: *Lori West and *Duane Davis, MD

8:00 AM Who are the Players: B Cells and Plasma Cells, Michael P. Cancro, MD, University of Pennsylvania School of Medicine, Philadelphia, PA

8:20 AM Discussion

8:25 AM Antibodies and Their Targets, Ronald H. Kerman, PhD, University of Texas Medical School, Houston TX

8:45 AM Discussion

*8:50 AM Clinical Therapies Currently in Use: Do Any of Them Work? Jon Kobashigawa, MD, University of California at Los Angeles, Los Angeles, CA

9:10 AM Discussion

9:15 AM When is Antibody not Destructive? Jeffrey L. Platt, MD, Mayo Foundation, Rochester, MN

9:30 AM Discussion

9:35 AM Future Directions in Therapy, Thomas F. Tedder, PhD, Duke University Medical Center, Durham, NC

9:55 AM Discussion

8:00 AM – NOON
SATellite Symposium 6
Joint ISHLT/ITNS/NATCO Clinical Update (Plaza Ballroom B)

Chairs: Nancy P. Blumenthal, CRNP and Bronwyn J. Levvey, RN

8:00 AM International Perspectives on Thoracic Transplantation, Susan M. Chernenko, MN, Toronto General Hospital, Toronto, ON, Canada

8:20 AM Discussion
8:25 AM Current Issues in Lung and Heart Transplantation: Impact of the New Allocation System, Jean B. Rea, RN, MS, CCTC, Duke University Medical Center, Durham, NC
8:45 AM Discussion
8:50 AM High Risk Behavior in the Recipient Pre-Transplant: Is it a Predictor of Poor Outcomes? Ashley Finlen Copeland, MSW, LCSW, Duke University Medical Center, Durham, NC
9:10 AM Discussion
9:15 AM Retransplantation: Indications, Outcomes, Allocation, and Equity, Katherine Hoercher, RN, Cleveland Clinic Foundation, Cleveland, OH
9:35 AM Discussion
9:40 AM BREAK
10:00 AM Bugs and Drugs: New Fungal Infections and Therapies, Kathy Schwab, RN BSN CCTC, Mayo Clinic, Rochester, MN
10:20 AM Discussion
*10:25 AM Patient Reported Outcomes in Transplantation, Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Leuven, Belgium
10:45 AM Discussion
10:50 AM Optimizing and Increasing Thoracic Organ Donors: Utilizing Virtual Cross-match, ECD, and Living Lobar Donors, Kevin C. Carney, RN, CCTC, University of Pennsylvania Medical Center, Philadelphia, PA
10:10 AM Discussion
11:15 AM Trading One Disease for Another? Can We Reduce the Co-Morbidities Post Transplant? Nancy K. Harrington, RN, BS, MS, CCTC, University Medical Center, Tucson, AZ
11:35 AM Discussion
11:40 AM Panel Discussion
10:00 AM – 10:15 AM
Coffee Break (Continental Foyer/West Foyer)
10:15 AM – 12:15 PM
SATELLITE SYMPOSIUM 7
Strategies and Results from MCS Therapy: Myocardial Recovery and Permanent Support (Grand Ballroom B)
*Chairs: Robert L. Kormos, MD and *Joseph G. Rogers, MD

Myocardial Recovery
*10:15 AM Berlin Heart Center Experience, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany
10:30 AM Harefield Hospital Experience, Emma Birks, MRCP, Harefield Hospital, Harefield, United Kingdom
10:45 AM Myocardial Recovery on Mechanical Circulatory Support: Fundamental Mechanisms, Guillermo Torre-Amione, MD, PhD, Baylor College of Medicine, Houston, TX
11:00 AM Discussion

Issues in Permanent Mechanical Circulatory Support
11:15 AM Criteria and Patient Selection, Leslie W. Miller, MD, Georgetown University Hospital, Washington, DC
*11:30 AM Anticoagulation, William L. Holman, MD, University of Alabama, Birmingham, AL
11:45 AM Building a DT Practice, Mark S. Slaughter, MD, Advocate Christ Medical Center, Oak Lawn, IL
*NOON Device Reliability and Durability Issues, James W. Long, MD, PhD, LDS Hospital, Salt Lake City, UT
10:15 AM – 12:15 PM
SATELLITE SYMPOSIUM 8
Hot Topics in Pulmonary Arterial Hypertension
Supported by an Unrestricted Educational Grant from Encysive Pharmaceuticals (Grand Ballroom A)
*Chairs: *Raymond L. Benza, MD and *Paul A. Corris, MB, FRCP

*10:15 AM Angiogenesis in PAH: Pathogenic or Compensatory? Duncan J. Stewart, MD, FRCP, St. Michael’s Hospital, Toronto, ON, Canada
10:35 AM Discussion
10:45 AM PH in Left Heart Disease – Role of Specific Therapies, José A. Tallaj, MD, University of Alabama at Birmingham, Birmingham, AL
11:05 AM Discussion
11:15 AM Treatment of PAH in Congenital Heart Disease, Michael J. Landzberg, MD, Children’s Hospital Boston, Boston, MA
11:35 AM Discussion
*11:45 AM Exploiting Novel Therapeutic Pathways in PAH, H. Ardeschir Ghofrani, MD, Justus-Liebig-University, Giessen, Germany
12:05 PM Discussion

10:15 AM – 12:15 PM
SATELLITE SYMPOSIUM 9
Continued Evaluation of Heart and Lung Allocation Using Evidence Based Research (Imperial Ballroom A)
*Chairs: J. David Vega, MD and *Bryan F. Meyers, MD

10:15 AM How is the Lung Allocation Score Working in the US? Leah Edwards, PhD, United Network for Organ Sharing, Richmond, VA
10:30 AM How to Get New Data Into an Existing Allocation Algorithm, Susan Murray, ScD, Scientific Registry of Transplant Recipients, Ann Arbor, MI
*10:45 AM Building a New Heart Allocation System That Goes Beyond Status, Maryl R. Johnson, MD, University of Wisconsin, Madison, WI
11:00 AM Issues in Heart and Lung Allocation in East and West Europe, Dirk van Raemdonck, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
11:15 AM Ethical Issues in Organ Allocation/Solicitation, James DuBois, PhD, DSc, St. Louis University, St. Louis, MO
11:45 AM Discussion
10:15 AM – 12:15 PM
SATellite Symposium 10
Interplay of Innate and Adaptive Immunity (Imperial Ballroom B)
*Chairs: *Scott M. Palmer, MD and Michael S. Mulligan, MD

10:15 AM *The Role of Innate Immune Signaling in Allograft Rejection*, Dianne McKay, MD, The Scripps Research Institute, La Jolla, CA
10:45 AM *The Role of Macrophages in Adaptive Immunity*, Allan D. Kirk, MD, PhD, National Institutes of Health, Bethesda, MD
11:15 AM *The Role of NK Cells in Adaptive Immunity*, Joren C. Madsen, MD, D.Phil., Massachusetts General Hospital, Boston, MA
11:45 AM *The Role of Mast Cells in Adaptive Immunity*, Soman N. Abraham, MD, PhD, Duke University Medical School, Durham, NC

10:15 AM – 12:15 PM
SATellite Symposium 11
Antibody-Mediated Rejection of the Lung: What are the Morphologic and Clinical Findings? (Plaza Ballroom A)
Chairs: Michael C. Fishbein, MD, and Susan Stewart, FRCPath

10:15 AM *Antibody Mediated Rejection in Extrapulmonary Organ Sites*, Michael C. Fishbein, MD, University of California School of Medicine, Los Angeles, CA
10:30 AM Discussion
10:35 AM *Antibody Mediated Rejection of the Lung: Are There Reliable Morphologic Criteria?*, Cynthia M. Magro, MD, Weill College of Medicine/Cornell University, New York, NY
10:50 AM Discussion
10:55 AM *Antibody Mediated Rejection of the Lung: Are There Reliable Morphologic Criteria?*, Samuel A. Yousem, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
11:10 AM Discussion
11:15 AM *The Clinical Prognostic Significance of the C3d and C4d Deposition in Lung Biopsy Specimens*, Glen P. Westall, FRACP, Alfred Hospital, Melbourne, Australia
11:30 AM Discussion
*11:35 AM *The Clinical Recognition of Antibody Mediated Rejection*, Martin R. Zamora, MD, University of Colorado Health Science Center, Denver, CO
11:50 AM Discussion

NOON – 7:15 PM
Exhibit Hall Open (Continental Ballroom)
General Poster Session 1 Viewing (Continental Ballroom)

12:15 PM – 12:30 PM
Box Lunch Pick-up (ticket required) (Yosemite Ballroom)

12:30 PM – 2:00 PM
Luncheon Symposium
Practical Implications of Using PSI's In Thoracic Transplantation (Grand Ballroom B)
Supported by an Unrestricted Educational Grant from Novartis
*Chairs: *John Dark, MB, FRCS and *Heather Ross, MD

*12:30 PM *The Challenge of Renal Dysfunction in Thoracic Transplantation: A Multi Disciplinary Approach*, Judson M. Hunt, MD, MD, Dallas Nephrology Associates, Dallas, TX
*12:50 PM *Unique Surgical Issues With PSIs: Tissue Regeneration and Beyond?*, Walter Klepetko, MD, University of Vienna, Vienna, Austria

1:10 PM Denovo CNI and PSI-based Immunosuppression: Achieving Optimal Balance
*1:10 PM (396) *Evelorilimus in De Novo Heart Transplant Recipients: Six Month Data on Cyclosporine Reduction and Impact on Renal Function*, A. Keogh, S.S. Wang, A. Zuckermann, H. Ross, M. Frigerio, H. Eisen, C. Bara, G. Laufer, M. Cotrufo, S. Lena, C. Sips, St. Vincent’s Hospital, Sydney, Australia; National Taiwan University Hospital, Taipei, Taiwan; University of Vienna, Vienna, Austria; Toronto General Hospital, Toronto, Canada; Az. Ops. Niguarda Ca’ Granda, Milano, Italy; Hahnemann Hospital, Philadelphia; Kliniken der Medizinischen Hochschule, Hannover, Germany; Universitätsklinik, Innsbruck, Austria; Azienda Ospedaliera Monaldi, Napoli, Italy; Novartis Pharma AG, Basel, Switzerland

*1:20 PM (397) *Evelorilimus with Reduced Cyclosporine Exposure vs. MMF and Conventional Cyclosporine: Results from a Study in De Novo Heart Transplant Recipients*, H. Lehmkulhu, U. Livi, P. Boissonnat, J. Arizon, M. Vigano, C. Magelli, L. Almenar, K.H. Abeywickrama, Y. Gezahegen, Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; Department Cardiovascular Sciences, Az. Osp. S. Maria della Misericordia, Udine, Italy; Cardiac Transplantation, Hospital Cardiologique de Lyon, Lyon, France; Cardiology, Hospital Universitario Reina Sofia, Cordoba, Spain; Cattedra di Cardiotoracico, Policlinico S. Matteo-IRCCS Università degli Studi di Pavia, Pavia, Italy; Cardiology, Az. Osp. di Bologna Policl. S. Orsola - Malpighi, Bologna, Italy; Cardiology, Hospital Universitario La Fe, Valencia, Spain; Infectious Diseases, Transplantation and Immunology, Novartis Pharma AG, Basel, Switzerland

1:30 PM Panel Discussion

2:15 PM – 4:15 PM
Opening Plenary Session (Grand Ballroom B)
*Chairs: *Robert C. Robbins, MD and *Duane Davis, MD
**2:15 PM Welcome and Program Committee Report**, Robert C. Robbins, MD, ISHLT President, Stanford University School of Medicine, Palo Alto, CA and *Duane Davis, MD, Scientific Program Chair, Duke University Medical Center, Durham, NC

**2:20 PM ISHLT International Thoracic Transplant Registry Report**, Marshall I. Hertz, University of Minnesota, Minneapolis, MN


**3:00 PM The New ISHLT International Heart Failure Guidelines**, Mandep R. Mehta, MD, University of Maryland, Baltimore, MD

**3:15 PM Promises and Limitations of Cell Therapy**, Kenneth Chien, MD, PhD, Massachusetts General Hospital, Harvard Medical School and Harvard Stem Cell Institute, Boston, MA

3:45 PM **The Application of Nanotechnology in Medicine and Transplantation**, Nan Marie Jokerst, Duke University, Durham, NC

**4:15 PM – 4:45 PM Coffee Break/View Posters (Continental Ballroom)**

**4:45 PM – 6:15 PM CONCURRENT SESSION 1 Myocardial Recovery During Mechanical Circulatory Support (Grand Ballroom B)**

*Chairs:* Guillermo Torre-Amione, MD, PhD and *Michael Dandel, MD

**4:45 PM Invited Lecture: The Role of INTERMACS in Facilitating Device Development**, James B. Young, MD, Cleveland Clinic Foundation, Cleveland, OH

5:00 PM (2) Complete Discontinuation of Mechanical Support and Assessment of Inotropic Reserve in Patients with Left Ventricular Assist Devices; R.S. George,* G. Tasci,* C.T. Bowles,* C. Webb,* G. Dreyfus,* A. Khaghani,* M.H. Yacoub,* E.J. Birks,* Transplant and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; *Heart Science Centre, Magdi Yacoub Institute, Imperial College, Harefield, Middlesex, United Kingdom

5:15 PM (3) Biplanar 2D-Echo Strain Imaging Documents Improvement in LV Function in Patients with VAD; S. Zieroth,* M. Thangaroopan,* S. Carasso,* V. Rao,* D. Delgado,* H. Rakowski,* H. Ross,* Department of Cardiology, St. Boniface General Hospital, Winnipeg, MB, Canada; Department of Cardiac Transplant, University Health Network, Toronto, ON, Canada; Massachusetts General Hospital, Boston, MA

5:30 PM (4) Which Factors Predict the Recovery of Natural Heart Function after Left Ventricular Assist System Insertion; A. Mano,* T. Nakatani,* N. Oda,* T.S. Kato,* K. Niwaya,* O. Tagusari,* H. Nakajima,* T. Funatsu,* K. Komamura,* A. Hanatani,* M. Kitakaze,* J. Kobayashi,* T. Yagihara,* S. Kitamura,* Organ Transplantation, National Cardiovascular Center, Suita, Osaka, Japan; Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan; Cardiology, National Cardiovascular Center, Suita, Osaka, Japan


6:00 PM (6) Cathepsin G Is Co-Localized in Trypsin/Chymase Positive Human Cardiac Mast Cells (MC_V) during Heart Failure and Mechanical Circulatory Support; J. Jahanyar,* K.A. Youker,* G.P. Noon,* G. Torre-Amione,* M. Loebe,* Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX

4:45 PM – 6:15 PM CONCURRENT SESSION 2 Cardiac Ischemic Time: Warm, Cold, or Pump? (Grand Ballroom A)

*Chairs:* John D. Vega, MD and *Martin Strueber, MD

**4:45 PM (7) The Cost-Effectiveness of Increasing the Supply of Hearts for Transplant; M.A. Schnitzler,* P.M. Buchanan,* J. Swindle,* R. Lee,* P.J. Hauptman,* Internal Medicine, Saint Louis University, St. Louis, MO

**5:00 PM (8) The Potential Impact of Reducing Cold Ischaemic Time on Cardiac Transplant Survival; J.H. Gooi,* A. Fracs,* L. Sharples,* K. Goldsmith,* D. Jenkins,* K. Dhital,* S. Large,* T. Tsu,* Transplant Surgery Department, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; Australia and New Zealand Cardiothoracic Organ Transplant Registry, funded by the Department of Health and Aged Care, Australia

**5:15 PM (9) Impact of Ischemia Time on the Outcomes of Heart Transplant; M.A. Schnitzler,* P.M. Buchanan,* T.E. Burroughs,* R. Lee,* P.J. Hauptman,* Saint Louis University, St. Louis, MO

**5:30 PM (10) Prospective Multi-Center European Trial To Evaluate the Safety and Performance of the Organ Care System for Heart Transplants (PROTECT); G. Tanderleh,* A. El-Banayosy,* B. Rosengard,* T. Tsu,* J. Wallwork,* R. Hetzer,* R. Koerfer,* W. Hassanein,* Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany; Cardiothoracic Surgery, Papworth Hospital, Papworth, United Kingdom; Cardiothoracic and Vascular Surgery, German Heart Institute, Berlin, Germany; TransMedics, Inc., Andover, MA

**5:45 PM (11) Use of Continuous Ex Vivo Perfusion to Resuscitate Hearts after Warm Ischemia: Animal Studies with Clinical Validation; M.J. Collins,* T. Ozeki,* J. Gu,* C. N.S. Burris,* R.N. Pierson,* B.P. Griffith,* R.S. Poston,* Division of Cardiac Surgery, Department of Surgery, University of Maryland Medical Center, Baltimore, MD; Department of Surgery, Veterans Administration Hospital, Baltimore, MD

**6:00 PM (12) Cardiac Storage with a Perfusion Device Prevents Tissue Lactate Accumulation; D.H. Rosenbaum,* M. Peltz,* M.E. Merritt,* H. Sasaki,* M.E. Jessen,* Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, TX; Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
Lung Allocation and Recipient Complications (Imperial Ballroom A)

Chairs: Vivek N. Ahya, MD and Dirk van Raemdonck, MD, PhD


*5:00 PM (14) Impact of the New Lung Allocation System in the United States; R.R. Hachem, B.F. Meyers, R.D. Yusen, G.A. Patterson, E.P. Trulock, Lung Transplant Program, Washington University School of Medicine, St. Louis, MO

5:15 PM (15) The ISHLT Primary Graft Dysfunction (PGD) Grading System: Time for Refinement?; T. Oto, B.J. Levvey, G.I. Snell, Lung Transplant Unit, The Alfred Hospital, Melbourne, Victoria, Australia


5:45 PM (17) A Prospective Study of a Management Algorithm to Minimise Lung Transplant (LTx) Primary Graft Dysfunction (PGD); J.A. Currey, D.V. Pilscher, A. Davies, C. Schienkestel, M. Botti, T. Oto, G. Snell, Alfred/Deakin Nursing Research Centre, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University and The Alfred, Melbourne, Victoria, Australia; Intensive Care Unit, Alfred Hospital, Melbourne, Victoria, Australia; Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia

6:00 PM (18) Long Term Outcome of Severe Reperfusion Injury Post Lung Transplantation Following the Administration of Endobronchial Surfactant; P.M. Hopkins, F. Kermeen, J. Dunning, K.D. McNeil, Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

4:45 PM – 6:15 PM CONCURRENT SESSION 4

Good Heart, Bad Vessels (Imperial Ballroom B)

Chairs: Stephen R. Large, FRCP, FRCS and Patricia P. Chang, MD

4:45 PM (19) C-Reactive Protein, Cardiac Allograft Vasculopathy and Coronary Interventions in Heart Transplant Patients; C.A. Labarrere, G. Campana, G. Boguslawski, M.A. Ortiz, M.J. Sosa, C. Terry, D.E. Pitts, J.A. O’Donnell, D.A. Hormuth, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; Clarian Health Transplant Center, Clarian Health Partners, Indianapolis, IN; Krannert Institute of Cardiology, Indiana University, Indianapolis, IN

5:00 PM (20) QT Dispersion for Detection of Cardiac Allograft Vasculopathy in Heart Transplant Patients; A. Kashem, S. Panse, R.C. Cross, W.P. Santamore, A.A. Bove, Section of Cardiology, Temple University, Philadelphia, PA; Internal Medicine, Abington Memorial Hospital, Philadelphia, PA


5:30 PM (22) Asymptomatic Cardiac Allograft Dysfunction in Heart Transplant Recipients with Normal Coronary Angiograms: Risk Factory Analysis and Predictive Role on Cardiac Allograft Vasculopathy Onset; F. Tona, A.L.P. Caforio, A. Gambino, A. Angelini, A. Ramondo, G. Feltrin, G. T oscano, G. Thiene, G. Gerosa, S. Iliceto, Cardiology, University of Padova, Padova, Italy; Cardiovascular Surgery, University of Padova, Padova, Italy; Cardiovascular Pathology, University of Padova, Padova, Italy

*5:45 PM (23) Quilty Effect (QE) Correlates with Biopsy Proven Acute Cellular Rejection but Does Not Predict Transplanted Heart Coronary Artery Vasculopathy (CAV); M. Zakliczynski, J. Nozynski, D. Konecka-Mrowka, M. Zembala, Department of Cardiology, Silesian Center for Heart Disease, Aalst, Poland

6:00 PM (24) Functional Evaluation Using Intracoronary Pressure-Flow Derived Analysis to Detect Transplant Coronary Vasculopathy; T.J.R. De Potter, J. Bartunek, S. Vercauteren, S. Verstreken, M. Goethals, B. De Bruyne, M. Vanderheyden, F. W e llens, Cardiovascular Center, OLV Hospital, Aalst, BE, Belgium

4:45 PM – 6:15 PM CONCURRENT SESSION 5

Immunosuppression After Cardiac Transplantation: New Cocktails at the Bar – Finding the Right Mix (Plaza Ballroom A)

*Chairs: *Joseph G. Rogers, MD and *Johan Vanhaecke, MD

4:45 PM (25) Sirolimus as Primary Immunosuppression Prevents Progression of Cardiac Allograft Vasculopathy: A 3-D IVUS Study; E. Raichlin, B.S. Edwards, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, J.A. Wagner, R.C. Daly, A. Lerman, S.S. Kushwaha, Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Cardiothoracic Surgery, Mayo Clinic, Rochester, MN

5:00 PM (26) Three Year Outcome of a Randomized Trial Comparing C4 Against C4 Monitoring in Stable Heart Transplant Patients; P.K.W. Lam, C. Payne, J. Lockhart, M. Kerr, A. Kirk, A.J. Murday, Scottish National Advanced Heart Failure Service, Glasgow Royal Infirmary, Glasgow, United Kingdom; Cardiothoracic Surgery, Western General Infirmary, Glasgow, United Kingdom
5:30 PM (28) Dose Reduction of MMF Due to Gastrointestinal Intolerance Is Associated with Increased Rejection in Heart Transplant Recipients; P.J. Galiwango,1 D. Delgado,1 H.J. Ross,1 Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada

5:45 PM – 6:15 PM

CONCURRENT SESSION 6

Immune Regulation and Tolerance (Plaza Ballroom B)

*Chairs:* William Weimar, MD and David S. Wilkes, MD

5:45 PM (31) Mixed Hematopoietic Chimerism Prevents Lung Allograft Rejection in Miniature Swine; H. Saharna,1 M.J. Weiss,1 K.J. Wikiel,1 J.K. Sayre,1 A.C. Pujara,1 C.Y. Ng,1 P.L. Cho,1 B.M. Horner,1 S.L. Houser,1 J.C. Wain,1 D.H. Sachs,1 J.C. Madsen,1 C.A. Huang,1 J.S. Allan,1 1Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

5:00 PM (32) High Suppressive Potency of Isolated CD25+ T Cells in Porcine Allogeneic Lung Transplantation In Vitro; S. Thissen,1 B. Kruse,1 G. Warnecke,1 M. Avsar,1 R. Reinhard,1 C. Peters,1 A.R. Simon,1 A. Haverich,1 M. Strueber,1 Division of Thoracic and CV Surgery, Hannover Medical School, Hannover, Germany

5:15 PM (33) Acute Rejection Is Associated with High FOXP3 mRNA Expression Levels in the Graft, but Not in the Peripheral Blood, of Heart Transplant Recipients; I.E. Dijke,1 K. Caliskan,2 S.S. Korevaar,1 A.H. Balk,2 P.E. Zondervan,1 A.P. Maat,2 W. Weimar,1 C.C. Baan,1 1Internal Medicine, Erasmus MC, Rotterdam, Netherlands; 2Thorax Center, Erasmus MC, Rotterdam, Netherlands; 3Pathology, Erasmus MC, Rotterdam, Netherlands

5:30 PM (34) FoxP3+ T Cells Can Be Expanded from Rejecting Human Cardiac Allografts; I.E. Dijke,1 J.H. Velthuis,1 A.H. Balk,2 P. de Kuiper,1 M. Klepper,1 K. Caliskan,1 W. Weimar,1 C.C. Baan,1 Internal Medicine, Erasmus MC, Rotterdam, Netherlands; 2Cardiology, Erasmus MC, Rotterdam, Netherlands; 3Cardiology, Erasmus MC, Rotterdam, Netherlands

5:45 PM (35) Frequency of FoxP3+ Regulatory CD4 Cells Recovered in Bronchoalveolar Lavage Does Not Predict Acute Rejection Score; D.C. Neujahr,1 E.C. Lawrence,1 A. Pelaez,1 A. Ramirez,1 S. Force,2 A. Gal,2 C.P. Larsen,2 1Medicine, Emory University, Atlanta, GA; 2Surgery, Emory University, Atlanta, GA; 3Pathology, Emory University, Atlanta, GA

5:45 PM (36) Deletional vs Suppressive Neonatal Tolerance to Cardiac Allografts Depends on Inoculum Source; K. Tao,1 L. Mai,1 L. J. West,1 1Pediatrics, Surgery and Immunology, University of Alberta, Edmonton, AB, Canada; 2Infection, Immunity, Injury and Repair, Hospital for Sick Children, Toronto, ON, Canada

6:15 PM – 7:15 PM

GENERAL POSTER SESSION 1/Wine and Cheese Reception (Continental Ballroom)

(37) Should Ambulatory Heart Failure Patients Be Transplanted?; N.R. Banner,1 C.A. Rogers,2 K. Ranganathan,1 S. Jayakumar,1 R.S. Bonser,3 1Cardiology and Transplant Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom; 2Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom; 3Cardiothoracic Surgery, Queen Elizabeth Hospital, Birmingham, United Kingdom

(38) The Selective If Channel Antagonist Ivabradine in Stable Patients after Heart Transplantation (HTX); A.O. Doesch,1 S. Celik,1 P.h Ehlermann,1 L. Frankenstein,1 A. Koch,2 T.J. Dengler,1 1Department of Cardiology, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiology, University of Heidelberg, Heidelberg, Germany

(39) Cardiac Reserve in the Transplanted Heart Depends on a Graft Polymorphism in the beta-1-Adrenergic Receptor; M. Scharin Täng, E. Lindberg, Y. Magnusson, B. Andersson Department of Metabolism and Cardiovascular Research and Wallenberg Laboratory, Institute of Medicin, Sahlgrenska Academy, Göteborg University, Sweden

(40) The Prognostic Value of Pre- and within One Year Postoperative Right Heart Hemodynamics in Heart Transplant Recipients; E. Gude,1 S. Arora,1 S. Simonsen,1 L. Gullestad,1 O. Geiran,1 A. Andreassen,1 1Department of Cardiology, Rikshospitalet-Radiumhospital Medical Center, Oslo, Norway

(41) Current Status of Heart Transplantation as Therapy for Advanced Heart Failure in African Americans; R.S.D. Higgins,1 L.L. Edwards,2 E.J. Okum,1 G.M. Mullin,2 S.H. Dunlap,1 P.J. Hauptman,1 F.D. Pagani,4 K.D. Aaronson,4 Cardiovascular-Thoracic Surgery, Rush University Medical Center, Chicago, IL; 2United Network for Organ Sharing, Richmond, VA; 3Heart Failure and Transplantation, Saint Louis University School of Medicine, St. Louis, MO; 4Heart Failure and Transplantation, University of Michigan, Ann Arbor, MI
(42) Detection of Renal Tubular Injury in Cardiac Transplant Recipients by Urine Proteomic Analysis; S. Zieroth,1 *H. Ross,2 S. Famure,2 S. Schaub,1 K. Sangster,1 J. Wilkins,1 D. Rush,1 P. Nickerson,1 1Medicine, University of Manitoba, Winnipeg, MB, Canada; 2Medicine, University of Toronto, Toronto, ON, Canada

(43) Renal Function after Thoracic Organ Transplantation; A.A. Mennander,1 P.P. Frohnhert,1 B.S. Edwards,1 R.C. Daly,1 S.G. Peters,1 S.D. Cassivi,3 C.G.A. McGregor,1 1Mayo Clinic-Roch William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

(44) New Insights in the Management of Cardiogenic Shock Complicating Myocardial Infarction Role of Urgent Heart Transplantation; D. Arzamendi,1 F. Perez Villa,1 E. Roig,1 A. Garcia-Alvarez,1 R. Kiamco,1 M. Masotti,1 A. Betriu,1 1Cardiology - Thorax Institute, Hospital Clinic, Barcelona, Spain

(45) Decreased Incidence of Clinically Significant Allograft Rejection Following Simultaneous Heart-Kidney Versus Isolated Heart Transplantation; S.M. Brunelli,1,3 V.V. Chambers,1 P. Curry-Stutman,2 E. Kotloff,2 A.M. Doyle,2 1Division of Renal-Electrolyte and Hypertension, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; 2Division of Cardiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; 3Division of Cardiology/Department of Medicine, Drexel University College of Medicine, Philadelphia, PA

(46) Identification of Cardiac Allograft Rejection Using Raman Spectroscopy; S. Rassadi,1 C. Chang,2 D. Cao,1 *H.J. Eisen,3 1Department of Medicine, Drexel University College of Medicine, Philadelphia, PA; 2Department of Biomedical Engineering, Drexel University, Philadelphia, PA; 3Division of Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA

(47) Rate of Kidney Function Decline after Heart Transplantation; M. Chandavimol,1 O. Johnston,1 C. Rose,1 A. Cheung,1 A. Ignaszewski,1 J. Gill,1 1Cardiology, Nephrology, Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada

(48) Association of CMV Activation with Th1 Chemokines in Human Heart Transplant Recipients; N. Khan,1 J.E. Fildes,1 M. Al-Aloul,1 S. Patel,1 C.T. Leonard,1 N. Yonan,1 1The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

(49) A1, A2, or A3 Adenosine Receptor Activation Ameliorates Lung Ischemia Reperfusion Injury; L.M. Gazoni,1 C.G. Tribble,1 P.I. Ellman,1 V.E. Laubach,1 J. Linden,1 I.L. Kron,1 1Surgery, University of Virginia, Charlottesville, VA

(50) Cell Free Soluble Interleukin-2 Receptor Is Associated with Clinical Stability Following Heart Transplantation; J.E. Fildes,1 N.U. Khan,1 M. Al-Aloul,1 S.G. Williams,1 C.T. Leonard,1 N. Yonan,1 1The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

(51) Rapamycin and Its Influence on Arterial Vascular Function after Short-Term Incubation; M.T. Grapow,1 D.C. Reineke,1 H.R. Zerkowski,1 E. Müller-Schweinitzer,1 T. Carrel,1 1University of Basel, Cardio-Thoracic Surgery, Basel, Switzerland; 2University of Berne, Cardiovascular Surgery, Berne, Switzerland

(52) Non-Hypoxic Ischemia: An Accurate Cell Culture Model of Ischemia Reperfusion Injury in Lung Transplantation; M. Casiraghi,1 A. Mendoza,2 J. Blackwell,2 L. Watson,2 J.R. Tatreaux,3 M. Sevala,2 S.H. Randell,2 T.M. Egan,2 1Division of General Thoracic Surgery, University of North Carolina, Chapel Hill, NC; 2Division of Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA

(53) Selective Blockade of Canonical IκB Kinase Activity Attenuates Inflammatory Responses to Lung Ischemia Reperfusion Signals; H.J. Huang,1 N.A. Das,2 M. Okazaki,2 J.M. Lai,3 G.A. Patterson,2 A.S. Krupnick,2 D. Kreisel,2 A.E. Gelman,2 1Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC; 2Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC

(54) Differential Gene Expression in Human Endothelial Cells after Stimulation with sCD40L; D. Schuster,1 B. Molitor,1 B. Parviz,1 A. Weber,1 A. Barth,1 P. Harwaldt,1 H. Holschermann,1 H. Tillmanns,3 T.H.W. Stadlbauer,1 1Medicine, University of Giessen, Giessen, Germany

(55) FR167653 Ameliorates Expression of Proinflammatory Mediators in HUVEC and Human Monocytes; M. Schaub,1 P. Harwaldt,1 B. Parviz,1 A. Weber,1 A. Barth,1 H. Holschermann,1 H. Tillmanns,3 T.H.W. Stadlbauer,1 1Medicine, University of Giessen, Giessen, Germany

(56) Reduced Levels of Transplant Arteriosclerosis after Treatment with Clopidogrel (Plavix®) Are Associated with Reduced Graft-Infiltration with Dendritic Cells; S. Abele,1 M. Wollin,1 B. Spriewald,2 N.E. Hiemann,1 M. Ramsperger-Gleixner,1 M. Weyand,1 S.M. Brunelli,1 S.V. Chambers,1 P. Curry-Stutman,2 E. Kotloff,2 A.M. Doyle,2 1Division of Renal-Electrolyte and Hypertension, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; 2Division of Cardiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

(57) Modulation of Leukocyte Subpopulations, Activation Marker Expression and Impaired T Cell Function in Patients with Chronic Heart Failure; M.H. Konstandin,1 C. Lorenz,1 N. Sommer,2 C. Zugck,1 A. Remppis,1 G.H. Wabnitz,2 H.A. Katus,1 T.J. Dengler,1 1Cardiology, Universitätsklinik Heidelberg, Heidelberg, Germany; 2Institute for Immunology, Universitätshospital Mannheim, Mannheim, Germany

(58) Unmasking Networks to Identify Key Regulatory Modules during Rejection and Quiescence. A Systems Biology Approach to Heart Transplantation; M.C. Deng,1 A. Sinha,2 M. Cadeiras,3 M.P. Bayern,4 W. Lim,5 R. Dedrick,6 T. Klingler,7 C.C. Marboe,8 A. Califano,9 1College of Physicians and Surgeons, Columbia University, New York, NY; 2R&D, XDi. Inc., South San Francisco, CA
(59) Proteasome Dysfunction during Cold Ischemia and Reperfusion in a Murine Heart Transplantation Model; M. Majetschak, M.B. Patel, C. Liotta, S. Li, L.T. Busby, S.M. Pham, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL

(60) Apoptotic Cell Death Occurs during Accelerated Rejection in Sensitized Recipients of Cardiac Allografts; T.H.W. Stadlbauer, N. Dongowski, N. Pfuhl, P. Kranich, H. Tillmanns, M. Schaub, 1Medicine, University of Giessen, Giessen, Germany

(61) Recombinant Adenoviral Gene Transfer by Ex Vivo Perfusion Does Not Affect Cardiac Allograft Vasculopathy; V.P. Rao, S.E. Branzoli, D. Ricci, N. Miyagi, T. O'Brien, H.D. Tazelaar, S.J. Russell, C.G. McGregor, William J. von Leibig Transplant Center, Mayo Clinic, Rochester, MN; Department of Molecular Medicine, Mayo Clinic, Rochester, MN

(62) Tetrahydrobiopterin Improves Myocardial Protection during Cardioplegic Arrest; U.M. Fischer, B. De Santis, Y. Heppelmann, J.H. Fischer, U. Mehlhorn, W. Bloch, Department of Cardiac Surgery, University of Cologne, Cologne, Germany; Institute for Experimental Medicine, University of Cologne, Cologne, Germany; Institute for Molecular and Cellular Sports Medicine, German Sports Medicine, Cologne, Germany

(63) Autoresponse to Collagen V Is Associated with the Development of OB Following Lung Transplantation; R.E. Fawson, J.D. Smith, M.R. Carby, M.L. Rose, Transplant Immunology, Imperial College, Harefield Hospital, London, Middlesex, United Kingdom; Cardiothoracic Department, Harefield Hospital, Harefield, Middlesex, United Kingdom

(64) Balanced Matrix Metalloproteinase Inhibition: Refining a Therapeutic Strategy for Developing Established Fibrosis of Airway Obliteration; M. Sato, T. Ogura, G. D'Cruz, M. Anraku, M. Cypel, T.K. Waddell, M. Liu, S. Keshavjee, Thoracic Surgery Research Laboratory, Toronto General Research Institute, University Health Network, Toronto, ON, Canada

(65) The Role of Interleukin-15 in Cytomegalovirus Activation Following Heart Transplantation; K. Rogacev, J.E. Fildes, N.U. Khan, M. Al-Aloul, S.G. Williams, C.T. Leonard, N. Yonan, The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

(66) Significance of Endothelial CD26 in Acute Rejection after Orthotopic Single Lung Transplantation in the Rat; C. Riemer, S.V. Hoersten, Y. Li, C. Moerike, A. Haverich, Hannover Thoracic Transplant Program (Division of Thoracic- and Cardiovascular Surgery), Hannover Medical School, Hannover, Germany; Division of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany

(67) Comparison of Twenty Eight Key Circulating Immunologic Messengers in Heart Transplant Recipients Treated with Azathioprine vs Mycophenolate Mofetil; N.U. Khan, J.E. Fildes, M. Al-Aloul, S.G. Williams, C.T. Leonard, N. Yonan, The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

* (68) Stress-Induced Premature Senescence in Airway Epithelium and Accelerated Lung Allograft Aging; S.M. Parker, C. Ward, G. Johnson, F. Black, J.L. Lordan, P.A. Corris, G.C. Saretzki, A.J. Fisher, Applied Immunobiology and Transplantation Research Group, University of Newcastle upon Tyne, Newcastle, United Kingdom; Institute for Aging and Health, University of Newcastle upon Tyne, Newcastle, United Kingdom

(69) Expression of Ghrelin, a Novel Cardiovascular Hormone, and Its Peptide in the Myocardium of Patients Undergoing Heart Transplantation; A. Beiras-Fernandez, I. Kaczmarek, M. Schmoeckel, A. Beiras, C. Vicol, B. Reichart, Department of Cardiac Surgery, University Hospital Grosshadern; LM-University, Munich, Germany; Department of Morphological Sciences, University of Santiago de Compostela, Santiago, Spain

(70) Kinetics of Bronchial Epithelial Chimerism after Transplantation – A Sex Mis-Match Independent Method; B. Banerjee, A. Saxena, D. Ravine, E. Gabay, D. Chambers, Lung Transplant Unit, Royal Perth Hospital, Perth, Western Australia, Australia; Western Australian Institute for Medical Research, University of Western Australia, Perth, Western Australia, Australia; School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia

(71) Nonischemic Dilated Cardiomyopathy Upregulates Myocardial Vascular Endothelial Growth Factor; B.H. Munee, M. Montpetit, A.M. Samarel, S. Danzi, A.L. Heroux, Department of Cardiology, Loyola University Medical Center, Maywood, IL; Department of Medicine, North American Institute for Medical Research, University of Western Australia, Perth, Western Australia, Australia

(72) Mannose-Binding Lectin – Influence on Acute Graft Rejection Following Heart Transplantation; J.E. Fildes, M. McAlindon, A.H. Walker, C.T. Leonard, B. Keevil, N. Yonan, The Transplant Centre, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom; Department of Biochemistry, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom

(73) Serum Interleukin-12 Concentration Is Associated with Circulating Basophils Following Heart Transplantation; J.E. Fildes, N.U. Khan, M. Al-Aloul, S.G. Williams, C.T. Leonard, N. Yonan, The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

(74) Permanent Circulatory Assist Device Implantation Using Counterpulsation; V. Jeyavanandam, M. Chen, M. Myren, A. Anderson, A. Kantrowitz, J. Raman, Cardiothoracic Surgery, University of Chicago, Chicago, IL; LVAD Technologies, Detroit, MI

(75) Clinical Utility of the Levitronix® CentriMag™ in Extracorporeal Membrane Oxygenation for Severe Cardiogenic Shock; D.A. Chung, L. Kizner, M. Al-Deiri, L. Arusoglu, M. Morshuis, D. Roef, R. Koerfer, A. El-Banayosy, Heart and Lung Division, Wythenshawe Hospital, Manchester, Greater Manchester, United Kingdom; Herzzentrum, Herz-und Diabeteszentrum, Bad Oeynhausen, Nordrhein-Westfalen, Germany
(76) Pulsatile ECMO as Bridge to Recovery and Cardiac Transplantation in Pediatric Population: A Comparative Study; S. Agati,1 G. Ciccarello,2 D. Salvo,1 A. Undar,3 C. Mignosa,1 Pediatric Cardiac Surgery, San Vincenzo Hospital, Taormina, Messina, Italy; 2Perfusion Service, EPS, Taormina, Messina, Italy; 3Pediatrics, Surgery, and Bioengineering, Penn State College of Medicine, Hershey, PA

(77) Out of Hospital Treatment in Patients with a Total Artificial Heart; A. El-Banayossy,1 M. Morshuis,1 L. Arusoglu,1 L. Kizner,1 H. Kastning,1 D. Cobaugh,1 R. Koerfer,1 Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

(78) Safety and Feasibility of No cannula Cardiac Surgery in Patients with Ventricular Assist Device Support; J.D. McCue,1 S.J. Prabhu,2 A.G. Kolb,3 M. Colvin-Adams,4 A. Boyle,5 K. Liao,6 L. Miller,7 L. Joyce,7 R. John,3 Department of Surgery, University of Minnesota, Minneapolis, MN; 2University of Minnesota Medical School, University of Minnesota, Minneapolis, MN; 3Center for Cardiovascular Repair, University of Minnesota, Minneapolis, MN; 4Department of Cardioiology, University of Minnesota, Minneapolis, MN; 5Department of Thoracic and Cardiovascular Surgery, University of Minnesota, Minneapolis, MN; 6Department of Cardiology, Georgetown University, Washington, DC

(79) Left Ventricular Pressure Unloading with Continuous and Pulsatile Left Ventricular Assist Devices in Advanced Heart Failure Patients; M.S. Slaughter,1 M.A. Sobieski,1 G.M. Pantalos,2 G.A. Giridharam,2 R.D. Dowling,3 S. Prabhu,4 D.J. Farrar,5 S.C. Koenig,6 Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL; 2Bioengineering & Surgery, University of Louisville, Louisville, KY; 6Medicine, University of Louisville, Louisville, KY; 4Thoratec Corporation, Pleasanton, CA

(80) Real-Time Hepatic Venous Saturation: Is It a Sensitive Indicator of Hemodynamic Compromise?; Y. Wadia,1 R.M. Delgado, III,2 B. Kar,2 I. Gregorio,1 O.H. Frazier, 3Cardiovascular Surgery and Transplant Research, Texas Heart Institute, Houston, TX; 3Mechanical Support Devices for Heart Failure, Texas Heart Institute, Houston, TX; 3Cardiopulmonary Transplantation, Texas Heart Institute, Houston, TX

(81) Bridge to Decision with Levitronix® Centrimag® Short-Term Ventricular Assist Device; F. De Robertis,1 E.J. Birks,2 P. Rogers,2 M. Petrou,3 M. Amrani,4 J.R. Pepper,1 A. Khaghani,1 G. Dreyfus,1 Cardiothoracic Surgery, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom; 4Cardiology, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom

* (82) Evolving Use of Left Ventricular (LVAD) vs Biventricular (BiVAD) Assist Devices; D. Nguyen,1 J. Bhma,1 C. Bermudez,1 Y. Toyoda,1 J. Teuteberg,1 M. Simon,1 K. McCurry,2 R. Kormos,3 Heart Lung and Esophageal Institute, University of Pittsburgh, Pittsburgh, PA; 3Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA

(83) Outcomes of Female Heart Transplant Recipients Bridged to Transplantation with a Ventricular Assist Device: D. Magyar,1 N.G. Smedira,2 K.J. Hoercher,2 J.L. Navia,1 T. Mihaljevic,1 D.O. Taylor,2 R.C. Starling,2 G.V. Gonzalez-Stawinski,2 School of Medicine, Case Western University, Cleveland, OH; 3Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH

(84) Preoperative Variables That Predict Postoperative Course and May Aide Timing of LVAD Implantation; S. Haj-Yahia,1,2 G. Tasca,1 M. Amrani,1 M. Petrou,1 N. Banner,1 J. Pepper,1 G. Dreyfus,1 A. Khaghani,1 E.J. Birks,1 Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; 2NHLI, Imperial College for Thechnology, science and Medicine, London, United Kingdom

* (85) Use of the Total Artificial Heart for Salvage of Patients with Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction; M.J. Slepian,1 R.G. Smith,1 P.E. Nolan,1 D. McClellan,1 P. Tsau,1 R. Bose,1 G. Sethi,1 J.G. Copeland,1 Sarver Heart Center, University of Arizona, Tucson, AZ

(86) New Generation Axial-Flow Left-Ventricular Assist Device Supports Patients with Various Degrees of Right Ventricular Dysfunction; G.V. Moukarbel,1 S. Ennis,2 S.A. Moore,3 T.E. MacGillivray,3 Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; 2Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA

(87) Ischemic Cardiomyopathy Independently Predicts Higher Mortality after Ventricular Assist Device Implantation; M.A. Simon,1 A. Shah,1 D. Nguyen,1 J. Bhma,1 C. Bermudez,1 Y. Toyoda,1 J. Teuteberg,1 K. McCurry,2 R. Kormos,2 Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; 3Heart Lung and Esophageal Institute, University of Pittsburgh, Pittsburgh, PA

(88) Significance of Anemia in Patients Undergoing Long-Term LVAD Support; B. Vrtovec,1 R. Radovancevic,1 R.M. Delgado, B. Radovancevic, A.W. Bracey, J.D. Gregorio, O.H. Frazier, Ljubljana University Medical Center, Ljubljana, Slovenia; Center for Cardiac Support, Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston, TX

(89) Systemic Vascular Input Impedance in Humans, Calves, and Pigs: Clinical Implications with Medical Devices and Xenotransplantation; S.C. Koenig,1 G.A. Giridharam,1 C. Ionan,1 G.M. Pantalos,1 R.D. Dowling,1 S. Prabhu,2 M.A. Sobieski,1 M.S. Slaughter,1 Bioengineering & Surgery, University of Louisville, Louisville, KY; 3Medicine, University of Louisville, Louisville, KY; 2Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL

(90) The Impact of Different LVADs on Rejections Pattern Post Cardiac Transplant; S. Kiotz,1 H. Welp,1 J. Stypmann,2 C. Schmid,1 A. Rukosujej,1 H.H. Scheld,1 Department of Thoracic- and Cardiovascular Surgery, University Hospial Muenster, Muenster, Germany; 2Department of Cardiology and Angiology, University Hospial Muenster, Muenster, Germany

* (91) Progress and Initial In-Vivo Experience of the Pediatric Jarvik 2000 Hearts; Z.J. Wu,1 A. Kilic,1 J. Zhang,1 G.W. Burgreen,2 G. Cheng,1 G.K. Yankey,1 T. Li,1 R. Jarvik,3 B.P. Griffith,1 Surgery, University of Maryland, Baltimore, MD; 3Computational Simulation and Design Center, Mississippi State University, Starkville, MS; 3Jarvik Heart, Inc., New York, NY

Cardiothoracic Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI; Heart Failure and Transplant Cardiology, University of Wisconsin School of Medicine and Public Health, Madison, WI

Increased Number of Circulating Progenitor Cells Following Implantation of Ventricular Assist Devices; A. Manginas, G. Giannouzis, A. Tsaiou, P. Sfikaikis, L. Tsourelis, E. Leontiadis, D. Degiannis, P.A. Alivizatos, D.V. Kokkinos, 1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; 1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; External Partner, Onassis Cardiac Surgery Center, Athens, Greece; 1st Cardiothoracic and Transplantation Services, Onassis Cardiac Surgery Center, Athens, Greece; 1st Cardiothoracic and Transplantation Services, Onassis Cardiac Surgery Center, Athens, Greece; 1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; Immuno-pathology & Histocompatibility Lab., Onassis Cardiac Surgery Center, Athens, Greece; 1st Cardiothoracic and Transplantation Services, Onassis Cardiac Surgery Center, Athens, Greece; 1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece

* (94) Diminished Left Ventricular Contractility Overtime during LVAD Support in Ischemic Heart Failure; P.I. McConnell, C.L. Del Rio, P. Kwiatkowski, D.J. Farrar, B.C. Sun, Cardiothoracic Surgery, The Ohio State University, Columbus, OH; Thoratec Corp, Pleasanton, CA

Effectiveness of Miniaturised Axial Flow Pumps (AFP) Compared to Large Pulsatile VADs in Rescuing the Endstage Heart Failure Patient; S. Haj-Yahia, G. Tasca, H. Taghipour, M. Petrou, M. Amrani, J. Pepper, G. Dreyfus, E.J. Birks, A. Khaghan, Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospital, London, United Kingdom; National Heart & Lung Institute, Imperial College for Science, Technology & Medicine, London, United Kingdom

Bridge-to-Transplant Experiences in Patients with Cardiogenic Shock after Acute Myocardial Infarction; S. Schenk, M. Morshuis, L. Arusoglu, G. Tenderich, R. Koerfer, A. El-Banayosy, Thoracic and Cardiovascular Surgery, Heart Center NRW, Bad Oeynhausen, Germany

The Impact of New Mechanical Circulatory Support Technology on Post-Operative Recovery and Length of Hospital Stay; S. Ennis, G.V. Moukarbel, S.A. Moore, C. Ennis, T.E. MacGillivray, Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Long Term Support with Continuous Flow LVAD: Effect of Reduced Pulsatility on Renal Function; M.S. Slaughter, M.A. Sobieski, C. Gallagher, M. Dia, M.A. Silver, Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL; Cardiovascular Research, Cardiac Surgery Clinical Research Center, Inc, Oak Lawn, IL; Cardiology, Advocate Christ Medical Center, Oak Lawn, IL

Is Native Cardiovascular Recovery Sustained Following Successful Ventricular Assist Device Support in Cardiogenic Shock Post Acute Myocardial Infarction?: M. Anderson, N. Madani, Y. Naka, D. Raess, L. Samuels, B. Sun, Department of Cardiac Surgery, Robert Wood Johnson, New Brunswick, NJ; Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA; Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; Department of Cardiothoracic Surgery, St. Francis Hospital, Indianapolis, IN; Department of Cardiothoracic Surgery, Lankenau Medical Science Hospital, Philadelphia, PA; Department of Cardiothoracic Surgery, Ohio State University Medical Center, Columbus, OH

Clinical Experience with the AB5000 as a Bridge-to-Transplant VAD: Successful Cross-Over for Extended Bridge-to-Recovery Patients; J. Elefteriades, N. Madani, A.J. Crumbley, D. Adams, M. Anderson, Department of Cardiothoracic Surgery, Yale University Medical Center, New Haven, CT; Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA; Cardiovascular Surgery, Medical University of South Carolina, Charleston, SC; Department of Thoracic Surgery, Mount Sinai Medical Center, New York, NY

Are Bridge to Recovery Patients Sick Enough to Require Ventricular Assist Device in Refractory Acute Myocardial Infarction Cardiogenic Shock?: Benchmark Against the SHOCK Trial; M. Anderson, M. Madani, Y. Naka, D. Raess, L. Samuels, B. Sun, Department of Cardiac Surgery, Robert Wood Johnson, New Brunswick, NJ; Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA; Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; Department of Cardiothoracic Surgery, St. Francis Hospital, Indianapolis, IN; Department of Cardiothoracic Surgery, Lankenau Medical Science Hospital, Philadelphia, PA; Department of Cardiothoracic Surgery, Ohio State University Medical Center, Columbus, OH; New England Research Institute, Watertown, MA

Omega-3 Fatty Acids Cause Blood Cells to Become Insensitive to Mechanical Stress in Patients with Cardiac Assist Devices; J. Mueller, M. Brodde, K. Brandes, P. Goettel, B. Kehrel, Hematology, University of Muenster, Muenster, Germany; Research and Development, Berlin Heart, Berlin, Germany

Improved Clinical Results with the Redesigned MicroMed DeBakey VAD; M. Loebe, G.P. Noon, R. Benkowski, P. Gruber, T. Richards, MicroMed Inc., Houston, TX

CCR4, CCR5, CCR6 and CCR7 Expression on BAL Lymphocytes and Macrophages of Patients with Bronchiolitis Obliterans Syndrome (BOS); F. Meloni, M. Morosini, S. Miserere, C. Pellegrini, A.M. Fietta, Department Haematol Pneumol Cardiovasc Sc - Sect Pneumology, University of Pavia & Pol San Matteo, Pavia, Italy; Department Cardiac Surgery, Pol San Matteo, Pavia, Italy

Elevation of Serum KL-6 Can Predict Development of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients; O. Elidemir, M.L. Doan, M.G. Schecter, E.D. McKenzie, J.S. Heinle, H. Seetharam, M.B. Mallory, Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; Medicine, Baylor College of Medicine, Houston, TX

Serum KL-6 during Acute Rejection Episodes after Lung Transplantation; O. Elidemir, M.L. Doan, M.G. Schecter, E.D. McKenzie, J.S. Heinle, H. Seetharam, M.B. Mallory, Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; Medicine, Baylor College of Medicine, Houston, TX
(107) Risk Factors for Primary Graft Dysfunction after Lung Transplantation; C. Van De Wauwer, 1 D.E.M. Van Raemdonck, 1 W. Coosemans, 1 G. Decker, 1 P. De Leyn, 1 L. Dupont, 2 P.H Nafteleu, 1 G.M. Verleden, 1 T. Lerut, 1 Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium; 2Department of Pulmonary Medicine, UZ Leuven, Leuven, Belgium

(108) Assessment of Toll-Like Receptors and Cytokines Within Lung Transplant Patients for Predictors of Infection and Graft Rejection; K.N. Taylor, E. Coehick, Y.L. Colson Department of Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA; Department of Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA; Department of Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA

(109) Postoperative Swallowing Disorders Are Associated with Increased Mortality after Lung Transplantation; B.Z. Atkins, 1 M. Trachtenberg, 2 K.R. Balsara, 1 G. Vess, 2 R.D. Davis, 1 Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, NC; 2Speech Pathology and Audiology, Duke University School of Medicine, Durham, NC

(110) Early Re-Admission Is a Predictor of Survival Following Isolated Lung Transplantation; F. Lamounier, 4 S. Bhorade, 2 E. Garrity, 2 C. Alex, 1 M. Hellenowski, 1 K. Pelletier, 1 W.T. Vigneswaran, 1 Surgery, University of Chicago, Chicago, IL; 2Medicine, University of Chicago, Chicago, IL; 3Medicine, Loyola University Medical Center, Maywood, IL; 4Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

(111) Predictors of Independent Lung Ventilation – An Analysis of 170 Single Lung Transplants; D.V. Pilcher, 1 G.M. Auzinger, 1 B. Mitra, 1 D.V. Tuxen, 1 R.F. Salamonsen, 1 A.R. Davies, 1 T.J. Williams, 1 G.I. Snell, 1 Department of Intensive Care Medicine, The Alfred Hospital, Melbourne, Victoria, Australia; 2Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia

(112) Symptom Experience Associated with Side Effects of Immunosuppressive Therapy in Lung Transplant Recipients; D.S. Bosscher, 1 O.H. Bosma, 1 P. Moons, 2 E.A.M. Verschuuren, 1 W. van der Bij, 1 Pulmonary Diseases, University Medical Centre Groningen, Groningen, Netherlands; 2Centre for Health Services and Nursing Research, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium

(113) Refractory Severe Complications of Lung Transplantation: Safety and Efficacy of Hyperbaric Oxygen Therapy; T. Higuchi, 1 T. Oto, 1 B.J. Levvey, 1 T.J. Williams, 1 L. Millar, 2 G.I. Snell, 1 Lung Transplant Service, Alfred Hospital & Monash University, Melbourne, Victoria, Australia; 2Department of Intensive Care & Hyperbaric Medicine, Alfred Hospital, Melbourne, Victoria, Australia

(114) Prolonged Postoperative Mechanical Ventilation of More Than Twenty-Four Hours (PPMV) Following Lung Transplantation: Incidence, Indications and Outcomes; C.K. Choong, 2 1,2 L.D. Sharples, 1 J.S. Parmar, 1 P.R. Sivasothy, 1 H. Castle, 1 J. Wallwork, 1 2 Transplant Unit, Papworth Hospital NHS Trust, Cambridge, England, United Kingdom; 2Department of Surgery, University of Cambridge, Cambridge, England, United Kingdom

(115) Aprotinin Use and Primary Allograft Dysfunction Following Off-Pump Bilateral Orthotopic Lung Transplantation; K.R. Balsara, 1 S.T. Morozowich, 1 E.L. Bush, 1 B. Phillips-Bute, 2 M. Hill, 2 R.D. Davis, 1 S.S. Lin, 1 1,2 L.J. Welsby, 1 Department of Surgery, Duke University Medical Center, Durham, NC; 1Division of Cardiothoracic Anesthesia and Critical Care, Duke University Medical Center, Durham, NC; 2Department of Immunology, Duke University Medical Center, Durham, NC

(116) Lung Malignancy Incidence Following Lung Transplantation; S. Evman, 2 A. Machaal, 1 N. Khasati, 1 C. Leonard, 1 N. Yonan, 1 Transplant Unit/Cardiothoracic Surgery Department, Wythenshawe Hospital, Manchester, United Kingdom; 2Thoracic Surgery, Marmara University Hospital, Istanbul, Turkey

(117) Antiviral Prophylaxis May Decrease Incidence of Post-Transplant Lymphoproliferative Disorder (PTLD) after Lung Transplantation; L.E. Leard, 1 J.D. Obata, 1 S.R. Hays, 1 C. Hoopes, 2 J.A. Golden, 1 Division of Pulmonary Medicine, University of California San Francisco, San Francisco, CA; 1Division of Cardiothoracic Surgery, Department of Surgery, University of California San Francisco, San Francisco, CA

(118) Specific Pattern of Serum HGF and Broncho-Alveolar Lavage MMP-9 in Acute and Chronic Lung Transplant Rejection; K. Krein, 1,2 S. Taghavi, 2 P. Jaksch, 2 W. Klepetko, 2 S. Aharinejad, 1 Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria; 2Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria

(119) Painful Sensory Neuropathy Induced by Voriconazole in Transplanted Patients; V. Boussaud, 1 N. Daudet, 2 R. Guillemain, 1 E. Billaud, 2 C. Le Beller, 2 P. Chevalier, 2 C. Amrein, 2 M. Berger, 2 R. Soulamas, 4 A. Lillo-Le Louet, 2 Cardiovascular Surgery, Hopital Européen Georges Pompidou, APHP, Paris, France; Pharmacovigilance, Hopital Européen Georges Pompidou, APHP, Paris, France; Pharmacology, Hopital Européen Georges Pompidou, APHP, Paris, France; Thoracic Surgery, Hopital Européen Georges Pompidou, APHP, Paris, France

(120) Elevated Levels of Pepsin in BALF of Lung Transplant Recipients with and without Allograft Dysfunction: Is Gastric Aspiration Important in the Development of BOS?. K. Blondeau, 1 V. Mertens, 2 B.M. Vanaudenaerde, 2 D.E. Van Raemdonck, 2 G.M. Verleden, 2 D. Sifrim, 1 L.J. Dupont, 1 Center for Gastroenterological Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

7:15 PM – 8:15 PM
General Poster Session 1 Removal (Continental Ballroom)
Mini Oral Sessions 1 - 4 Poster Mounting (Yosemite Ballroom)

7:30 PM – 8:00 PM
Bus Departure for Gala Reception (?????)
8:00 PM – 10:00 PM
GALA RECEPTION (City Hall)

THURSDAY, APRIL 26, 2007

24 Hours
Internet Café Open (Continental Ballroom Foyer)

6:00 AM – 6:00 PM
Registration Desk Open (West Foyer)

6:00 AM – 7:45 PM
Slide Ready Room Open (Green Room)

7:00 AM – 8:00 AM
Mini Oral Sessions 1-4 Poster Mounting (Yosemite Ballroom)

7:00 AM – 9:00 AM
General Poster Session 2 Mounting (Continental Ballroom)

7:00 AM – 6:00 PM
Press Office Open (Executive Boardroom)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 1
Immunobiology for Clinicians: Basic Biology (Imperial Ballroom A)
Chairs: Dianne McKay, MD and James S. Allan, MD

*7:00 AM Overview of Innate Immunity, Scott M. Palmer, MD, Duke University, Durham, NC
7:30 AM Overview of Adaptive Immunity, Thomas K. Waddell, MD, Toronto General Hospital, Toronto, ON, Canada

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 2
State of the Art Management Options for Bronchiolitis Obiterans (Imperial Ballroom B)
*Chairs: *Selim M. Arcasoy, MD and *Jonathan B. Orens, MD

*7:00 AM Novel Immune Therapies, Selim M. Arcasoy, MD, Columbia University, New York, NY
7:30 AM Non-Immune Therapies, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 3
Fungal Disease: New Diagnostics, New Treatments (Plaza Ballroom A)
*Chairs: *Bernard M. Kubak, MD, PhD and Robin Avery, MD

*7:00 AM Tests for Diagnosis and Disease Management, Shahid Husain, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
7:20 AM The Azoles – Important Options, Especially for Oral Therapy, Jose G. Montoya, MD, Stanford University, Stanford, CA
*7:40 AM The Echinocandins – A Wealth of Choice, Aimee K. Zaas, MD, Duke University Medical Center, Durham, NC

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 4
Management Issues with Continuous Flow Devices (Plaza Ballroom B)
*Chairs: *Nader Moazami, MD and *Yoshifumi Naka, MD, PhD

*7:00 AM Operative Issues, Carmelo Milano, MD, Duke University Medical Center, Durham, NC
*7:20 AM Setting Flow Rate, Stuart D. Russell, MD, John’s Hopkins Hospital, Baltimore, MD
7:40 AM Anticoagulation, Mark S. Slaughter, MD, Advocate Christ Medical Center, Oak Lawn, IL

8:00 AM – 6:45 PM
Mini Oral Sessions 1-4 Poster Viewing (Yosemite Ballroom)

8:15 AM – 10:15 AM
PLENARY SESSION (Grand Ballroom B)
Chairs: Stephan Schueler, MD, PhD, FRCS and Mark L. Barr, MD

8:15 AM INTERMACS Report, James K. Kirklin, MD, University of Alabama, Birmingham, AL
8:30 AM Report on the Summit on Mechanical Support for Advanced Heart Failure, Robert C. Robbins, MD, Stanford University Medical Center, Palo Alto, CA
9:00 AM HeartMate II Trial, Frances D. Pagani, MD, PhD, University of Michigan Hospital, Ann Arbor, MI

9:15 AM Update on the Revised Working Formulation for the Diagnosis of Lung Transplant Rejection, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

*9:35 AM Immunobiology of the B Cell, Lori West, MD, D.Phil, University of Alberta, Edmonton, AB, Canada

*9:55 AM ABCs of HLA and non-HLA Antibodies in Transplantation, Howard M. Gebel, PhD, Emory University Hospital, Atlanta, GA

9:30 AM – 6:45 PM
Exhibit Hall Open (Continental Ballroom)

General Poster Session 2 Poster Viewing (Continental Ballroom)

10:15 AM – 10:45 AM
Coffee Break/Poster Viewing (Continental Ballroom)

10:45 AM – 12:15 PM
CONCURRENT SESSION 7
Management Issues During Mechanical Circulatory Support (Grand Ballroom B)

*Chairs: H. Todd Massey, MD and *George M. Wiesenthaler, MD

10:45 AM (122) Is VAD Therapy Coming of Age? Perspectives from a 10 Year History of 200 Patients and 100 Patient-Years of Support; Y. Suzuki, J. Haft, D.B. Dyke, K.D. Aaronson, S. Wright, F.D. Pagani, J.C. Woodard, S. Rosenberg, K.D. Aaronson, 1Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI; 2Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI

11:00 AM Invited Lecture: The Role of INTERMACS in Capturing Adverse Events After Mechanical Circulatory Support Therapy, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

11:15 AM (123) Survival and Weight Loss in the Obese Patient after the Implantation of Ventricular Assist Devices; J.J. Teuteberg, S. Weaver, E. Stanford, M. Simon, D. McNamara, Y. Toyoda, C. Bermudez, K. McCurry, R. Kormos, Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; Cardiovascular Surgery, University of Pittsburgh, Pittsburgh, PA

11:30 AM (124) Preoperative Risk Assessment for Right Ventricular Failure Following Implantation of a Left Ventricular Assist Device; L.C. Matthews, F.D. Pagani, K.D. Aaronson, Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI; Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI

*11:45 AM (125) Treatment of HLA Sensitized Pre-Transplant Patients with Mechanical Support Is Effective for PRA Reduction; P.C. Patel, C.L. Fitzsimmons, P.A. Kaiser, P. Stastny, J.M. DiMaio, W.S. Ring, C.W. Yance, M.H. Drazner, D.M. Meyer, D.W. Markham, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX; Division of Cardiothoracic Surgery, UT Southwestern Medical Center, Dallas, TX; Department of Transplantation Immunology, UT Southwestern Medical Center, Dallas, TX

Noon (126) Left Ventricular Assist Device Exchange – Indications and Outcomes; R. Johnson, K. Liao, K. Lietz, M. Colvin-Adams, A. Boyle, L. Miller, L. Joyce, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; Division of Cardiology, University of Minnesota, Minneapolis, MN

11:45 AM – 12:15 PM
CONCURRENT SESSION 8
Find and Fight Rejection (Grand Ballroom A)

*Chairs: Randall C. Starling, MD and Andre R. Simon, MD

10:45 AM (127) Monitoring of Cell-Mediated Immunity during Immunosuppression Reduction in Heart Transplant Patients with Systemic Infections: An Objective Measurement; M.W. Weston, D. Rinde-Hoffman, M. Lopez-Cepero, L. DiChiara, LifeLink HealthCare Institute, Tampa, FL; Immunology, LifeLink Immunology Laboratory, Tampa, FL; Cardiology, Tampa General Hospital, Tampa, FL

*11:00 AM (128) Novel Immunosuppressive Strategies: Using a Molecular Diagnostic Assay for Weaning of Immunosuppressive Agents; K. Albright, T. Rowe, S.R. Hankins, H.J. Eisen, Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA; Division of Cardiology/Department of Medicine, Drexel University College of Medicine, Philadelphia, PA


11:30 AM (130) HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation; Q. Zhang, K. Si, P. Ge, G. Wu, J.K. Patel, A. Kfoury, M.C. Fishbein, E.F. Reed, Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA; Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

*11:45 AM (131) Gene Expression and Prediction of Early Cardiac Allograft Rejection: Discovery of a Gene-Based Corticosteroid Efficacy Measure; M.R. Mehra, R.C. Starling, P.G. Lal, R.G. Woodward, R.L. Dedrick, S. Rosenberg, Medicine, University of Maryland Medical Center, Baltimore, MD; Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH; Research and Development, XDx, South San Francisco, CA
NOON (132) TGF-β Polymorphisms, Gender and Age and Their Effect on Acute Cardiac Rejection; D.M. Pekarek,1 J.A. Barchue,2 H.E. Grenett,2 J.A. Tallaj,2 R.C. Bourge,2 J.A. Kirklin,4 B.K. Rayburn,2 C.S. Coffey,2 R.L. Benza;2 Genetics, University of Alabama at Birmingham, Birmingham, AL; 2Medicine/Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; 4Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 2Surgery, University of Alabama at Birmingham, Birmingham, AL

10:45 AM – 12:15 PM
CONCURRENT SESSION 9
Clinical and Immunological Predictors of BOS (Imperial Ballroom A)
*Chairs: *Bryan F. Meyers, MD and *Andrew J. Fisher, MRCP, PhD

*10:45 AM (133) Severity of Lymphocytic Bronchiolitis Predicts Long Term Outcome after Lung Transplantation; A.R. Glanville,1 C.L. Aboyoun,1 J. Ahrvyk,1 M. Pit,1 S. Rainer,1 M.A. Malouf,2 Lung Transplant Unit, St. Vincent’s Hospital, Sydney, NSW, Australia

11:00 AM (134) Impact of Airway Colonization with Gram-Negative Bacteria on Development of Bronchiolitis-Obliterans-Syndrome in Lung Transplant Recipients with Cystic Fibrosis; J. Gottlieb,1 F. Mattner,2 H. Weissbrodt,2 M. Dierich,3 A. Simon,3 M. Strueber,3 T. Welte,1 Pulmonary Medicine, Hannover Thoracic Transplant Program, Hannover, Germany; 2Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; 3Thoracic and Cardiovascular Surgery, Hannover Thoracic Transplant Program, Hannover, Germany

11:15 AM (135) Donor Glutathione-S-Transferase (GST) mu Null Genotype in Lung Transplant Recipients Is Associated with Increased Rates of Bronchiolitis Obliterans Syndrome (BOS) Independent of Acute Rejection; D. Hadijadi,1 R. Lingaraju,1 J. Mendez,1 A. Pochevito,2 V.N. Ahya,1 J.S. Sager,1 R.M. Kodoff,2 J.D. Christie,1 Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

*11:30 AM (136) Low Rate of Bronchiolitis Obliterans Syndrome Following Pre-Emptive Treatment of Post-Transplant Lymphoproliferative Disease after Lung Transplantation; E.A.M. Verschuuren,1 M.E. Erasmus,2 B.G. Hepkema,1 N. Veeger,2 C.G.M. Kallenberg,1 W. van der Bij,1 Pulmonary Diseases, University Medical Center, Groningen, Netherlands; 2Cardio-Thoracic Surgery, University Medical Center, Groningen, Netherlands; 1University Medical Center, Groningen, Netherlands; 3Clinical Epidemiology, University Medical Center, Groningen, Netherlands; 2Clinical Immunology, University Medical Center, Groningen, Netherlands

11:45 AM (137) Pre-Transplant MICA, HLA Class I or II Antibodies Are Associated with Earlier Onset of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipient; D.M. Lyu,1 M. Nicolls,1 B. Freed,1 L. Cagle,1 M.R. Zamora,1 Medicine, University of Colorado Health Sciences Center, Denver, CO

*NOON (138) Impact of Primary Graft Dysfunction on Bronchiolitis Obliterans Syndrome after Lung Transplantation; R.R. Hachem,1 R.D. Yusen,1 G.A. Patterson,1 E.P. Trulock,1 Lung Transplant Program, Washington University School of Medicine, St. Louis, MO

10:45 AM – 12:15 PM
CONCURRENT SESSION 10
Improving the Donor Lung (Imperial Ballroom B)
Chairs: Michael S. Mulligan, MD and Michel Erasmus, MD, PhD

10:45 AM (139) Fibrinolytic Treatment Improves the Quality of Lungs Retrieved from Non-Heart-Beating Donors; J. Inci,1 W. Zhai,1 S. Arni,1 D. Inci,2 S. Hillinger,1 D. Lardinois,1 W. Weder,1 Department of Thoracic Surgery, University Hospital, Zurich, Switzerland; 2Department of Pediatrics, University Children Hospital, Zurich, Switzerland

11:00 AM (140) Lung Transplantation from Deceased Donors without Pretreatment; T.A. Butt,1 J.D. Aitchison,1 P.A. Corris,1 J. Wardle,1 S. Clark,1 J.H. Dark,1 Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; 2Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; 1Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; 1Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; 1Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:15 AM (141) Inhibition of Poly (ADP-Ribose) Polymerase Improves Endothelial and Myocardial Function after Brain Death; G. Szabó,1 U. Hegedüs,1 C. Michel-Görschel,1 C. Szabó,2 S. Hagt,1 S. Bährle,1 Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 1Cellscreen Applied Research Center, Semmelweis University, Budapest, Hungary

11:30 AM (142) Resuscitation of the Brain Dead Organ Donor with Arginine Vasopressin (AVP) – An Alternative Vasoconstrictor; A.J. Rostron,1 V.S. Avlonitis,1 D.M.W. Cork,1 D.S. Grenade,1 J.A. Kirby,1 J.H. Dark,1 School of Surgical and Reproductive Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom

11:45 AM (143) Azithromycin Reduces Inflammation in a Murine Lung Ischemia-Reperfusion Injury Model; N. Geudens,1 L. Timmermans,1 B.M. Vanaudenaere,1 C. Van De Wauwer,1 T. Lerut,1 E. Verbeke,3 G.M. Verleden,2 D.E.M. Van Raemdonck,1 Experimental Thoracic Surgery, Katholieke Universiteit, Leuven, Belgium; 2Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; 3Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium; 1Department of Pathology, University Hospital Gasthuisberg, Leuven, Belgium

NOON (144) A New Concept of Reconditioning Predamaged Donor Lungs in an Ex-Vivo Reperfusion Pig Model; S.H. Wipper,1 J. Schirmer,1 B. Martens,1 A. Lebatschi,1 H.C. Reichenspurner,1 F.M. Wagner,1 Cardiovascular Surgery, University Heart Center, Hamburg, Germany

10:45 AM – 12:15 PM
CONCURRENT SESSION 11
Transplant Transmission Infections: Risk and Outcomes (Plaza Ballroom A)
*Chairs: *Barbara D. Alexander, MD and *Shahid Husain, MD

*10:45 AM Respiratory and Vector Borne Viruses, Atul Humar, MD, MSC, FRCP, University of Toronto, Toronto, ON, Canada

11:10 AM Chagas Disease: An Increasing Threat, Edimar A. Bocchi, MD, University of Sao Paulo, Sao Paulo, Brazil
11:35 AM Hepatitis C, Robin Avery, MD, The Cleveland Clinic, Cleveland, OH

NOON Discussion

10:45 AM – 12:15 PM
CONCURRENT SESSION 12
Mechanisms of Allograft Vasculopathy (Plaza Ballroom B)

Chairs: Roel A. de Weger, PhD and Vivek Rao, MD, PhD

10:45 AM (145) A Synthetic Retinoid, Am80, Suppresses IL-6 Expression, and Inhibits Both Acute Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation; Y. Ogawa, T. Shindo, I. Manabe, J. Suzuki, M. Isobe, R. Nagai, Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Department of Organ Regeneration, Graduate School of Medicine, Shinshu University, Matsumoto-shi, Nagano, Japan; Department of Cardiovascular Medicine, Graduate School of Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

11:00 AM (146) IFN-γ Production by Graft Antigen Specific CD4+ T Cells Is Not Required for the Development of Intimal Hyperplasia; S.J. Huddleston, W.S. Hays, E. Ingulli, M.K. Jenkins, Department of Surgery, University of Minnesota, Minneapolis, MN; Department of Pediatrics, University of Minnesota, Minneapolis, MN; Department of Microbiology, Center for Immunology, University of Minnesota, Minneapolis, MN

11:15 AM (147) Airway Wall Endothelin-1 (ET-1) Expression Is Increased Prior to the Development of BOS in Lung Transplant Recipients; L. Zheng, G.I. Snell, K. Kotsimbos, B. Levvey, G. Westall, H.M. Whitford, T.J. Williams, Department of Medicine, Monash Medical School, Monash University, Prahran, Vic, Australia; Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Monash University, Melbourne, Vic, Australia

11:30 AM (148) The IL-23/IL-17 Axis in Human Cardiac Allograft Vasculopathy; J. van Kuik, E. de Koning, D.F. van Wichelen, M.F.M. van Oosterhout, F.H.J. Gmelig-Meyling, N. de Jonge, R.A. de Weger, Pathology, University Medical Center, Utrecht, Netherlands; Immunology, University Medical Center, Utrecht, Netherlands; Heart Lung Center, University Medical Center, Utrecht, Netherlands

11:45 AM (149) Cytochrome p450 (CYP) 2C Contributes to Cardiac Allograft Vasculopathy; A.L. Hunter, A. Kerjner, K.J. Mueller, B.M. McManus, D.J. Granville, James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, BC, Canada

NOON (150) Increased Levels of Transplant Arteriosclerosis in the Absence of CCR7 Are Associated with Reduced Expression of Foxp3; S.M. Ensminger, S. Helm, L. Ohi, B. Spriewald, M. Weyand, R. Foerster, Cardiothoracic Surgery, University of Erlangen-Nuernberg, Erlangen, Bavaria, Germany; Institute for Immunology, Medizinische Hochschule Hannover, Hannover, Lower Saxony, Germany; Medicine III, University of Erlangen-Nuernberg, Erlangen, Bavaria, Germany

12:15 PM – 12:30 PM
Box Lunch Pick-up (ticket required) (Yosemite Ballroom)

12:30 PM – 2:00 PM
LUNCHEON SYMPOSIUM
Emerging Issues In Immunosuppression and Antiviral Therapy In Heart and Lung Transplantation (Grand Ballroom B)
Supported by an Unrestricted Educational Grant from Roche

*Chairs: Axel Haverich, MD and Barbara D. Alexander, MD

*12:30 PM A) Has Modern Immunosuppression Altered Long Term Outcomes After Heart and Lung Transplantation? Hermann Reichenspurner, MD, PhD, University of Hamburg, Hamburg, Germany

1:00 PM Discussion

*1:10 PM B) Striking an Optimal Balance Between CMV Prophylaxis and Emergence of Resistance

*1:10 PM Optimal Prophylaxis: Balancing Prevention with Resistance, Scott M. Palmer, MD, Duke University Medical Center, Durham, NC

1:25 PM Ganciclovir Resistance: Management Strategies, Sunwen Chou, MD, Oregon Health and Science University, Portland, OR

1:40 PM Viral Related Causes of Rejection and Graft Failure, Jeffrey A. Towbin, MD, Texas Children’s Hospital, Houston, TX

1:55 PM Discussion

12:30 PM – 2:00 PM
FELLOWS LUNCHEON (ticket required) (Union Square 15/16)

Chairs: Robert C. Robbins, MD and Paul A. Corris, MB, FRCP

12:30 PM – 2:00 PM
JHLT Editorial Board Meeting (Union Square 19/20)

12:30 PM – 2:00 PM
International Thoracic Transplant Registry Meeting (Union Square 23/24)

12:30 PM – 2:00 PM
MINI ORAL SESSION 1 (Imperial Ballroom A)

*Chairs: Gregory I. Snell, FRACP, MBBS and Annette Boehler, MD
1:45 PM (181) Pre-Existing Neoplasms and Risk for Malignancy after Heart Transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry; J.F. Delgado,1 M.G. Crespo,2 L.A. Pulpon,3 J.M. Arizón,4 L. Almenar,5 J. Palomo,6 N. Maito,7 G. Rabago,8 E. Lage,9 E. Roig,10 D. Pascual,11 T. Blasco,12 L. Fuente,14 M. Vals,15 M. Camprecios,16 J. Muniz,1 Hospital Doce de Octubre, Madrid, Spain; 2Hospital Juan Canalejo, A Coruña, Spain; 3Hospital Puerta de Hierro, Madrid, Spain; 4Hospital Reina Sofia, Cordoba, Spain; 5Hospital La Fe, Valencia, Spain; 6Hospital Gregorio Maranon, Madrid, Spain; 7Hospital de Bellvitge, Barcelona, Spain; 8Clinica Universitaria de Navarra, Pamplona, Spain; 9Hospital Virgen del Rocio, Sevilla, Spain; 10Hospital Central de Asturias, Oviedo, Spain; 11Hospital Clinic, Barcelona, Spain; 12Hospital Virgen de la Arrixaca, Murcia, Spain; 13Hospital Miguel Servet, Zaragoza, Spain; 14Hospital Clínico, Valladolid, Spain; 15Hospital Marques de Valdecilla, Santander, Spain; 16Hospital S. Cruz y S. Pablo, Barcelona, Spain

2:15 PM – 3:45 PM

CONCURRENT SESSION 13

Outcomes Following Lung Transplantation (Grand Ballroom B)

*Chairs: * Paul A. Corris, MB, FRCP and * Lianne G. Singer, MD, FRCP

2:15 PM (182) Time Course of Physical Reconditioning during 3 Years after Lung Transplantation – Effects of Exercise Rehabilitation; U. Tegtbjer,1 J. Gottlieb,2 C. Kugler,1 E. Gueteltllf,2 L. Stein,2 A. Simon,3 T. Welte,3 A. Haverich,1 M. Strube,1 Hannover Thoracic Transplant Program, Thoracic and Cardiovascular Surgery, Medical School, Hannover, Germany; 2Sportsmedicine, Medical School, Hannover, Germany; 3Pulmonology, Medical School, Hannover, Germany

2:30 PM (183) Comparative Study of Lung Transplantation Long Term Results with Non Heart Beating Donors (NHBD): A Sustained Break Through?; P. Ussetti,1 C. Lopez Garcia-Gallo,1 D. Gomez de Antonio,2 R. Laporta,1 C. Carreño,3 P. Gamez,1 M. Cordoba,2 M. Ramos,1 M. J. Ferreiro,1 A. Varela,1 Pneumology, Clínica Puerta de Hierro, Madrid, Spain; 2Thoracic Surgery, Clínica Puerta de Hierro, Madrid, Spain; 3Internal Medicine, Clínica Puerta de Hierro, Madrid, Spain

2:45 PM (184) 90 Day Lung Transplant Mortality Following New Organ Allocation Guidelines; J.D. McCue,1 C.S. Herrington,1 I.I. Hertz,1 P.S. Dahlberg,1 Thoracic Transplantation, University of Minnesota, Minneapolis, MN

3:00 PM (185) Survival Outcomes Following Lung Transplantation for Cystic Fibrosis Patients Infected with Burkholderia Cenocepacia – A UK Experience; G.J. Meachery,1 L. Archer,2 A. De Soyza,1 G. Parry,1 S. Clark,1 K. Tocewicz,1 A. Fisher,1 J.ordan,1 S. Schueler,1 F.K. Gould,2 J.H. Dark,3 P.A. Corris,3 Applied Immunobiology and Transplantation Group, The Freeman Hospital, Newcastle Upon Tyne, United Kingdom; 2Department of Medical Microbiology, The Freeman Hospital, Newcastle Upon Tyne, United Kingdom

3:15 PM (186) Combined Lung and Liver Transplantation in Patients with Cystic Fibrosis; P. Soulalas,1 R. Guillemin,2 V. Boussaud,3 C. Amrein,4 P. chevalier,3 J.-N. Fabiani,4 1Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN; 2Laboratory Medicine, Mayo Clinic College of Medicine, Rochester, MN; 3Biostatistics, Mayo Clinic College of Medicine, Rochester, MN; 4Department of Medical Microbiology, The Freeman Hospital, Newcastle Upon Tyne, United Kingdom

3:30 PM (187) Lung Transplantation in Patients with Connective Tissue Disorders and Esophageal Dysmotility; W.J. Gasper,1 M.P. Sweet,1 M.G. Patti,1 C. Hoopes,1 L.E. Leard,3 S.R. Hays,1 J.A. Golden,2 1Department of Surgery, University of California, San Francisco, San Francisco, CA; 2Department of Medicine, University of California, San Francisco, San Francisco, CA

2:15 PM – 3:45 PM

CONCURRENT SESSION 14

Fat, Flow, and Function: New Insights into Allograft Vasculopathy (Grand Ballroom A)

*Chairs: * Gregory A. Ewald, MD and * Jan Groetzner, MD

2:15 PM (188) Donor Specific IL2A Antibodies Predict the Risk for Vasculopathy and Decreased Survival after Heart Transplantation; L. Kaczmarek,1 A. Betras-Fernandez,2 O. Delgado,3 S. Michel,1 T. Kauke,2 M. Schmoeckel,1 B. Meiser,1 B. Reichart,1 Cardiovascular Surgery, University Hospital Grosshadern, LMU Munich, Munich, Germany; 2Laboratories for Immunogenetics, University Hospital Grosshadern, LMU Munich, Munich, Germany

2:30 PM (189) Relationship between Insulin Resistance Features and Progression of Cardiac Allograft Vasculopathy; S.A. Virani,1 A.M. Wilson,1 M.X. Pham,1 H.A. Valantine,1 J.P. Cooke,1 W.F. Fearon,2 Cardiovascular Medicine, Stanford University, Stanford, CA

2:45 PM (190) Predictors of Microvascular Damage in Heart Transplant Recipients without Cardiac Allograft Vasculopathy: A Contrast-Enhanced Echocardiographic Study; F. Tonni,1 A.L.P. Cafforio,1 R. Montisci,1 A. Gambino,1 A. Ramondo,1 G. Toscano,1 M. Ruscario,1 A. Angeli,2 G. Gerosa,2 S. Iliceto,2 Cardiology, University of Padova, Padova, Italy; 3Cardiology, University of Cagliari, Cagliari, Italy; 4Cardiovascular Surgery, University of Padova, Padova, Italy; 5Cardiovascular Pathology, University of Padova, Padova, Italy

3:00 PM (191) Rapamycin Inhibits Endothelial Cell Recovery after Hypoxic Injury; J.L. Jackman,1 L. Tumiati,1 N. Xu,1 D. Ramzay,1 R. Sheshgiri,1 M. Badiwala,1 V. Rao,1 Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada

3:15 PM (192) Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy; E.R. Raichlin,1 J.P. McConnell,2 W.K. Kremers,3 B.S. Edwards,1 S.S. Kushwaha,1 A.L. Clavell,1 R.J. Rodeheffer,1 R.P. Frantz,1 Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN; 2Laboratory Medicine, Mayo Clinic College of Medicine, Rochester, MN; 3Biostatistics, Mayo Clinic College of Medicine, Rochester, MN

3:30 PM (193) Allomap Test Does Not Correlate with Late Survival or Coronary Artery Vasculopathy in Heart Transplantation; D. Torres,1 M. Macha,1 E.J. Molina,1 J. deFranco,1 J.P. Gaughan,1 D. Beltramo,1 J.B. Mcclurken,1 S. Furukawa,1 Surgery, Temple University, Philadelphia, PA

2:15 PM – 3:45 PM

CONCURRENT SESSION 15

“Humoral” Factors in Rejection (Imperial Ballroom A)
2:15 PM (194) *Normal* Myocardial Complement Deposition after Heart Transplantation; L.M. Hamour,1 M.L. Rose,2 D. Simpson,3 B. Mitchelson,3 N.R. Banner,1 M.M. Burke,3 Cardiology and Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom; 3Transplant Immunology, Heart & Science Center, Imperial College, Harefield Hospital, Harefield, Middlesex, United Kingdom; 2Transplant Pathology, Harefield Hospital, Harefield, Middlesex, United Kingdom

2:30 PM (195) Cardiac C4d Staining Is Not Associated with Abnormal Hemodynamics; S.E. Fedson,1 S.S. Daniel,2 A.S. Anderson,1 A.Y. Kim,1 A.N. Husain,1 Medicine, University of Chicago, Chicago, IL; 1Pritzker School of Medicine, Chicago, IL; 2Pathology, University of Chicago, Chicago, IL.

2:45 PM (196) Pattern of C4d Staining Is Important in Cardiac Transplantation; S.E. Fedson,1 S.S. Daniel,2 A.N. Husain,1 Medicine, University of Chicago, Chicago, IL; 1Pritzker School of Medicine, Chicago, IL; 2Pathology, University of Chicago, Chicago, IL.

3:00 PM (197) Deposition of C4d in Heart Transplants: A Factor in the Development of CAV?; E. Moseley,3 C. Atkinson,2 J. Cornelissen,1 J. Wallwork,1 M. Goddard,1 Pathology Department, Papworth NHS Trust Hospital, Cambridge, Cambridgeshire, United Kingdom; 2Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.


3:30 PM (199) Endothelin-1 Antagonism Prevents CyA Induced Vasomotor Impairment: Implication for Transplant Related Vascular Injury; D. Ramzy,1 L.C. Tumiati,1 N. Xu,1 E. Tepperman, D.H. Delgado,1 J. Jackman,1 R. Sheshgiri,1 M. Badiwala,1 V. Rao,1 Cardiac Surgery, University of Toronto, Toronto, ON, Canada.

3:45 PM (200) ATGs Reduce the Expression of Inflammation and Adhesion Molecules In Vivo in a Model of Ischemia/Reperfusion; A. Beiras-Fernandez,1,2 D. Chappell,1 E. Thein,1 B. Reichart,1 C. Hammer,1 Institute for Surgical Research, LM-University, Munich, Germany; Department of Cardiovascular Surgery, LM-Universty, Munich, Germany.

4:00 PM (201) Pharmacokinetics of Aerosolized Tacrolimus in Rats; S. Schrepfer,1 T. Deuse,2 J. Hoffmann,1 M. Haddad,3 M.P. Fischbein,1 H. Reichenspurner,2 R.C. Robbins,1 M.P. Pelletier,1 Cardiotoracic Surgery, Stanford University School of Medicine, Palo Alto, CA; 2Cardiovascular Surgery, University Heart Center Hamburg gGmbH, Hamburg, Germany; 3Clinical Chemistry, University Hospital Hamburg, Hamburg, Germany.

4:30 PM (202) The Effect of Calcineurin Inhibitors (CNI) on the Release of Secretory Leucoproteinase Inhibitor (SLPI) by Lung Epithelial Cells in the Presence of Transforming Growth Factor-beta (TGF-ß); R.L. Anderson,1 P.S. Hiemstra,1 L. Borthwick,1 J. Lordan,1 P.A. Corris,1 A.J. Fisher,1 Applied Immunobiology and Transplant Research Group, Newcastle University, Newcastle, United Kingdom; Pulmonary Department, Leiden University Medical Centre, Leiden, Netherlands.

5:00 PM (203) Dasatinib, a Novel Immunosuppressant Specifically Targeting T Cell Antigen Receptor Activation; A.E. Schade,1,2 H. Szpurka,1 A. Jankowska,3 G. Gonzalez-Stawinski,1 B.W. Lytle,1 J.P. Maciejewski,1 Section of Experimental Hematology and Hematopoiesis, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH; 2Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH; 3Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.

5:30 PM (204) mTOR Knockdown Inhibits Anti-HLA Antibody Induced MHC Class I Signaling; P.T. Jindra,1 E.F. Reed,1 UCLA Immunogenetics Center, David Geffen School of Medicine, UCLA, Los Angeles, CA.

6:00 PM – 6:30 PM CONCURRENT SESSION 17 Better Living Through Drugs (Imperial Ballroom B)

6:00 PM Invited Lecture: Cardiopulmonary Stress Testing: What do the ISHLT Guidelines Tell Us? Stuart D. Russell, MD, John's Hopkins Hospital, Baltimore, MD.

6:15 PM (205) Improved Survival on Heart Transplant (HT) Waiting Lists – Analysis of UNOS/OPTN 1988-2006; K. Lietz,1 L.W. Miller,1 Cardiovascular Division, Georgetown University - Washington Hospital Center, Washington, DC.

6:45 PM (206) Intravenous Sildenafil Citrate for Selective Pulmonary Vasodilatation in Heart Failure; P. Botha,1 G. Parry,1 J.H. Dark,1 G.A. MacGowan,1 Cardiopulmonary Transplantation, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom.

7:00 PM (207) Panel Reactive Antibody Screening and Treatment Practices Following Bridge to Transplant Ventricular Assist Device Placement; I. Tawfik,1 M. Shinnar,1 M.B. Anderson,1 T. Prendergast,2 R.S. Freudenberger,1 Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ; 2Surgery, Robert Wood Johnson Medical School, New Brunswick, NJ.
3:15 PM (208) Value of the Natriuretic Peptide NT-proBNP for Selecting Patients with High Priority for Heart Transplantation; T. Komoda,¹ H.B. Lehmkuhl,¹ C. Knosalla,¹ E. Potapov,¹ M. Dandel,¹ O. Grauhan,¹ R. Hetzer,¹ Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

3:30 PM Invited Lecture: Novel Biomarkers for Risk Prediction in Heart Failure; Thomas J. Dengler, MD, PhD, University of Heidelberg, Heidelberg, Germany

2:15 PM – 3:45 PM

CONCURRENT SESSION 18

Monitoring for Heart Transplant Rejection (Plaza Ballroom B)

*Chairs: *Michael Burch, MD and Jacqueline M. Lamour, MD

2:15 PM (209) Elevated Doppler Tissue Imaging-Derived Indices Reflect Cellular and Humoral Rejection in Pediatric Heart Transplant Recipients; S.K. Behera,¹ J. Trang,¹ S. Drant,¹ J.C. Alejos,¹ Pediatric Cardiology, University of California, Los Angeles, Los Angeles, CA; ²Pediatric Cardiology, University of Pittsburgh, Pittsburgh, PA

2:30 PM (210) Screening for Rejection in Symptomatic Pediatric Heart Transplant Patients: The Sensitivity of BNP; D.E. Harake,¹ M.K. Geiger,¹ D.S. Levi,¹ N.J. Halnon,¹ J.C. Alejos,¹ Pediatric Cardiology, University of California, Los Angeles, Los Angeles, CA

2:45 PM (211) Coronary Flow Reserve Detects Endothelial Dysfunction and Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Patients; S. Schubert,¹ H. Abdul-Khaliq,¹ P. Ewert,¹ H.B. Lehmkuhl,³ B. Peters,¹ E. Wellhofer,¹ N. Hiemann,² R. Meyer,¹ R. Hetzer,¹ F. Berger,¹ Pediatric Cardiology, German Heart Center, Berlin, Germany; ²Thoracic and Cardiovascular Surgery, German Heart Center, Berlin, Germany; ³Cardiology, German Heart Center, Berlin, Germany

3:00 PM (212) Ultrasound Cardiac Output Monitor Measurements in Pediatric Cardiac Transplant Patients; J.H. Fuuchi, Mathur, R. Larsen, A. De-Amaya, L.L. Bailey, R. Chinnock, S.A. Abd-Allah, Pediatrics, Nursing, and Cardiothoracic Surgery, Loma Linda University Children’s Hospital, Loma Linda, CA

3:15 PM (213) Pediatric Heart Transplantation: Implications for 2 Hour Cyclosporin A Blood Levels Greater 600 ng/ml for Graft Protection Monitoring; L. Ablonczy,¹ S. Schubert,² H. Lehmkuhl,² O. Miera,² M. Hufebier,² C. Knosalla,² O. Grauhan,² H. Abdul-Khaliq,² F. Berger,² R. Hetzer,² Hungarian Institute of Cardiology, Budapest, Hungary; ²Deutsches Herzzentrum, Berlin, Germany

3:30 PM (214) Complement Fragments C4d and C3d Deposition Does Not Correlate with Rejection in Pediatric Heart Transplant Recipients with a Positive Crossmatch; D.B. Holt,¹ H. Liapis,¹ D.R. Phelan,¹ S.K. Gandhi,¹ C.B. Huddleston,¹ C.E. Canter,¹ Pediatric Cardiology, Washington University, St. Louis, MO; ²Pathology, Washington University, St. Louis, MO; ³Laboratory Medicine, Washington University, St. Louis, MO; ⁴Surgery, Washington University, St. Louis, MO

3:45 PM – 4:15 PM

Coffee Break/Poster Viewing (Continental Ballroom)

4:15 PM – 5:45 PM

CONCURRENT SESSION 19

Complication Amelioration: Prevention of Rejection, Restriction, and Renal Dysfunction (Grand Ballroom B)

*Chairs: *Nicholas G. Smedira, MD and *Mark J. Zucker, MD

*4:15 PM (215) Gene Expression Profiling in Patients with Antibody Mediated Rejection; A.R. Gangadin,¹ M. Cadeiras,¹ A. Sinha,¹ M.P. Bayern,¹ A.S. Oz,¹ S. Memon,¹ C.C. Marboe,¹ N. Suciu-Foca,¹ H. Baron,² R. Dedrick,² A. Califano,¹ M.C. Deng,¹ Columbia University College of Physicians and Surgeons, New York, NY; ²XDx Inc., South San Francisco, CA

4:30 PM (216) Cell Death in Acute Cardiac Graft Rejection Is Mediated by Suppression of Apoptosis Inhibitor Apollon; S. Aharinejad,¹ R. Schaefer,² P. Paulus,² K. Krenn,³ A. Zuckermann,¹ A. Aliabadi,¹ E. Wolner,¹ M. Grimm,¹ Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; ²Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

4:45 PM (217) Predictors of Early Development of Chronic Kidney Disease Following Heart Transplantation; G.D. Lewis,¹ D.S. Frankel,¹ R.N. Brown,¹ R.J. Rodeheffer,¹ A.L. Heroux,¹ B.M. Cabuay,¹ S.A. Keck,¹ J.K. Kirklin,² M.J. Semigran,¹ Cardiology Division, Massachusetts General Hospital, Boston, MA; ²Surgery Department and the Cardiac Transplant Research Database, University of Alabama at Birmingham, Birmingham, AL; ³Cardiology Division, Mayo Clinic, Rochester, MN; ⁴Cardiology Division, Loyola University Medical Center, Maywood, IL; ⁵Cardiology Division, University of Iowa, Iowa City, IA

5:00 PM (218) Replacement of Calcineurin-Inhibitors with Sirolimus to Preserve Renal Function in Stable Cardiac Transplant Recipients; E. Raichlin,¹ Z. Khalpey,¹ A.L. Clavell,¹ B.S. Edwards,¹ R.P. Franz,¹ J.A. Wagner,¹ R.J. Rodeheffer,¹ S.S. Kushwaha,¹ Cardiovascular Diseases, Mayo Clinic, Rochester, MN

5:15 PM (219) Widespread Fibrosis of Myocardial and Adjacent Tissues Causing Restrictive Cardiac Physiology in Patients Needing Re-Do Heart Transplant; B.K. Itagaki,¹ J.A. Kobashigawa,¹ G.W. Wu,¹ J.K. Patel,¹ M.A. Kawano,¹ M.M. Kittleson,¹ M.C. Fishbein,² Medicine, University of California at Los Angeles, Los Angeles, CA; ²Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA

*5:30 PM (220) Prognostic Impact of the Quilty Phenomenon for the Development of Stenotic Microvasculopathy after Heart Transplantation: Evidence from 9,715 Biopsies; N.E. Hiemann,¹ E. Wellhofer,¹ C. Knosalla,¹ H.B. Lehmkuhl,¹ R. Hetzer,¹ R. Meyer,¹ Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
4:15 PM – 5:45 PM
CONCURRENT SESSION 20
GERD and Lung Transplantation (Grand Ballroom A)
Chairs: Cecilia Chaparro, MD and David W. Zaas, MD

4:15 PM (221) Exhaled Breath Condensate Pepsin: A New Noninvasive Marker of GERD after Lung Transplantation; A. Krishnan,1 S. Chow,2 P.S. Thomas,2 M.A. Malouf,1 A.R. Glanville,1 D.H. Yates,1 1The Lung Transplant Unit, St. Vincent’s Hospital, Sydney, NSW, Australia; 2Thoracic Medicine, University of New South Wales, Sydney, NSW, Australia

4:30 PM (222) Effect of Azithromycin on Gastroesophageal Reflux (Acid-Non Acid) and Pepsin in BALF of Lung Transplant Patients; K. Blondeau,1 V. Mertens,1 B.M. Vanaudenaerde,2 D.E. Van Raemdonck,2 G.M. Verleden,2 D. Sifrim,1 L.J. Dupont,2 1Center for Gastroenterological Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

4:45 PM (223) Quantitative Assessment of Lipid Laden Macrophages with Oil Red O Stain Is an Effective Screening Test for GORD; M.T. Musk,1 P.M. Hopkins,1 K. Kermeen,1 J. Dunning,1 J. Gradwell,2 L. Whitfield,2 C. Godinez,2 K. McNeil,1 1Queensland Heart-Lung Transplant Unit, Prince Charles Hospital, Brisbane, Queensland, Australia; 2Pathology Department, Prince Charles Hospital, Brisbane, Queensland, Australia

5:00 PM (224) Prevalence of Gastroparesis before and after Lung Transplant, and Association with Lung Allograft Outcomes; Y. Raviv, A. Pierre, C. Chaparro, S. Keshavjee, L.G. Singer, Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada

5:15 PM (225) Gastroesophageal Reflux Does Not Impact Survival after Lung Transplantation; M. Macha,1 E.J. Molina,1 G. Monteiro,1 S. Short,1 J.P. Gaughan,1 D. Beltramo,1 J.B. Mcclurken,1 S. Furukawa,1 Surgery, Temple University, Philadelphia, PA

5:30 PM (226) Lung Transplant Recipients with Nocturnal Reflux Have an Increased Risk of Gastric Aspiration, Irrespective of the Presence of BOS; K. Blondeau,1 V. Mertens,1 B.M. Vanaudenaerde,2 D.E. Van Raemdonck,2 G.M. Verleden,2 D. Sifrim,1 L.J. Dupont,2 1Center for Gastroenterological Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

4:15 PM – 5:45 PM
CONCURRENT SESSION 21
Ischemia Reperfusion Injury (Imperial Ballroom A)

*Chairs: *Daniel Kreisel, MD and Seth D. Force, MD

4:15 PM (227) Endothelin Axis Up-Regulation in a Marine Model of Brain Stem Death; A.J. Sutherland,1 F. Kermeen,1 J. Dunning,1 J.F. Fraser,1 1Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia

4:30 PM (228) Hypoxia-Reperfusion Injury Increases Cell Specific Endothelial Progenitor Cell Adhesion in an ICAM-1 Dependent Manner; J.L. Jackman,1 E. Partidge,1 M. Ward,2 L. Tumiati,1 M. Badiwala,1 R. Sheshgiri,1 D. Stewart,2 V. Rao,1 Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada; 2Division of Cardiology, University of Toronto, Toronto, ON, Canada

4:45 PM (229) Apoptosis Inhibition Improves Left Ventricular Function after Prolonged Cold Cardioplegic Arrest; U.M. Fischer,1 W.O. Monzon-Posadas,1 J.H. Fischer,2 H.J. Geissler,2 K. Hekmat,2 U. Mehlhorn,2 W. Bloch,1 1Department of Cardiac Surgery, University of Cologne, Cologne, Germany; 2Institute for Experimental Medicine, University of Cologne, Cologne, Germany; 3Institute of Experimental Medicine, University of Cologne, Cologne, Germany

5:00 PM (230) Long-Term Ischemic Storage: A New Approach with Apoptosis Inhibition for Cardiac Allograft Protection; U.M. Fischer,1 W.O. Monzon-Posadas,1 J.H. Fischer,2 H.J. Geissler,2 K. Hekmat,2 U. Mehlhorn,2 W. Bloch,1 1Department of Cardiac Surgery, University of Cologne, Cologne, Germany; 2Institute of Experimental Medicine, University of Cologne, Cologne, Germany; 3Department of Cardiac Surgery, University of Freiburg, Freiburg, Germany; 4Department of Cardiac Surgery, University of Ulm, Ulm, Germany; 5Institute for Molecular and Cellular Sports Medicine, German Sports Medicine, Cologne, Germany

5:15 PM (231) Synergistic Protection in Lung Ischemia Reperfusion Injury with Calcineurin and Thrombin Inhibition; A.S. McCourtie,1 H.E. Merry,1 A.S. Fairvar,1 M.S. Mulligan,1 1Division of Cardiothoracic Surgery, University of Washington, Seattle, WA

5:15 PM (232) Donor Treatment with Simvastatin Abolishes Ischemia-Reperfusion Injury in Rat Cardiac Allografts; R. Tuuminen,1 A.I. Nykanen,1 M.A.I. Keranen,1 H. Sandelin,1 R. Krebs,1 P.K. Koskinen,1 K.B. Lemstrom,1 1Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

5:30 PM (233) Ectopic Expression of Bcl-3 Improves Lung Function and Selectively Inhibits NF-kB Driven Expression of Pro-Inflammatory Genes; M. Okazaki,1 J.M. Lai,1 N.A. Das,1 H.J. Huang,1 A.S. Krupnick,1 G.A. Patterson,1 D. Kreisel,1 A.E. Gelman,1 Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO; 2Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine

4:15 PM – 5:45 PM
CONCURRENT SESSION 22
Airways and Vessels in Rejection (Imperial Ballroom B)

*Chairs: *Gerald J. Berry, MD and Margaret Burke, FRCPath

4:15 PM (234) Morphologic Differences in Epicardial and Microvascular Alterations after Heart Transplantation – Intimal vs. Medial Disease; N.E. Hiemann,1 C. Knoasla,1 E. Wellhofer,1 H.B. Lehmkühl,1 R. Hetzer,1 R. Meyer,1 1Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; 2Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
4:30 PM (235) Transforming Growth Factor-β (TGF-β) and Smad Mediated Epithelial Mesenchymal Transition (EMT) in Obliterative Bronchiolitis (OB); M. Southwood,1 D. Rassl,1 P. Sivastooy,2 J. Parameshwar,2 K. Dhill,2 N. Morell,1 S. Stewart,1 S. Tsui,2 J. Wallwork,2 J. Parmar,2 1Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; 2Transplant Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom

4:45 PM (236) Preserved Microcirculation Allows Cardiomyocyte Engraftment in Human Sex-Mismatched Heart Transplantation; A. Angelini,1 F. Tona,1 C. Testalli,1 A.P. Caforio,2 A. Gambino,1 M. Della Barbera,1 G. Feltrin,1 M. Valente,1 S. Iliceto,2 G. Gerosa,1 G. Thiene,1 1Department of Pathology, University of Padua, Padua, Italy; 2Department of Cardiology, University of Padua, Padua, Italy; 3Department of Cardiac Surgery, University of Padua, Padua, Italy

5:00 PM (237) M2 Macrophages: Keyplayers in the Fibro-Proliferative Response in Cardiac Allograft Vasculopathy; E. de Koning,1 J. van Kuik,1 D.F. van Viljien,1 M.F.M. van Oosterhout,1 F.H.J. Gmelig-Meyling,2 N. de Jonge,3 R.A. de Weger,1 1Pathology, University Medical Center, Utrecht, Netherlands; 2Immunology, University Medical Center, Utrecht, Netherlands; 3Heart Lung Center, University Medical Center, Utrecht, Netherlands

5:15 PM (238) Progression of Mild Rejection: Impact on New ISHLT Classification; L. Potenza,1 G. Berry,2 O. Leone,3 F. Grigioni,1 C. Holweg,4 G. Magnani,1 F. Coccoli,1 F. Fallani,1 A. Russo,1 C. Magelli,1 A. Branzi,1 H. Valantine,4 1Cardiovascular Diseases, University of Bologna, Bologna, Italy; 2Pathology, Stanford University, Palo Alto, CA; 3Pathology, University of Bologna, Bologna, Italy; 4Cardiovascular Medicine, Stanford University, Palo Alto, CA

5:30 PM Invited Lecture: Pathology of Chronic Rejection in Heart and Lung Transplantation, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

4:15 PM – 5:45 PM
CONCURRENT SESSION 23
CMV: Immunity and Damage Control (Plaza Ballroom A)

*Chairs: Margaret M. Hannan, MD and Martin R. Zamora, MD

4:15 PM (239) Measurement of CMV-Specific Immunity to Risk Stratify Individual Lung Transplant Recipients with Regard to CMV Reactivation; G.P. Westall,1 N.A. Mifsud,1 T.C. Kotsimbos,1 1Lung Transplant Unit, Alfred Hospital, and Monash University Medical School, Melbourne, Vic, Australia

4:30 PM (240) Acquisition of CMV-Specific CD8+ T Cell Memory during Primary CMV Infection in Lung Transplant Recipients; M.R. Pipeling,1 E.E. West,1 C.M. Osborne,2 S.A. Migueles,2 M. Connors,2 J.F. McDyer,2 1Medicine, Johns Hopkins University, Baltimore, MD; 2National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

4:45 PM (241) Asymptomatic CMV Viremia Is Associated with Adverse Outcomes Following Lung Transplantation; D.M. Lyu,1 M. Nicolls,1 M.R. Zamora,1 1Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO

5:00 PM (242) Cytomegalovirus Replication Is Associated with Endothelial Dysfunction in Pediatric Heart Transplant Recipients; J.D. Simmonds,1 M.J. Fenton,1 J.P.J. Halcox,2 N.J. Klein,2 L.M. Ellinns,2 C. Story,2 S. Omeagher,2 L.M. Redmond,2 A.E. Donald,2 C.A. Scott,2 M. Burch,1 1Department of Paediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom; 2Vascular Physiology Department, Institute of Child Health, University College London, London, United Kingdom

5:15 PM (243) Meta-Analysis of CMV-Hyperimmune Globulin Studies for the Prevention of CMV Infection and Disease in Solid Organ Transplant Recipients; N. Bonoras,1 A. Kocher,1 B. Mayer,1 G. Laufer,1 1Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria

5:30 PM (244) Predictive Value of Plasma CMV PCR for CMV Pneumonitis in Lung Transplant Recipients; J.M. Magill,1 S. Fernandez-Bussy,2 O. Akindipe,2 A.B. Deem,2 E.D. Staples,3 P.A. Drew,1 M.A. Baz,1 1Pathology, University of Florida, Gainesville, FL; 2Medicine, University of Florida, Gainesville, FL; 3Surgery, University of Florida, Gainesville, FL, United Kingdom

4:15 PM – 5:45 PM
CONCURRENT SESSION 24
Growing Pains: Psychosocial Issues in Pediatric Transplant Recipients (Plaza Ballroom B)

Chairs: Mary H. Freeman, MSW, LCSW and Alison Drabble, BSCN

4:15 PM Invited Lecture: Little People, Big Concerns, Alexandria Berg, RN, Children's Healthcare of Atlanta, GA

4:35 PM Discussion

4:45 PM (245) Quality of Life as Perceived by 8-13 Yr Old Heart Transplant Recipients; K. Uzark,1 J. Johnston,2 P. Murphy,3 R. Rodriguez,4 C. Nasman,1 J. Slusher,1 Cincinnati Children’s Hospital, Cincinnati, OH; 2Loma Linda University Medical Center, Loma Linda, CA; 3St Louis Children’s Hospital, St. Louis, MO; 4Children’s Hospital of New York, New York, NY; 5Cleveland Clinic Foundation, Cleveland, OH

5:00 PM (246) Neurodevelopmental Outcomes in Pediatric Heart Transplant Recipients; K. Uzark,1 J. Slusher,1 D. Beebe,2 R. Spicer,1 1Cardiology, Cincinnati Children’s Hospital, Cincinnati, OH; 2Psychology, Cincinnati Children’s Hospital, Cincinnati, OH

5:15 PM (247) Social Competence after Paediatric Transplantation – Should We Be Concerned?: J. Wray,1 B.K. Field,1 T. Lunnon-Wood,1 1Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

5:30 PM (248) Symptoms of Post-Traumatic Stress Disorder in Children and Adolescents Undergoing Transplantation: A Complex Issue; J. Wray,1 B.K. Field,1 T. Lunnon-Wood,1 1Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

5:45 PM – 6:45 PM
GENERAL POSTER SESSION 2/Wine and Cheese Reception (Continental Ballroom)
(265) Cardiac Allograft Vasculopathy: Real or a Normal Morphologic Variant?; S. Houser,1 A. Muniappan,2 J. Allan,2 J. Madsen,1 Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA; 2Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA

(266) Pathoanatomical Diagnosis after Heart Transplant in Patients with Cardiomyopathy – Does It Match Pretransplant Diagnosis?; M. Metawee, F. Gustafsson, J. Butany, D. Delgado, R. Smith, H. Ross, Department Cardiology and Heart Transplantation and Department of Pathology, Toronto General Hospital, Toronto, ON, Canada

* (267) Presence of Lipofuscin Deposition in Cardiomyocytes but Not Vascular Abnormalities Observed in Endomyocardial Biopsies (EMBs) Predicts Development of Transplanted Heart Coronary Artery Vasculopathy (CAV); M. Zakliczynski,1 J. Nozynski,1 D. Konecka-Mrowka,1 M. Zembala,1 1Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland

(268) The Real Estate of Cellular Cardiac Transplantation – Negative Remodeling Is Associated with Location; J.D. McCue,1 C.J. Swingen,4 D.L. Gatlin,1 T. Feldberg,2 A. Kolb,4 G. Caron,2 B. Breviu,2 S.J. Prabhu,2 D.A. Taylor,3 Department of Surgery, University of Minnesota, Minneapolis, MN; 2University of Minnesota Medical School, University of Minnesota, Minneapolis, MN; 3Center for Cardiovascular Repair, University of Minnesota, Minneapolis, MN; 4Department of Radiology, University of Minnesota, Minneapolis, MN

(269) Granulocyte-Based Immune Response Against Decellularized Vascular Tissue: Activation of Complement and CD11b; F. Bastian,1 E. Rieder,1 E. Eichmair,1 M.T. Kasimir,1 P. Simon,1 G. Weigel,1 Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria

(270) Cultured Cardiomyocytes Expressed CD80 but Not CD86 Can Attenuate CTL; N.W. Ke, J.J. Lei, Y.P. Li, T. Qiang, S.H.F. Li Key, Lab of Transplant Engineering and Immunology MOH, West China Hospital, Sichuan University, Chengdu, Sichuan, China

(271) Magnetofection-Enhanced Lentiviral Mediated Gene Transfer to Cardiac Cells in a Heterotopic Heart Transplantation Model; L. Burdoff,1 A. Hofmann,2 J. Postrach,1 D. Messow,2 B. Gleich,3 T. Veyh,3 E. Thein,2 V. Mordstein,2 B. Reichart,1 Pfeifer,2 M. Schmoockel,1 1Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany; 2Institute for Pharmacology and Toxicology, University of Bonn, Bonn, Germany; 3The Heinz Nixdorf Chair for Medical Electronics, Technical University, Munich, Germany; 4Institute of Pathology, Ludwig-Maximilians University, Munich, Germany

(272) Use of Tacrolimus, Sirolimus, and FK778 in Experimental Xenotransplantation – A Detailed Analysis of Drug Efficacy on Cellular and Humoral Xenorejection; T. Deuse,1 S. Schrepfer,2 F. Koch-Nolte,3 M.P. Fischbein,2 M.P. Pelletier,2 R.C. Robbins,2 H. Reichenspurner,1 1Cardiovascular Surgery, University Heart Center Hamburg gGmbH, Hamburg, Germany; 2Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; 3Immunology, University Hospital Hamburg, Hamburg, Germany

(273) National Transplantation Pregnancy Registry (NTPR): Pregnancy Outcomes in Female Thoracic Transplant Recipients; L. Ohler,1 L.A. Coscia,2 C.H. McGrory,2 M.J. Moritz,2 V.T. Armenti,1 Nursing, Virginia Commonwealth University/MCV, Richmond, VA; 2Surgery, Temple University School of Medicine, Philadelphia, PA

(274) The Burdens Experienced by Caregivers of Candidates Waiting for Lung Transplant; C.J. Whytehead,1 Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

(275) Television, Heart Transplantation and “On Line” National Donor Register Registrations; S.A. Beer, P. Pocock, R.S. Bonser, Department of Heart & Lung Transplantation, Cardiothoracic Surgery, University Hospital of Birmingham NHSF Trust: Queen Elizabeth, Edgbaston, Birmingham, United Kingdom; Statistics and Audit Directorate, UK Transplant & Blood, Bristol, Avon, United Kingdom; Department of Heart & Lung Transplantation and Cardiothoracic Surgery, University Hospital of Birmingham: Queen Elizabeth, Edgbaston, Birmingham, United Kingdom

(276) Teaching on Postoperative Day One: A Feasible Approach to Reduce Length of Stay in Ventricular Assist Device Patients; M.A. Murray,1 J.A. Hoffmann,2 J. Drayton,1 S. Osaki,1 D. Murray,2 M.R. Johnson,2 N.M. Edwards,1 T. Kohmoto,1 Cardiothoracic Surgery, University of Wisconsin Hospital and Clinics, Madison, WI; 2Heart Failure and Transplant Cardiology, University of Wisconsin Hospital and Clinics, Madison, WI; 3Nursing Staff Development, University of Wisconsin Hospital and Clinics, Madison, WI

(277) Challenges Associated with Development of a ‘Stand-Alone’ Donation after Cardiac Death (DCD) Lung Transplant (LTx) Program: Translating Research into Reality; B. Levey,1 R. McEgan,2 T. Oto,1 A. Griffiths,3 M. Mennen,1 D. Davies,1 D. Pelcher,1 T. Williams,1 F. Rosenfeldt,2 G. Snell,1 Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia; “Cardiac Perfusion Services, Alfred Hospital, Melbourne, Victoria, Australia; “Intensive Care, Alfred Hospital, Melbourne, Victoria, Australia; “Cardiothoracic Surgical Research, Alfred Hospital, Melbourne, Victoria, Australia

(278) Gender Differences in Symptom Experiences before and up to 6 Months after Lung Transplant (LT): D.M. Lanzuza,1 C.A. Lefaiver,2 R.L. Brown,1 S.M. Bhorade,2 R. Love,2 School of Nursing, University of Wisconsin-Madison, Madison, WI; 2Loyola University Medical Center, Maywood, IL; 3Lung Transplant Program, University of Chicago, Chicago, IL; 4Lung Transplant Program, University of Wisconsin Madison, Madison, WI

(279) Quality of Life Surveys: Are Responders Different from Non-Responders?; D. Naftel,1 S. Myers,1 J. Kirklin,1 K. Grady,2 Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; 2Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL

* (280) Lung Allocation Score Is Not Associated with Health-Related Quality of Life in Lung Transplant Candidates; A.J. Gurr,1 N. Chowdhury,1 L.G. Singer,1 L.G. Singer,1 Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada
(297) A Comparison of the Efficacy of Nebulised Amphotericin (NAM) Against Oral Itraconazole (ITR) in Prophylaxis Against Infection with Aspergillus spp. (ASP) in Lung Transplantation (LTx); A.C. Church, P. Sivasothy, J. Parmar, J. Powner, K. Venz, Transplant Unit, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom

(298) Female Gender Is Associated with Cardiac Dysfunction in Brain Dead Organ Donors; K.K. Khush, R.L. Menza, W.D. Babcock, J.G. Zaroff, Medicine/Cardiology, University of California, San Francisco, CA; California Transplant Donor Network, Oakland, CA; Surgery, University of California, San Francisco, CA

(299) Oxygenated Perfusion of Donor Hearts Reduces Ischemic Damage during Preservation; A. Halldorsson, H.A. Goolsby, M.D. Tomison, B.S. Prien, Surgery, Texas Tech University Health Sciences Center, Lubbock, TX; Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Lubbock, TX

(300) Elevated IL-8 Levels in Retrograde Flush Effluent Is Associated with Unexpected Donor Pulmonary Embolism: A Novel Predictor for Primary Rejection after Lung Transplantation; T. Higuchi, T. Oto, L. Zheng, G.P. Westall, B.J. Levvey, T.J. Williams, G.I. Snell, Lung Transplant Service, The Alfred, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia

(301) Ex Vivo Infrared Scanning for the Detection of Transmitted Coronary Disease in Human Donor Hearts; R.S. Poston, N. Burris, C. Tang, B.P. Griffith, Division of Cardiac Surgery, University of Maryland, Baltimore, MD

(302) Erythropoietin May Improve Long Term Preservation of the Donor Heart; S. Zangwill, K. Mussatto, J. Su, J.E. Baker, Pediatrics - Children’s Research Institute, Medical College of Wisconsin, Milwaukee, WI

(303) Impact of the Lung Allocation Score on Disease Transplanted and Post-Transplant Survival; C.J. De Ruiter-Gries, J.R. Curtis, M.S. Mulligan, J.E. Edelman, C.H. Goss, Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA

(304) Expanded Thoracic Donors: Beyond Elderly, Hypertensive and Metabolic Disorders; B. Mahillo, B. Miranda, E. Martin, G. Garrido, R. Matesanz, Medical Unit, Organizacion Nacional de Transplantes, Madrid, Spain

(305) Audit of 3 Months Data of Reasons for the Non-Use of Thoracic Organs in the United Kingdom; W.N. Wrightson, T. Wellman, J.H. Dark, Cardio-Thoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; UKTSSA

(306) Minimally Invasive Lung Transplantation in More Than 145 Patients with Emphysema: It Should Be the Standard Approach; A.R. Simon, J. Gottlieb, B. Gohrbandt, C. Hagl, S. Fischer, A. Meyer, C. Kuehn, A. Goerler, Y. Li, A. Haverich, M. Strueber, Hannover Thoracic Transplant Program (Division of Thoracic- and Cardiovascular Surgery), Hannover Medical School, Hannover, Germany; Division of Pneumology, Hannover Medical School, Hannover, Germany
(314) Long-Term Results of Combined Heart-Lung Transplantation: Analysis of 325 First Transplants over Twenty-Two Years at a Single Centre; J. Wallwork,1,2 C.K. Choong,1,2 L.D. Sharples,3 J.S. Parmar,1 P.R. Sivasothy,3 S.S.L. Tsui,1 Transplant Unit, Papworth Hospital NHS Trust, Cambridge, England, United Kingdom; 2Department of Surgery, University of Cambridge, Cambridge, England, United Kingdom

(315) Interaction of Type of Transplant and Intraoperative Pulmonary Artery Pressures (PAP) in Patients with Idiopathic Pulmonary Fibrosis (IPF) Undergoing Lung Transplantation; D. Hadjiiladiis,1 R. Lingaraju,1 J.D. Christie,1 J. Mendez,1 N.P. Blumenthal,1 J.Y. Woo,1 V.N. Ahya,1 J.S. Sager,1 R.M. Kotloff,1 Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

(316) The T Cell Infiltrate in Acute Cellular Rejection Biopsies Is a Temporally Homogeneous Restricted T Cell Repertoire; C.M. Magro,1 C. Morrison,2 P. Ross,2 A. Pope-Harmon,2 Pathology, Weill College of Medicine, New York, NY; 2Pathology, Ohio State University, Columbus, OH; 3Cardiothoracic Surgery, Ohio State University, Columbus, OH; 4Pulmonary Medicine, Ohio State University, Columbus, OH

(317) A Single-Institution Study Evaluating the Utility of Surveillance Bronchoscopy Following Lung Transplantation; Y.G. Valentine,1 D. Weill,2 G.A. Lombard,1 S.G. LaPlace,1 L. Seoane,1 D.E. Taylor,1 G.S. Dhillon,1 Lung Transplantation, Ochsner Medical Center, New Orleans, LA; 2Medicine, Stanford University Hospital, Stanford, CA

(318) Sleep Disordered Breathing before and after Lung Transplantation; M.A. Malouf,1 R.A. Milross,2 R.R. Grunstein,2,3 P.N. Chhajed,1 D.M. Jankelson,1 C.L. Aboyoun,1 P.T. Bye,1 A.R. Glanville,1 The Lung Transplant Unit, St. Vincent’s Hospital, Sydney, NSW, Australia; 2The Woolcock Research Institute of Medical Research, University of Sydney, Sydney, NSW, Australia; 3The Sleep Disorders Unit, St. Vincent’s Hospital, Sydney, NSW, Australia

(319) Differences in the Distribution of ISHLT Primary Graft Dysfunction Grades: Intubated vs Extubated Patients; T. Otto,1 B. Levvey,1 A. Griffiths,1 T. Higuchi,1 T. Kotsimbos,1 T. Williams,1 G. Snell,1 Lung Transplant Service, Alfred Hospital & Monash University, Melbourne, Victoria, Australia

(320) Thoracic Organ Transplantations in the Nordic Countries 1983-2005, Nordic Thoracic Transplantation Study Group. 1st Official Registry Report–2006; B. Andersson,1 for the Nordic Thoracic Transplantation Study Group, 1Cardiology, Sahlgrenska University Hospital, Goteborg, Sweden

(321) Correlation of Cylex ImmuKnow Assay with Lung Allograft Biopsy; Y. Huang,1 I. Nizami Nazih Zahdi,1 Transplantation Institute, Integris Baptist Medical Center, Oklahoma City, OK

(322) A Randomized, Placebo Controlled Trial of Aprotinin to Reduce Primary Graft Dysfunction Following Lung Transplantation; C.S. Herrington,1 M.E. Prekker,1 M.I. Hertz,1 D.M. Radosevich,1 R.F. Kelly,1 J. V. Sullivan,1 L.L. Studenski,1 H.B. Bittner,2 S.J. Shumway,1 P.S. Dahlberg,1 Thoracic Transplantation, University of Minnesota, Minneapolis, MN; 2Cardiovascular and Thoracic Surgery, University of Leipzig, Leipzig, Germany

(323) Effect of IL-2 Induction Therapy on Reperfusion Edema after Lung Transplantation: A Radiographic Study; E. Ruttmann,1 E.M. Gassner,2 H.B. Hangler,1 B. Bucher,1 C. Geltner,1 S. Sensroth,1 R. Margreiter,1 G. Lauber,1 L.C. Mueller,1 Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Tyrol, Austria; 2Department of Radiology, Innsbruck Medical University, Innsbruck, Tyrol, Austria; 3Department of Pneumology, Innsbruck Medical University, Innsbruck, Tyrol, Austria; 4Department of General and Transplant Surgery, Innsbruck Medical University, Innsbruck, Tyrol, Austria

(324) Effect of HLA Antibodies Detected by Flow on Lung Transplant Outcomes at a Single Center; R. Lingaraju,1 J. Mendez,1 V.N. Ahya,1 R.M. Kotloff,1 J.S. Sager,1 J.D. Christie,1 N.P. Blumenthal,1 D. Isaia,1 A. Pochettino,1 D. Hadjiiladiis,1 Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

(325) Survival and Functional Status in Patients 10 Years after Lung Transplantation in Lund, Sweden; L. Eriksson,1 K. Heimburg,1 L. Mared,1 Department of Respiratory Medicine, University Hospital, Lund, Sweden

(326) Ethnic Differences in Diagnoses and Outcomes of Lung Transplant (LTx) Recipients – Single Center Experience; R. Lingaraju,1 N.P. Blumenthal,1 J. Mendez,1 J.D. Christie,1 R.M. Kotloff,1 V.N. Ahya,1 J.S. Sager,1 J.Y. Woo,1 A. Pochettino,1 D. Hadjiiladiis,1 Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

(327) Physiologic Outcomes of ARDS Ventilator Management Strategy in Lung Transplant Recipients; J.D. McCue,1 M.E. Prekker,2 S.J. Prabhu,4 C.S. Herrington,1 M.I. Hertz,1 P.S. Dahlberg,1 Thoracic Transplantation, University of Minnesota, Minneapolis, MN; 2Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN; 3University of Minnesota Medical School, University of Minnesota, Minneapolis, MN

(328) Lung Function Tests for Prediction of BOS; G. Martensson,1 G. Riise,1 A. Thylem,1 F. Nilsson,2 B. Bake,1 Respiratory Medicine, Medicine, Sahlgrenska Academy, Gothenburg, Sweden; 2Thoracic Surgery, Medicine, Sahlgrenska Academy, Gothenburg, Sweden

(329) Early “Surveillance” Biopsies Detect Lung Allograft Rejection and Lymphocytic Bronchiolitis; D.J. Ross,1 W.D. Wallace,2 J.P. Lynch,1 B. Kubak,1 R. Saggar,1 A. Ardehali,4 R. Belyeu,4 M.C. Fishbein,2 Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, CA; 2Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA; 3Infectious Disease, University of California, Los Angeles, Los Angeles, CA; 4Thoracic Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

(330) Long-Term Outcome of Combined Heart-Lung Transplantation: Primary Pulmonary Hypertension Vs. Secondary Pulmonary Hypertension Due to Congenital Heart Diseases; Y. Toyoda,1 R. Santos,1 J. Thacker,1 J. Bhamra,1 D. Nguyen,1 C. Bermudez,1 B.G. Hattler,1 R.L. Kormos,1 J. Wallwork,1 C.K. Choong,1 L.D. Sharples,3 J.S. Parmar,1 P.R. Sivasothy,3 S.S.L. Tsui,1 Transplant Unit, Papworth Hospital NHS Trust, Cambridge, England, United Kingdom; 2Department of Surgery, University of Cambridge, Cambridge, England, United Kingdom
6:15 PM – 7:45 PM
SATellite symposium 12
Malignancy in thoracic transplantation (Imperial Ballroom A)
*Chair(s): *Mandeep R. Mehra, MD and Richard E. Chinnock, MD

*6:15 PM How does immunosuppression influence the genesis and propagation of malignancy? Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA
*6:30 PM Post-transplant lymphoproliferative disorders in the thoracic transplant recipient, Steven A. Webber, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA
6:45 PM Skin cancers and melanomas: nuisance or a determinant of outcome? Cynthia M. Magro, MD, Weill College of Medicine/Cornell University, New York, NY
7:00 PM A German nationwide post-HTX malignancy registry, Hans Lehmkuehl, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
7:15 PM A perspective on pre-existing cancer in the donor and recipient, Mark De Perrot, MD, Toronto General Hospital, Toronto, ON, Canada
7:30 PM Discussion

6:15 PM – 7:15 PM
Scientific council meeting on pathology and basic science (Plaza B)
Scientific council meeting on infectious diseases (Union Square 23/24)
Scientific council meeting on pediatric transplantation (Plaza A)
Scientific council meeting on pulmonary hypertension (Union Square 15/16)

6:45 PM – 8:00 PM
General poster session 2 removal (Continental Ballroom)

Friday, April 27, 2007

24 hours
Internet café open (Continental Ballroom Foyer)

6:00 AM – 6:00 PM
Registration desk open (West Foyer)

6:00 AM – 6:00 PM
Slide ready room open (Green Room)

7:00 AM – 9:00 AM
General poster session 3 poster mounting (Continental Ballroom)

7:00 AM – 6:00 PM
Press office open (Executive Boardroom)

7:00 AM – 8:00 AM
Sunrise symposium 5
Immunobiology for clinicians: principles of therapy (Imperial Ballroom A)
*Chair(s): *David A. Baran, MD and George Tellides, MD

*7:00 AM Overview of immunosuppression: old and new, Bruce R. Rosengard, MD, Massachusetts General Hospital, Boston, MA
7:30 AM Overview of tolerance, Bill A. Pietra, MD, Children’s Hospital, Littleton, CO

7:00 AM – 8:00 AM
Sunrise symposium 6
Novel insights in mechanisms of bronchiolitis obliterans (Imperial Ballroom B)
*Chair(s): *Annette Boehler, MD and *Andrew J. Fisher, MRCP, PhD

7:00 AM Mechanisms of airway inflammation, Mark R. Nicolls, MD, University of Colorado Health Sciences Center, Denver, CO
7:20 AM Chemokines and airway fibrosis, John A. Belperio, MD, University of California at Los Angeles, Los Angeles, CA
7:40 AM Antibody mediated airway fibrosis, Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St. Louis, MO

7:00 AM – 8:00 AM
Sunrise symposium 7
From observation to research in nursing and social sciences: acting on your ideas (Plaza Ballroom A)
Chair(s): Annette J. DeVito Dabbs, RN, PhD and Connie White-Williams, MSN

7:00 AM From observation to science: realities of clinical research, Bernice L. Coleman, PhD, RN, ACNP, Cedars Sinai Medical Center, Los Angeles, CA
*7:20 AM Panel discussion
7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 8
When Palliation Fails: Transplantation for the Adult with Congenital Heart Disease (Plaza Ballroom B)
Chairs: James K. Kirklin, MD and Mark Boucek, MD

7:00 AM How Big is the Problem: The Growing Population, Dan J. Murphy, Jr., MD, Stanford University, Palo Alto, CA
*7:20 AM How Far Can Medicine Go: Predictors of Decline in Congenital Heart Disease, F. Jay Fricker, MD, University of Florida, Gainesville, FL
7:40 AM Is There Any Problem the Surgeon Can’t Fix? Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:00 AM – 6:45 PM
Mini Oral Sessions 1-4 Poster Viewing (Yosemite Ballroom)

8:15 AM – 10:15 AM
PLENARY SESSION (Grand Ballroom B)
Chairs: Joren C. Madsen, MD, D.Phil. and Axel Haverich, MD

*8:15 AM (331) Featured Abstract: Gene Expression Profiles in Peripheral Blood for the Noninvasive Diagnosis of Chronic Lung Allograft Rejection; S.M. Studer, T. Richards, W. Wu, K.R. McCurry, N. Kaminski, Division of Pulmonary, Allergy, Critical Care, University of Pittsburgh, Pittsburgh, PA; Division of Thoracic Foregut Surgery, University of Pittsburgh, Pittsburgh, PA
*8:30 AM The Application of Genomics in Medicine and Transplantation, Daniel Salomon, PhD, The Scripps Institute, La Jolla, CA

9:00 AM (332) Featured Abstract: Does the UNOS Lung Allocation Score Predict Early Mortality in Lung Transplantation? Early Outcomes with the New US Allocation System; A.S. Shah, C.A. Merlo, M.C. Borja, M. Diener-West, J.V. Conte, J.B. Orens, Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

9:15 AM Controversies and Ethical Dilemmas in Thoracic Organ Allocation, John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
9:30 AM International Heart Allocation, J. David Vega, MD, Emory Clinic, Atlanta, GA
*9:50 AM International Lung Allocation, Walter Klepetko, MD, University of Vienna, Vienna, Austria

9:30 AM – 6:45 PM
Exhibit Hall Open (Continental Ballroom)
General Poster Session 3 Viewing (Continental Ballroom)

10:15 AM – 10:45 AM
ANNUAL BUSINESS MEETING (Grand Ballroom B)
Coffee Break/Poster Viewing (Continental Ballroom)

10:45 AM – 12:15 PM
CONCURRENT SESSION 25
Permanent Mechanical Circulatory Support (Grand Ballroom B)
*Chairs: Yoshifumi Naka, MD, PhD and Carmelo Milano, MD

10:45 AM (333) Center Experience and Outcomes of Left-Ventricular Assist Device (LVAD) Implantation as Destination Therapy (DT) – Analysis of Thoratec; DT Registry 1998-2003; K Lietz, J. Long, A. Kfoury, M. Slaughter, C. Milano, J. Rogers, Y. Naka, D. Mancini, L. Miller, Cardiovascular Division, Georgetown University - Washington Hospital Center, Washington, DC; Cardiovascular and Cardiothoracic Divisions, LDS Hospital, Salt Lake City, UT; Cardiovascular and Cardiothoracic Divisions, Advocate Christ Medical Center, Oak Lawn, IL; Cardiovascular and Cardiothoracic Divisions, Duke University Medical Center, Durham, NC; Cardiovascular and Cardiothoracic Divisions, Columbia-Presbyterian Medical Center, New York, NY


11:45 AM (337) MCS Out-of-Hospital Patients: Is There a Difference Between Pulsatile and Non-Pulsatile Devices?; A. El-Banayosy, L. Arusoglu, M. Morshuis, L. Kizner, D. Cobaugh, R. Koerfer, Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

*NOON (338) A Low Hemolysis Rate Is Not a Sufficient Criterion for the Qualification of Rotary Blood Pumps; J.H. Mueller, M. Brodde, K. Brandes, P. Muesser, J. Mueller, K. Graichen, B. Kehrel, Hematology, University of Muenster, Muenster, Germany; Research and Development, Berlin Heart, Berlin, Germany
Organ Allocation in the 21st Century (Plaza Ballroom A)

Chairs: Edward R. Garrity, Jr., MD and Ashish S. Shah, MD

11:00 AM (353) Pulmonary Arterial Hypertension in End-Stage Pulmonary Sarcoidosis: Assessment of the Therapeutic Effect of Sildenafil; N. Milman, C.M. Burton, M. Iversen, R. Videback, J. Carlsten, The Heart Centre, Rigshospitalet, Copenhagen, Denmark

11:05 AM (354) Effects of Bosentan on Both Pulmonary Vascular Remodeling and Cardiac Function and Remodeling in Pulmonary Hypertension; M.E. van Albada, R.G. Schoemaker, R.M. Berger, Dept of Pediatric Cardiology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; Dept of Experimental Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands


NOON (357) Augmentation of Type I Immune Response Cytokines/Chemokines Is Associated with Pulmonary Arterial Hypertension; D.J. Ross, J.A. Belperio, M.D. Burdick, S. Shapiro, R. Saggar, D. Zisman, J.P. Lynch, A. Ardehali, R.M. Strieter, Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, CA; MD-Inland Pulmonary, University of Virginia, Charlottesville, VA; Cardiology, University of California, Los Angeles, Los Angeles, CA; Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

10:45 AM – 12:15 PM
CONCURRENT SESSION 29
Organ Allocation in the 21st Century (Plaza Ballroom A)

10:45 AM (358) Prevalence and Extent of Coronary Atherosclerosis in the Donor Pool; O. Grauhahn, G. Schmidt, R. Krueger, F. Polster, C. Wesslau, R. Hetzer, Thoracic and Cardiovascular Surgery, German Heart Institute, Berlin, Germany; Deutsche Stiftung Organtransplantation, Berlin, Germany


(364) WITHDRAWN

10:45 AM – 12:15 PM
CONCURRENT SESSION 30
Beyond Surviving: Thriving Post-Transplant (Plaza Ballroom B)

Chairs: Diane V. Skojec, NP and Christiane Kugler, PhD, MSc, RN

10:45 AM (365) Prospective, Randomized Intervention on Physical Functioning and HRQoL after Lung Transplantation; C. Kugler, U. Tegtbuer, J. Gottlieb, A. Simon, M. Dierich, T. Welte, A. Haverich, M. Stueber, Hannover Thoracic Transplant Program; Division of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; Sportsphysiology/Medicine, Hannover Medical School, Hannover, Germany; Division of Pulmonary Medicine, Hannover Medical School, Hannover, Germany

11:00 AM (366) Patterns and Predictors of Physical Functional Disability at 5-10 Years after Heart Transplantation; K.L. Grady, D.C. Naftel, J.B. Young, D. Pelegrin, J. Czerv, R. Higgins, A. Heroux, M. McLeod, B. Rybarchczyk, J. Kobashigava, J. Chait, C. White-Williams, S. Myers, J.K. Kirklin, Cardiothoracic Surgery, Northwestern Memorial Hospital, Chicago, IL; Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH; Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, IL; Cardiology, Loyola University Medical Center, Maywood, IL; Psychology, Virginia Commonwealth University, Richmond, VA; UCLA Heart and Lung Transplant Program, UCLA Medical Center, Los Angeles, CA

11:15 AM (367) Posttransplant Infections after Lung Transplantation Reduce HRQoL in the Long-Term: Results of a Prospective Cohort Study; C. Kugler, F. Mattner, A. Simon, J. Gottlieb, T. Welte, A. Haverich, M. Stueber, Hannover Thoracic Transplant Program; Division of
Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; 2Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; 3Division of Pulmonary Medicine, Hannover Medical School, Hannover, Germany

*11:30 AM (368) Rates and Risk Factors for Nonadherence to the Medical Regimen after Transplantation; M.A. Dew,1 A.F. DiMartini,2 A. De Vito Dabbs,2 R. Zomak,2 R.L. Kornos,2 Psychiatry, Psychology and Epidemiology, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; Psychiatry and Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; 2Acute and Tertiary Care Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA; 3Cardiothoracic Transplantation, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA

11:45 AM (369) Time Course and Determinants of Functional Recovery the First Year after Lung Transplantation; J.C.A. Trappeburg,2 E.A. van de Graaf,1 K. Valkenet,2 G.D. Nossent,1 E. Lindeman,2 1University Medical Center Utrecht, Heart Lung Center, Utrecht, Netherlands; 2University Medical Center Utrecht, Department of Rehabilitation and Sports Medicine, Utrecht, Netherlands

NOON (370) Physical Activity in Patients Newly Listed for Heart Transplantation: Results from the “Waiting for a New Heart Study”; H. Spaderna,1 G. Weidner,1 A. Becker,1 D. Zahn,1 J.M.A. Smits,1 1Department of Psychology, Johannes Gutenberg University, Mainz, Germany; 2Preventive Medicine Research Institute, Sausalito, CA; 3Eurotransplant International Foundation, Leiden, Netherlands

12:15 PM – 12:30 PM
Box Lunch Pick-up (ticket required) (Yosemite Ballroom)

12:30 PM – 2:00 PM
LUNCHEON SYMPOSIUM: Beyond the Biopsy: Strengths and Pitfalls of Non-Invasive Diagnostics in Heart Transplantation (Grand Ballroom B)
Supported by an Unrestricted Educational Grant from XDx
*Chairs: *Andreas O. Zuckermann, MD and *Nicholas R. Banner, FRCP

12:30 PM Endomyocardial Biopsy: Is it the Gold Standard in the Diagnosis of Rejection? Michael C. Fishbein, MD, University of California, Los Angeles, Los Angeles, CA
12:40 PM The Role of Echocardiography and MRI in Diagnosing Acute Rejection, Hannah A. Valantine, MD, Stanford University School of Medicine, Stanford, CA
12:55 PM Monitoring Global Immune Function, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA
*1:10 PM Protein Biomarkers in Heart Transplantation, Mandep R. Mehta, MD, University of Maryland, Baltimore, MD
*1:20 PM Clinical Application of Peripheral Blood Gene Profiling in the Management of Heart Transplant Recipients, Randall C. Starling, MD, Cleveland Clinic Foundation, Cleveland, OH
1:35 PM Incorporating Noninvasive Monitoring into Management Protocols, Thomas P. Cappola, MD, ScM, University of Pennsylvania Hospital System, Philadelphia, PA
1:50 PM Discussion

12:30 PM – 2:00 PM
Second Summit on Mechanical Circulatory Support for Advanced Heart Failure (Union Square 19/20)

12:30 PM – 2:00 PM
MINI ORAL SESSION 3 (Imperial Ballroom A)
*Chairs: *Richard N. Pierson III, MD and Kenneth R. McCurry, MD

12:30 PM (371) Endothelial Progenitor Cells Possess Monocyte-Like Antigen-Presenting and T Cell-Activating Capacity; P.C. Raemer,1 S. Haemmerling,1 T. Giese,2 T.J. Dengler,2 S. Vijayshankar,1 1Department of Cardiology, Heidelberg University, Heidelberg, Germany; 2Institute of Immunology, Heidelberg University, Heidelberg, Germany

12:35 PM (372) IL-10 Inhibits Endothelium-Dependent T-Cell Costimulation by Upregulation of ILT3/4 in Human Vascular Endothelial Cells; C.A. Gleissner,1 M.H. Konstandin,1 S. Celik,1 R. Klingenberg,1 T. Giese,2 T.J. Dengler,2 1Department of Cardiology, University of Heidelberg, Heidelberg, Germany; 2Department of Immunology, University of Heidelberg, Heidelberg, Germany

12:40 PM (373) Alloimmune Response Induces HIF-1 Activation in Vascular and Inflammatory Cells of Transplanted Hearts – Possible Link to Cardiac Allograft Vasculopathy; M.A.I. Keränen,1 A.I. Nykänen,1 R. Krebs,1 H. Sandelin,1 R. Tuuminen,1 P.K. Koskinen,1,2 K.B. Lemström,1,3 1Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 2Department of Medicine, Division of Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 3Department of Cardiothoracic Surgery, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

12:45 PM (374) Thyromectomy Does Not Abrogate Long-Term Acceptance of MHC Class I-Dissparate Lung Allografts; H. Sahara,1 M.J. Weiss,1 C.Y. Ng,1 S.L. Houser,1 A.C. Pujara,1 J.K. Sayer,1 J.C. Wain,1 D.H. Sachs,1 J.C. Madsen,1 J.S. Allan,1 1Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

12:50 PM (375) Increased Serum Concentrations of Th1 Chemokines Are Associated with Acute Rejection Following Heart Transplantation; N.U. Khan,1 J.E. Fildes,1 M. Al-Aloul,1 A. Baynes,1 C.T. Leonard,1 N. Yonan,1 1The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

12:55 PM (376) Anti-Proliferative Properties of CMV Hyperimmunoglobulin Are Related to Activation Induced Cell Death In Vitro: Possible Role in Tolerance Induction; K. Hoftzenecker,1 S. Hacker,1 W. Hoftzenecker,2 K. Sadeghi,1 A. Poltreisz,1 A. Mangold,1 B. Moser,1 M. Grimm,1 F. Muelhbacker,1 W. Klepetko,1 E. Wolner,1 H.J. Ankermitt,1 1Department of Surgery, Medical University of Vienna, Vienna, Austria; 2Department of Dermatology, Medical University Tübingen, Tübingen, Germany; 3Department of Surgery, Columbia University, New York
**1:20 PM (394)** Portable Drivers for a Total Artificial Heart; A. El-Banayosy,1 L. Arusoglu,1 L. Morshuis,1 K. Kizner,1 D. Roefe,2 C. Raddatz,1 D. Cobough,1 R. Koerfer,1 Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

**1:25 PM (395)** Bridge to Recovery with Pulsatile Pump Support in Children under Two Years of Age; J.G. Copeland,1 R.G. Smith,2 P.E. Nolan,2 B. Barber,1 R. Samson,1 Surgery, University of Arizona, Tucson, AZ; 2Pharmacy, University of Arizona, Tucson, AZ; 3Pediatrics, University of Arizona, Tucson, AZ

(396) SEE WEDNESDAY LUNCHEON SYMPOSIUM

(397) SEE WEDNESDAY LUNCHEON SYMPOSIUM

*1:30 PM (398) Premature Termination of a Prospective, Open Label, Randomized, Multicenter Study of Sirolimus to Replace Calcineurin Inhibitors (CNI) in a Standard Care Regimen of CNI, MMF and Corticosteroids Early after Heart Transplantation; J. Hunt,1 H. Bedanová,2 R.C. Starling,2 G. Rabágo,3 N.R. Banger,2 J. Kobashigawa,4 A. Keogh,5 R. Kormos,5 M. Mehra,6 T. Wahlers,1 J. Noeleeke,7 Medical City Hospital, Dallas, TX; 2CKTCH, Brno, Czech Republic; 3Cleveland Clinic Foundation, Cleveland, OH; 4Clinica Universitaria, Navarra, Pamplona, Spain; 5Royal Brompton and Harefield NHS Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; 6The David Geffen School of Medicine at UCLA, Los Angeles, CA; 7St. Vincent’s Hospital, Darlinghurst, NSW, Australia

**1:35 PM (399)** Therapeutic Monitoring of Mycophenolate Mofetile Dose by Twelve-Hour-Area under the Curve to Avoid Acute Rejection in Heart Transplant Recipients; K. Wada,1 T.S. Kato,2 N. Oda,1 I. Ochi,1 Y. Maeda,1 A. Mano,2 T. Kotake,1 T. Nakatani,2 Department of Pharmacy, National Cardiovascular Center, Suita, Osaka, Japan; 2Department of Organ Transplantation, National Cardiovascular Center, Suita, Osaka, Japan

**1:40 PM (400)** A French Multicenter Prospective Randomized Study Evaluating the Benefit, on Renal Function, of Two Doses of Cyclosporine: Low Dose Versus Usual Dose, in Association with Mycophenolate Mofetil and Corticoids, in De Novo Cardiac Transplant: Results at 6 Months; P.-Boissonnal1, S. Gaillard1, F. Noel-Baron1, C. Mercier1, A. Roussoulieres1, O. Bastien1, L. Sebbag1, Direction de Transplantation Cardiaque, Hopital Cardiovasculaire et Pneumologique - CHU de Lyon, Bron, France, Metropolitan; 2INSERM - CHU de Lyon, Bron, France, Metropolitan; 3Service de Biostatistique - UMR CNRS 5558, CHU de Lyon, Lyon, France, Metropolitan

**1:45 PM (401)** Novel Short-Course Total Lymphoid Irradiation Protocol for Refractory Cardiac Rejection; T.S. Lee,1 J. Freund,1 V. Petersen,1 J. Heywood,1 G. O’Driscoll,1 Perivascular Radiation Oncology, Royal Perth Hospital, Perth, Western Australia, Australia; 2Advanced Heart Failure & Cardiac Transplant Services, Royal Perth Hospital, Perth, Western Australia, Australia; 3School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia

**2:15 PM – 3:45 PM**

CONCURRENT SESSION 31

Clinical Heart Transplantation: Will You Still Love me 20 Years Later? (Grand Ballroom A)

*Chairs:* Ari L. J. Harjula, MD and *Barry K. Rayburn, MD

**2:15 PM (402)** Outcomes in Bicaval Versus Biatrial Techniques in Heart Transplantation: An Analysis of the UNOS Database; E.S. Weiss,1 L.U. Nwakanma,1 S.D. Russell,2 J.V. Conte,1 A.S. Shah,1 Department of Surgery, Division of Cardiac Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD; 2Department of Medicine, Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD

**2:30 PM (403)** The Effect of Body Mass Index on Survival Following Heart Transplantation: A Critique of the ISHLT’s Revised Listing Criteria for Heart Transplantation; M.J. Russo,1 J.M. Chen,1 A. Moskowitz,2 K.N. Hong,2 R.R. Davies,1 F. Cheema,1 D.D. Ascheim,2 M. Argenziano,1 M.C. Oz,1 A.C. Gelijns,1 Y. Naka,1 Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, NY, NY; 2International Center for Health Outcomes and Innovation Research, Columbia University College of Physicians and Surgeons, NY, NY; 3Division of Cardiology, Columbia University College of Physicians and Surgeons, NY, NY

**2:45 PM (404)** Twenty-Five Years of Heart Transplantation at a Single Centre: Changes in Factors Influencing Short- and Long-Term Survival over Time; K. Goldsmith,2 L. Sharples,2 C. Sudarshan,1 J. Parameshwar,1 S. Tsui,1 J. Wallwork,1 S. Large,1 Transplant Unit, Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; 2Research & Development Department, Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; 3MRC Biostatistics Unit, Cambridge, United Kingdom

**3:00 PM (405)** 129 Cardiac Transplantations with Hearts from Donors Older Than 50: A Five Years Single Center Experience; C. D’Alessandro,1 P. Leprince,2 S. Varnous,1 E. Vaissier,1 M. Landi,1 E. Barreda,1 A. Rama,1 I. Gandjbakhch,1 A. Pavie,1 N. Bonnet,1 CT Surgery Department, University Paris VI, AP-HP, Hospital Pitie Salpetriere, Paris, France; 2Anesthesiology Department, University Paris VI, AP-HP, Hospital Pitie Salpetriere, Paris, France

**3:15 PM (406)** Estimated GFR Predicts Survival Following Heart Transplantation; M.J. Russo,1 J.M. Chen,1 K.N. Hong,2 F.H. Cheema,1 R.R. Davies,1 D.D. Ascheim,2 M. Argenziano,1 A.C. Gelijns,1 Y. Naka,1 Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, NY, NY; 2International Center for Health Outcomes and Innovation Research, Columbia University College of Physicians and Surgeons, NY, NY; 3Division of Cardiology, Columbia University College of Physicians and Surgeons, NY, NY

**3:30 PM (407)** Outcomes in Patients Older Than Sixty Undergoing Orthotopic Heart Transplantation: An Analysis of UNOS Data; E.S. Weiss,1 L.U. Nwakanma,1 D.D. Yuh,1 Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD

**2:15 PM – 3:45 PM**

CONCURRENT SESSION 32
Lung Retransplantation (Imperial Ballroom A)

Chairs: Jason Christie, MD and Christine Fegbeutel, MD

2:15 PM (408) A UNOS Registry Analysis of Lung Retransplantation (ReTxp) in the Modern Era; S.M. Kawut,1 D.J. Lederer,1 J.S. Wilt,1 F. D’Ovidio,1 J.R. Sonett,2 S.M. Arcasoy,3 S. Keshavjee,3 M.L. Barr,4 1Medicine, Columbia University, New York City, NY; 2Surgery, Columbia University, New York City, NY; 3Surgery, University of Toronto, Toronto, ON, Canada; 4Cardiothoracic Surgery, University of Southern California, Los Angeles, CA

2:20 PM (409) Pulmonary Retransplantation – Is It Worth the Effort? A Long Term Analysis of 46 Cases; C. Aigner,1 P. Jaksch,1 S. Taghavi,1 G. Lang,1 A. Hoda,1 W. Wisser,1 W. Klepetko,1 1Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria

2:25 PM (410) Repeat Heart-Lung Transplantation Outcome United States: An Update from the UNOS Registry; J.H. Shuhaimer, J.B. Kim, R. Gibbons, Thoracic and Cardiovascular Surgery, Loyola University Stritch School of Medicine, Chicago, IL; Department of Biostatistics, University of Illinois, Chicago, IL; Department of Biostatistics, University of Illinois, Chicago, IL

*3:00 PM DEBATE: Retransplantation Should Not Be Performed

PRO: Keith McNeil, FRACP, Prince Charles Hospital, Brisbane, Australia

CON: Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC

2:15 PM – 3:45 PM

CONCURRENT SESSION 33

Sex, Drugs, and Devices in Heart Failure (Imperial Ballroom B)

*Chairs: Edoardo G. Gronda, MD and *Paul J. Mather, MD

2:15 PM Invited Lecture: Optimal Heart Failure Management: The ISHLT Guidelines, Mariell Jessup, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

*2:30 PM (411) Women Are at Higher Risk for Recurrence of Cardiomyopathy; E.A. Carraway,1 B.K. Rayburn,1 J.A. Tallaj,1 S.V. Pamboukian,1 R.L. Benza,1 R.C. Bourge,1 Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL

2:45 PM (412) Gender Related Considerations in Patients Referred for Heart Transplant Evaluation; S.M. Yala,1 M. Cadeiras,1 M.P. Bayern,1 A.R. Gangadin,1 Y. Naka, D.M. Mancini, E.V. Giardina, M.C. Deng,1 Medicine, Columbia University, New York, NY

3:00 PM (413) Whole Transcriptome Analysis of Heart Transplantation Candidates Supported by Pulsatile and Non-Pulsatile Ventricular Assist Devices; H. Milting,1 P. Ellinghaus,2 D. D’Urso,2 M. Seewald,2 R. Cebulla,1 A. Kassner,1 M. Morshuis,1 L. Arusoglu,1 R. Koerfer,1 A. El Banayosy,1 Erich und Hanna Blessmann-Institut fuer Kardiovaskulare Forschung und Entwicklung, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; 2Target Research, Bayer Healthcare AG, Wuppertal, NRW, Germany

*3:15 PM (414) The Effect of Clenbuterol on Skeletal Muscle, Cardiac Function and Exercise Capacity in Patients with Chronic Heart Failure; S. Maybaum,1 I. George,1 C. Petrilli,1 E. Shane,1 G. Kamalakkanman,1 D. Rossi,1 J. LaManca,2 D.M. Mancini,2 Montefiore Medical Center, Bronx, NY; Columbia University Medical Center, New York, NY

*3:30 PM (415) Seeing the Future: Strategic Decision Support for Heart Transplant; M.S. Sharma,2 K.I. Hoercher,1 R.C. Starling,1,2 I.M. Alster,1 J. Deglurkar,1 E.H. Blackstone,3 G.V. Gonzalez-Stawinski,1,2 N.G. Smedira,1,2 Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH; Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; 2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

2:15 PM – 3:45 PM

CONCURRENT SESSION 34

Immunosuppressive Jumble Sale (Plaza Ballroom A)

Chairs: Geert M. Verleden, MD, PhD and David Weill, MD

*2:15 PM (416) A Longitudinal Study of Airway Vascularity Post-Lung Transplantation (LTxs): Everolimus (ERL) vs Azathioprine (AZA); B.J. Levy,1 L. Zheng,2 B. Orsida,2 M. Bailey,3 T.J. Williams,3 G.I. Snell,4 Lung Transplant Service, The Alfred, Melbourne, Victoria, Australia; 1Department of Medicine, Monash University, Melbourne, Victoria, Australia; 2Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia

2:30 PM (417) Cyclosporine Does Not Penetrate, but Accumulates at High Concentrations within, Differentiated Human Airway Epithelial Cells In Vitro: Possible Implications for the Use of Inhaled Cyclosporine; R. Aris,1 P. McNellie,1 O. Olusesi,1 S. Thomas,1 M. Paine,2 C. Hammett-Stabler,3 I. Neuringer,1 Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; 2School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC; 3Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

2:45 PM (418) Mycophenolate Mofetil Is Associated with Decreased De Novo Anti-HLA Alloantibodies in the First Year after Lung Transplantation; A.L. Gimita,1 A. Zeevi,1 S.A. Yousem,1 J. Pilewski,1 G. Zdanowicz,1 K.J. Spichy,1 J. Howe,1 D. Zaldonis,1 K.R. McCurry,1 University of Pittsburgh Medical Center, Pittsburgh, PA

3:00 PM (419) Initial Cyclosporin C2 Monitoring Following Lung Transplantation Provides Long-Term Clinical Benefits: A Prospective Randomised Study; J. Cornelisissen,1 M. Goddard,1 A. Wood,2 J. Wallwork,2 P. Sivasothy,3 Department of Pathology, Papworth NHS Trust Hospital, Cambridge, United Kingdom; 1MRC Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom; 3Transplant Unit, Papworth NHS Trust Hospital, Cambridge, United Kingdom
*3:15 PM (420) Final 3 Year Analysis of a Prospective Randomized International Multicenter Investigator Driven Study Comparing Tac and CsA (+ MMF/Steroids) after Lung Transplantation in 274 Patients; H. Reichenspurner, W. Klepetko, C. Aboyoun, C. Bravo, M. Estenne, S. Hirt, J. Aubert, H. Treede, A. Glanville, the European and Australian Investigators in Lung Transplantation, Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; University of Vienna, Vienna, Austria; Alfreds Hospital, University of Sydney, Sydney, Australia; University of Barcelona, Barcelona, Spain; University of Brussels, Brussels, Belgium; University of Kiel, Kiel, Germany; University of Lausanne, Lausanne, Switzerland; University Heart Center Hamburg, Hamburg, Germany; Alfreds Hospital, University of Sydney, Sydney, Australia

*3:30 PM (421) Effect of Induction Therapy on the Peripheral Blood Genomic Signature in the LARGO Lung Transplant Study; S. Keshavjee, 1 K.R. McCurry, 2 R.D. Davis, 3 J.M. Pilowski, P.A. Corris, A. Zeevi, T.K. Waddell, S.M. Areasy, J.G. Golden, M. Streeber, R.L. Doyle, P. Jakusch, A.C. Mchta, 10 M.S. Mulligan, 11 O.E. Pajaro, 12 M.R. Zamora, 13 S. Sweet, 14 R.N. Woodward, 15 R.D. Dedrick, 12 H. Wolters, 12 K.C. Fang, 13 E.P. Trulock, 14 University of Toronto, Toronto, ON, Canada; 2University of Pittsburgh, Pittsburgh, PA; 3Duke University, Durham, NC; 4University of Newcastle, Newcastle Upon Tyne, MO, United Kingdom; 5Columbia University, New York, NY; 6University of California, San Francisco, San Francisco, CA; 7Hannover Medical School, Hannover, Germany; 8Stanford University, Stanford, CA; 9University Hospital, Vienna, Austria; 10Cleveland Clinic Foundation, Cleveland, OH; 11University of Washington, Seattle, WA; 12Mayo Clinic Jacksonville, Jacksonville, FL; 13University of Colorado, Denver, CO; 14Washington University, St. Louis, MO; 15XDr, South San Francisco, CA

2:15 PM – 4:15 PM
CONCURRENT SESSION 35
Caves Candidate Award Presentations (Plaza Room B)
Chairs: Mark L. Barr, MD and Bruno Reichart, MD

2:15 PM (422) CXCR3 and CCR5 Blockade Prevents Acute Rejection Via Induction of Regulatory CD4 Lymphocytes; S. Bastani, 1 2 G.T. Schnickel, 1 2 G.R. Hsieh, 1 2 C. Garcia, 1 2 M.C. Fishbein, 1 2 R. Ardehali, 1 2 Department of Surgery, Division of Cardiac Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA; 3Department of Surgery, Division of Cardiac Surgery, West Los Angeles VA Medical Center, Los Angeles, CA; 4Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA

2:30 PM (423) Adenoviral Mediated Interleukin 10 (AdhIL-10) Gene Therapy in Normothermic Ex-Vivo Lung Perfusion; M. Cypel, M. Rubacha, M. Sato, S. Hirayama, S. Fischer, K. McRae, M. Liu, T.K. Waddell, M. de Perrot, S. Keshavjee, Thoracic Surgery Research Laboratory, Toronto Lung Transplant Program, Toronto General Research Institute, University of Toronto, Toronto, ON, Canada

2:45 PM (424) Anti-CD20 Prevents Alloantibody Production and Attenuates Cardiac Allograft Vasculopathy in Monkeys Treated with Anti-CD154; S.S. Kelishadi, 1 T. Zhang, 1 B.N. Nguyen, 1 G. Wu, 1 E. Welty, 1 C.J. Avon, 1 S. Pfeiffer, 1 C. Schroder, 1 A. Azimzadeh, 1 R.N. Pierson, 1 3, Cardiac Surgery, University of Maryland School of Medicine and Baltimore VAMC, Baltimore, MD

3:00 PM (425) VAD-Associated Thromboembolism: Possible Role for Intrinsic Coagulation Cascade; S. Kallam, 1 R.N. Sangrampurkar, 1 3 Z. Kon, 1 R.N. Pierson, 1 B.P. Griffith, 1 R.S. Poston, 1 1Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD

3:15 PM (426) Vascular Endothelial Growth Factor-C Enhances Experimental Obliterative Bronchiolitis by Inducing Lymphangiogenesis; R. Krebs, 1 J.M. Tikkanen, 1 A.I. Nykänen, 1 S. Ylä-Herttuala, 1 P.K. Koskinen, 1 K.B. Lemström, 1 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland; 2A. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland

3:30 PM (427) The Effects of Hormone Resuscitation on Transplantable Organs in the Brain Dead Donor; A. Hinge, 1 M. Hicks, 1 L. Gao, 1 S.C. Faddy, 1 P. Tran, 1 S.H. Kesteven, 1 A.F. Sharland, 1 G.J. Stewart, 1 P.S. Macdonald, 1 1Transplant Program, The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; 2The Collaborative Transplant Research Group, The University of Sydney, Sydney, NSW, Australia; 3Cardiovascular Mechanics Program, The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia

3:45 PM (428) Lipopolysaccharide Preconditioning is Protective in Lung Ischemia Reperfusion Injury; H.E. Merry, 1 A.S. McCourtie, 1 P.S. Wolf, 1 A.S. Farivar, 1 M.S. Mulligan, 1 1Cardiothoracic Surgery, University of Washington, Seattle, WA

*4:00 PM (429) B-Type Natriuretic Peptide Is a Sensitive Screening Tool for Acute Rejection in Pediatric Heart Transplant Patients; J.W. Rossano, 1 S.W. Denfield, 1 J.J. Kim, 1 J.L. Jefferies, 1 J.F. Price, 1 J.A. Decker, 1 S.K. Clunie, 1 J.A. Towbin, 1 W.J. Dreyer, 1 1Cardiology, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX

4:15 PM – 5:45 PM
CONCURRENT SESSION 36
Whom To Transplant or Not to Transplant: That is the Question (Grand Ballroom A)
Chairs: *Leyaw Chen, MD, MPH and *Nicholaas De Jonge, MD

4:15 PM (430) Clinical Outcomes after Cardiac Transplantation in Muscular Dystrophy Patients; R.S. Wu, 1 R.N. Brown, 1 C.W. Yancy, 1 J.W. Wald, 1 P. Kaiser, 1 N.M. Kirklin, 1 D.J. Garry, 1 S.S. Kelishadi, 1 R.N. Sangrampurkar, 1 Z. Kon, 1 W. Klepetko, C. Aboyoun, C. Bravo, M. Estenne, S. Hirt, J. Aubert, H. Treede, A. Glanville, the European and Australian Investigators in Lung Transplantation, Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; University of Vienna, Vienna, Austria; Alfreds Hospital, University of Sydney, Sydney, Australia; University of Barcelona, Barcelona, Spain; University of Brussels, Brussels, Belgium; University of Kiel, Kiel, Germany; University of Lausanne, Lausanne, Switzerland; University Heart Center Hamburg, Hamburg, Germany; Alfreds Hospital, University of Sydney, Sydney, Australia

4:30 PM (431) Heart Transplantation for AL Amyloidosis; C.G.A. McGregor, 1 B.S. Edwards, 1 R.J. Rodeheffer, 1 R.P. Frantz, 1 S.S. Kushwaha, 1 A.L. Clavell, 1 J.A. Dearn, 1 T.M. Sundt, 1 R.C. Daly, 1 1Mayo Clinic-Rochester William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

4:45 PM (432) Long-Term Results of Combined Heart and Kidney Transplantation: A French Multicenter Study; E. Vermees, 1 L. Sebbag, 2 B. Barrou, 1 A. Pavi, 2 D. Loisonne, 1 M. Kirsch, 1 1Cardiac Surgery, Henri Mondor Hospital, Creteil, France; 2Cardiac Surgery, Lyon, France; 3Cardiac Surgery, Renal Transplantation, Pitie Salpetriere Hospital, Paris, France
5:00 PM (433) Outcomes in Simultaneous Heart and Kidney Transplantation: The University of Wisconsin Experience; J.L. Hermesen,1 D.S. Nath,1 J.D. Lindsey,1 C.H. Wigfield,1 N.M. Edwards,1 Cardiothoracic Surgery, University of Wisconsin, Madison, WI

5:15 PM (434) Infections in Alternate Versus Standard List Heart Transplant Patients: Implications for Immunosuppression; B. Lima,1 K. Rajagopal,1 R.G. Mesis,1 R.P. Petersen,1 B. Soule,1 G.M. Felker,1 J.G. Rogers,1 A.J. Lodge,1 C.A. Milano,1 Department of Surgery, Duke University Medical Center, Durham, NC

5:30 PM (435) Long-Term Outcomes of Transplantation for Peripartum Cardiomyopathy. A Multinstitutional Analysis; K.D. Rasmussen,1 J. Stehlk,1 R.N. Brown,2 D.G. Renlund,1 L.E. Wagoner,3 G. Torre-Amione,1 J.W. Folsom,4 D.H. Silber,5 J.K. Kirklin,5 LDS Hospital, Utah Transplant Affiliated Hospitals, Salt Lake City, UT; 5VA Salt Lake City HCS, Utah Transplant Affiliated Hospitals, Salt Lake City; 4University of Alabama at Birmingham, Birmingham; 4University of Cincinnati Medical Center, Cincinnati; 5Baylor College of Medicine, The Methodist Hospital, Houston; 4Hershey Medical Center, Penn State University, Hershey; 3Cardiac Transplant Research Database

4:15 PM – 5:45 PM

CONCURRENT SESSION 37
Mechanisms and Treatment of Lung Rejection (Imperial Ballroom A)

Chairs: *Scott M. Palmer, MD and Christine L. Lau, MD

4:15 PM (436) The Involvement of the IL23/IL17 Pathway in the Development of Bronchiolitis Obliterans Syndrome after Lung Transplantation; B.M. Vanauendaere,1 R. Vos,1 N. Geudens,1 L.J. Dupont,1,2 D.E. Van Raemdonck,2 G.M. Verleden,1,2 Laboratory of Pneumology, KULeuven, Leuven, Belgium; Lung Transplant Unit, UZ Gasthuisberg, Leuven, Belgium

4:30 PM (437) Azithromycin Inhibits IL17-Induced 8-Isoprostane Production in Human Airway Smooth Muscle Cells: A Role for Anti-Oxidative Effects in Bronchiolitis Obliterans Syndrome after Lung Transplantation?; R. Vos,1 B.M. Vanauendaere,1 W.A. Wuyts,1,3 N. Geudens,1 L.J. Dupont,1,2 D.E. Van Raemdonck,2,3 G.M. Verleden,1,2 Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; Lung Transplant Unit, University of Alabama at Birmingham, Birmingham; Respiratory Disease, University Hospital Gasthuisberg, Leuven, Belgium; Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

4:45 PM (438) Comparative Broncho-Alveolar Lavage Fluid (BAL-f) and Plasma Proteome Analysis in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome (BOS); F. Meloni,1,2,3 D.E. Van Raemdonck,2,4 G.M. Verleden,1,2,3 Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; Lung Transplant Unit, University Hospital Gasthuisberg, Leuven, Belgium; Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium; Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

5:00 PM (439) Efficacy of Combination Therapy with High Dosages of IVIG and Anti-CD25* (Basiximab) for Acute Lung Allograft Rejection or Organizing Pneumonia: A Pilot Study; D.J. Ross,1 J.P. Lynch,1 R. Saggar,1 B. Kubak,2 J.A. Belperio,1 R. Byegui,3 W.D. Wallace,1 M.C. Fishbein,3 A. Ardehali,4 Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, CA; Infectious Disease, University of California, Los Angeles, Los Angeles, CA; Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA; Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

5:15 PM (440) Decreasing Regulatory T-Cell Dynamics Early Post Lung Transplant Is Associated with Histopathological Acute Rejection; T. Higuchi,1 N.A. Mifsud,2 G.P. Westall,1 T.J. Williams,1 G.I. Snell,1 T.C. Kotsimbos,1 Lung Transplant Service, The Alfred, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia

5:30 PM (441) Defining Humoral Rejection: A Detailed Longitudinal Study of Lung Transplant Recipients; G.P. Westall,1 T.C. Kotsimbos,1 G.I. Snell,1 C. McLean,1 C.M. Macgo,2 Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia; Weill College of Medicine, Cornell University, New York, NY

4:15 PM – 5:45 PM

CONCURRENT SESSION 38
Mechanisms of Rejection in Heart Transplantation (Imperial Ballroom B)

Chairs: Suzanne Roedler, MD and David S. Feldman, MD, PhD

4:15 PM (442) Viral Interleukin-10 Gene Therapy Via Mesenchymal Stem Cells Prolonged Cardiac Transplant Survival; S. Salgar,1 S. Li,1 M. Hernandez,2 Y. Wei,1 D. Mateu,1 J. Mathew,2 S. Pham,1 Surgery, University of Miami, Miami, FL

4:30 PM (443) VEGFR-3 Mediates Lymphangiogenesis and Alloimmune Responses in Cardiac Allografts; H. Sandelin,1 A.I. Nykanen,1 M.A.I. Keranen,1 R. Tuurninen,1 P.K. Koskinen,1 K. Alitalo,1 K.B. Lemstrom,1 Transplantation Laboratory, University of Helsinki, Helsinki, Finland; Molecular Cancer Laboratory, University of Helsinki, Helsinki, Finland

4:45 PM (444) Persistent PDGFA-A, -C, -D Transgene Expression Enhances Cardiac Allograft Vasculopathy and Fibrosis, but PDGFB-B Induces Myocardial Angiogenesis; R. Tuurninen,1 M.A.I. Keranen,1 A.I. Nykanen,1 R. Krebs,1 K. Alitalo,1 P.K. Koskinen,1 K.B. Lemstrom,1 Transplantation Laboratory, University of Helsinki, Helsinki, Finland; Molecular Cancer Biology Laboratory, University of Helsinki, Helsinki, Finland

5:00 PM (445) Preferential Expression of CD44 V1 Isomers by Intragraft Fibroblasts from Cardiac Allografts with Chronic Rejection; G.D. Wu,1 H. Zhu,1 Y. He,1 M. Barr,2 A.S. Klein,1 Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; Cardiothoracic Surgery, Keck School of Medicine, USC, Los Angeles, CA

5:15 PM (446) Antivincoxin Antibodies Mediate Acute and Chronic Damage in MHC-Matched Allografts; B. Mahesh,1 H.S. Leong,1 P. Sarathchandra,1 A.M. McCormack,1 A.L. Holder,1 J.D. Smith,1 M.L. Rose,1 Transplant Immunology, Heart Science Center, Harefield Hospital, Harefield, United Kingdom

*Chair
5:00 PM (451) *Epidemiology of Late Bacterial Pneumonia in a Prospective Cohort of Lung Transplant Recipients (LTRs)*; K. Raza,1 S. Studer,2 D.L. Paterson,1 M. Crespo,2 D.L. Pakstis,1 M.E. Carey,1 A. Zeze,3 J. Pilewski,2 K.R. McCurry,3 S. Husain,1 Div of Infect Dis, Univ of Pitt, Pittsburgh, PA; Div of Pulm & Crit Care, Univ of Pitt, Pittsburgh, PA; Dept of Surgery, Univ of Pitt, Pittsburgh, PA

5:15 PM (452) *Effectiveness and Safety of Epstein-Barr Virus DNA-Load Guided Reduction of Immunosuppression Late after Lung Transplantation*; N.A. Bakker,1 E.A.M. Verschuuren,1 M.E. Erasmus,1 B.G. Hepkema,1 N.J.G.M. Veeger,5 C.G.M. Kallenberg,6 W. van der Bij,2 Hematology, University Medical Center, Groningen, Netherlands; Pulmonary Diseases, University Medical Center, Groningen, Netherlands; Cardiothoracic Surgery, University Medical Center, Groningen, Netherlands; Pathology and Laboratory Medicine, University Medical Center, Groningen, Netherlands; Clinical Epidemiology, University Medical Center, Groningen, Netherlands; Clinical Immunology, University Medical Center, Groningen, Netherlands

5:30 PM (453) *Usefulness of Polymerase Chain Reaction Strategies for Early Diagnosis of Chagas Disease Reactivation and Treatment Follow-Up in Heart Transplantation*; M. Diez,1 L. Favaloro,1 J.M. Burgos,2 M. Peradejordi Lastras,1 A. Bertolotti,1 C. Vigliano,1 A.G. Schijman,1 R.R. Favaloro,1 Intrathoracic Transplant Unit, Fundacion Favaloro, Buenos Aires, Argentina; Laboratorio de Biologia Molecular de la Enfermedad de Chagas, INGEBI-CONICET, Buenos Aires, Argentina

4:15 PM – 4:55 PM CONCURRENT SESSION 39 Post-Transplant Infections: Bacteria, Moulds, and Parasites (Plaza Ballroom A)

*Chairs: Martha L. Mooney, MD and Kate Gould, FRePath

4:15 PM (448) *Infections in Lung Allograft Recipients: Ganciclovir Era*; Y.G. Valentine,1 R.W. Bonvillain,2 G.A. Lombard,1 S.G. LaPlace,1 G.S. Dhillon,1 G. Wang,2 Lung Transplantation, Ochsner Medical Center, New Orleans, LA; Medicine and Genetics, LSU Health Sciences Center, New Orleans, LA; Medicine, Stanford University Hospital, Stanford, CA

*4:30 PM (449) Aspergillus Infection in Lung Transplant Patients: Incidence and Prognosis*; M. Iversen,1 C.M. Burton,1 S. Vand,2 L. Skovfoged,2 N. Milman,1 J. Carlsen,1 M. Rasmussen,2 Division of Lung Transplantation, The Heart Centre, Rigshospitalet, Copenhagen, Denmark; Department of Pharmacology and Pharmacotherapy, Danish University of Pharmacological Sciences, Copenhagen, Denmark

*4:45 PM (450) Invasive Aspergillus in Lung Transplant Recipients: The Impact of Pretransplant Colonization*; F. Mattner,1 S. Fischer,2 H. Weissbrodt,1 B. Haubitz,2 J. Gottlieb,2 I.F. Chaberny,1 A. Simon,2 P. Gastmeier,1 M. Strueber,5 Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; Division of Thoracic Surgery, University Toronto, Toronto, Canada; Neuroradiology, Hannover Medical School, Hannover, Germany; Respiratory Medicine, Hannover Medical School, Hannover, Germany; Division of Thoracic Surgery, Hannover Medical School, Hannover, Germany

5:00 PM (451) *Epidemiology of Late Bacterial Pneumonia in a Prospective Cohort of Lung Transplant Recipients (LTRs)*; K. Raza,1 S. Studer,2 D.L. Paterson,1 M. Crespo,2 D.L. Pakstis,1 M.E. Carey,1 A. Zeze,3 J. Pilewski,2 K.R. McCurry,3 S. Husain,1 Div of Infect Dis, Univ of Pitt, Pittsburgh, PA; Div of Pulm & Crit Care, Univ of Pitt, Pittsburgh, PA; Dept of Surgery, Univ of Pitt, Pittsburgh, PA

5:45 PM (447) *The Role of Interleukin-7 in Acute Rejection Following Heart Transplantation*; J.E. Fildes,1 N.U. Khan,1 M. Al-Aloul,1 S.G. Williams,1 C.T. Leonard,1 N. Yonan,1 1The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

4:55 PM – 6:45 PM GENERAL POSTER SESSION 3/Wine and Cheese Reception (Continental Ballroom)

(454) *First Human Application of Right Ventricular Endocardial Thermography in Transplanted and Coronary Artery Disease Patients*; A. Manginas,1 E. Andreanidis,1 E. Leontiadis, P. Sifakis,1 D.V. Kokkinos,1 P.A. Alivizatos,1 1Heart, Lung & Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; 1Department of Medicine, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan

(455) *Mid-Term Results of Cardiac Transplantation in Adults with Congenital Heart Disease*; J.K. Bham,1 D.Q. Nguyen,1 C. Benjamin,1 R.L. Kormos,1 K.R. McCurry,1 S.A. Webber,2 C.A. Bermudez,1 1Heart, Lung & Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; 1Pediatric Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA

(456) *Hyperhomocysteinemia Accelerates Cardiac Allograft Vasculopathy*; S. Nunoda,1 O. Matsuoka,1 K. Okajima,1 K. Shitakura,1 S. Oinuma,1 Y. Kubo,1 K. Otsuka,1 1Department of Medicine, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan

(457) *Absence of Sinus Rhythm or Its Loss as Risk Factors for Cardiac Graft Failure after Heart Transplantation*; R. Baretti,1 B. Debus,1 D. Kemper,1 C. Knossalla,1 S. Buz,1 H. Lehmkuhl,1 R. Hetzer,1 1Deutsches Herzzentrum Berlin, Berlin, Germany

(458) *A Single-Centre Retrospective Study on Human Leukocyte Antigen-G Expression in Heart Transplant Recipients Prior To, During, and Following Episodes of Rejection*; R. Sheshgiri,1 D. Ramzy,1 J. Jackman,1 E.D. Carosella,2 N. Rouas-Freiss,2 J. Butany,3 H. Ross,4 V. Rao,1 D. Delgado,3 1Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; 2Research Institute for Hemato-Immunology, Saint-Louis Hospital, Paris, France; 3Department of Pathology, Toronto General Hospital, Toronto, ON, Canada; 4Divisions of Cardiology and Transplantation, Toronto General Hospital, Toronto, ON, Canada

(459) *Reduced Systolic Strain and Systolic Strain Rate Could Detect Sub-Clinical Acute Rejection in Heart Transplant Recipients*; C. Kamiya,1 T.S. Kato,1 N. Oda,1 A. Mano,1 K. Hashimura,1 S. Hashimoto,1 K. Komamura,1 M. Kitakaze,1 S. Kitamura,2 T. Nakatani,3 1Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan; 2Department of Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan; 3Department of Organ Transplantation, National Cardiovascular Center, Suita, Osaka, Japan
* (460) Ezetimibe Effectively Lowers LDL Cholesterol in Cardiac Allograft Recipients on Stable Statin Therapy; M.H. Konstandin,1 S. Celik,1 A. Dösch,1 A. Koch,2 Fé-U. Sack,2 H.A. Katus,1 T.J. Dengler,1 Cardiology, Universitätssklinik Heidelberg, Heidelberg, Germany; 2Cardiac Surgery, Universitätssklinik Heidelberg, Heidelberg, Germany

* (461) Recurrent Mild Rejection in the First Year after Heart Transplantation Does Not Affect Outcomes: Validation of the Revised ISHLT Grading System; J.K. Patel,1 J.C. Kawano,1 G.W. Wu,1 L. Chimakarn,1 M.A. Kawano,1 B.I. Kobashigawa,1 M.M. Kittleson,1 A.L. Gordon,1 S.M. Kagimoto,1 J.A. Kobashigawa,1 Medicine, University of California at Los Angeles, Los Angeles, CA

* (462) Evolution of Renal Function and Prognostic Implications of Impaired Renal Function One Year after Heart Transplantation; S. Arora,1 A.K. Andreassen,1 S. Simonsen,1 A. Rebro,1 O. Geiran,23 L. Gullestad,1 Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; 2Department of Cardiothoracic Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; 3Department of Medicine, University of California - San Francisco (UCSF), San Francisco, CA

* (463) Impact of Donor Left Ventricular Hypertrophy on Survival after Cardiac Transplantation; K. Sharma,1 M.P. Pelletier,1 R. Menza,2 J.G. Zaroff,3 S.C. Malaisrie,1 T.A. Timek,1 E.L. Houston,2 E.P. Oyer,1 B.A. Reitz,1 R.C. Robbins,1 Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; 2California Transplant Donor Network, Oakland, CA; 3Department of Medicine, University of California - San Francisco (UCSF), San Francisco, CA

* (464) Donor Age Influences Orthotopic Heart Transplant (OHTX) Outcome Independent of Traditional Risk Factors; D. Nguyen,1 J. Bhma,1 C. Bermudez,1 Y. Toyoda,1 Y. Thacker,1 J. Teuteberg,1 K. McCurry,1 R. Kormos,1 Heart Lung and Esophageal Institute, University of Pittsburgh, Pittsburgh, PA

* (465) Influence of CNI–Free Versus CNI–Based Immunosuppression on Rejection and Infection after Heart Transplantation; A.S. Leet,1 R. Martin,1 M. Richardson,1 P. Bergin,1 D. Esmore,1 D.M. Kaye,1 Heart Transplant Unit, The Alfred Hospital, Melbourne, Australia

* (466) First-Year Mycophenolate Mofetil Dose Reductions: Do They Portend Poor Outcome?; J.A. Kobashigawa,1 M.A. Kawano,1 G.W. Wu,1 J.C. Kawano,1 M. Yajnik,1 M.M. Kittleson,1 J.K. Patel,1 Medicine, University of California at Los Angeles, Los Angeles, CA

* (467) Sirolimus Dose Adjustment in Heart and Lung Transplant Recipients on Voriconazole Therapy; H. Windham,1 J.Y. Lee,1 S.R. Hays,2 L.E. Leard,2 J.A. Golden,2 T. De Marco,3 C. Hoopes,2 R.F. Boettger,1 Department of Clinical Pharmacy, University of California, San Francisco Medical Center, San Francisco, CA; 2Department of Medicine, University of California, San Francisco Medical Center, San Francisco, CA; 3Department of Cardiology, University of California, San Francisco Medical Center, San Francisco, CA; 4Department of Surgery, University of California, San Francisco Medical Center, San Francisco, CA

* (468) Discontinued Use of Mycophenolate Mofetil and Graft Loss in Heart Transplant Recipients; A.P. Legorreta,1 A.S. Gilmore,2 J. Marehbian,2 G. Machnicki,3 1UCLA School of Public Health, Los Angeles, CA; 2Health Benchmarks, Inc., Woodland Hills, CA; 3Novartis Pharma AG, Basel, Switzerland

* (469) Prospective, Randomized, Multicenter Trial Comparing Conversion to a CNI-Free Regimen (MMF & Sirolimus) vs. a CNI-Reduced, MMF-Based Immunosuppression to Improve Renal Function in Late Cardiac Transplant Recipients; J. Groetzner,1 U. Schulz,2 I. Kaczmarek,1 E. Stegemann,1 K. Kaiser,1 M. Voss,3 T. Wittwer,6 T.H. Wahlers,7 J. Schirmer,8 H.Y. Sohn,1 H. Welp,9 C. Schmid,2 B. Meiser,1 B. Reichart,1 Department of Clinical Pharmacy, University of California, San Francisco Medical Center, San Francisco, CA; 2Department of Medicine, University of California, San Francisco Medical Center, San Francisco, CA; 3Department of Cardiology, University of California, San Francisco Medical Center, San Francisco, CA; 4Department of Cardiothoracic Surgery, University of California, San Francisco Medical Center, San Francisco, CA

* (470) Daclizumab Induction Therapy in Clinical Lung Transplantation – A Prospective, Double-Blinded, Randomized Trial; M. Struiber,1 J. Gottlieb,2 A.R. Simon,1 B. Gohrbandt,1 S. Fischer,1 A. Goerler,1 A. Haverich,1 T. Welte,2 Hannover Thoracic Transplant Program, Division Thoracic and Cardiovasc. Surg, Hannover Medical School, Hannover, Germany; 3Respiratory Medicine, Hannover Medical School, Hannover, Germany

* (471) Transition to Sirolimus from Calcineurin Inhibitor for Renal Impairment Is Not Associated with an Increase in Brochiolitis Obliterans Syndrome or Acute Rejection; S.R. Hays,1 L.E. Leard,1 G. Horns,1 M. Sweet,1 C. Hoopes,2 J.A. Golden,1 Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, CA; 2Cardiothoracic Surgery, University of California, San Francisco, San Francisco, CA

* (472) Predictors of Mycophenolate Mofetil Adverse Effects in Thoracic Transplant Recipients; L.S.L. Ting,1 N. Partovi,1,4,5 M. Fritz,1 K.W. Riggles,1 R.D. Levy,2 C. Imai,1 A.P. Ignaszewski,1 M.H.H. Ensom,1 Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; 3Heart Transplant Program, St. Paul’s Hospital, Vancouver, BC, Canada; 4Lung and Heart Transplant Programs, British Columbia Transplant Society, Vancouver, BC, Canada

* (473) Superiority of Antithymocyte-Globulin Induction Therapy in Lung Transplant Recipients with Cystic Fibrosis; P. Jaksch,1 B. Zweytick,1 G. Lang,1 C. Aigner,1 G. Dekan,1 W. Wisser,1 W. Klepetko,1 Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria; 2Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria
(474) Assessing Safety and Efficacy of Neoral®/Everolimus Maintenance Therapy in Cardiac Transplant Recipients: 12 Month Data; H. Ross, J. Burton, P. Pflugfelder, M. Cantarovich, A. Ignaszewski, J. Howlett, M. White, H. Haddad, R. Dorent, C. Sips, M. Vaillancourt, 1Toronto General Hospital, Toronto, Canada; 2Walter Mackenzie Center, Edmonton, Canada; 3London HSC - University Campus Site, London, Canada; 4Mc Gill University Health Centre, Montreal, Canada; 5St. Paul’s Hospital, Vancouver, Canada; 6Queen Elizabeth II Health Sciences Centre - New Halifax Infirmary, Halifax, Canada; 7Institut de Cardiologie de Montreal, Montreal, Canada; 8University of Ottawa Heart Institute, Ottawa, Canada; 9Service de Medicine Interne, Centre Hospitalier Universitaire Pitie-Salpetriere, Paris, France; 10Novartis Pharma AG, Basel, Switzerland; 11Novartis Pharma, Dorval, Canada

(475) Sirolimus vs Azathioprine from the Time of Heart Transplantation: 65 Month Followup for Vascular (MACE) and Malignant Events; A. Keogh, M. Richardson, P. Ruygrok, P. Macdonald, L. Schneider, G. O’Driscoll, A. Galbraith, St. Vincent’s Hospital, Sydney, Australia; Alfred Hospital, Melbourne, Australia; Auckland City Hospital, Auckland, New Zealand; Royal Perth Hospital, Perth, Australia; Prince Charles Hospital, Brisbane, Australia

(476) Steroid-Free Maintenance Immunosuppression with Campath-1H Induction in Cardiac Transplantation; S. Aggarwal, S. Pagni, D. Pidwell, R.D. Dowling, Surgery, University of Louisville, Louisville, KY; Immunology, University of Louisville, Louisville, KY

(477) The Daily Steroid Dose Correlates More Strongly Than the Time Since Heart Transplant with a Gene Expression Profile Assessment of Immune Activation; D.F. Pauly, J.M. Aranda, R.S. Schofield, S.J. Normann, J.A. Hill, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL; Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL

(478) Pharmacokinetics of Tacrolimus and Everolimus When Used Concomittantly in De Novo Heart Transplantation Patients; C. van Kesteren, N. de Jonge, J.H. Kirkels, C. Klöpping, F.F.T. Ververs, Department of Clinical Pharmacy, University Medical Centre, Utrecht, Netherlands; Heart Lung Centre, University Medical Centre, Utrecht, Netherlands

(479) Induction Therapy with Thymoglobulin after Heart Transplantation: Impact of Therapy Duration on Lymphocyte Depletion and Recovery, Rejection and CMV Infection Rates; L.S.C. Czer, S. Goland, R.M. Kass, M. De Robertis, J. Mirocha, K. Zivari, J. Lee, B. Coleman, A. Trento, Cardiology, Cedars Sinai Medical Center, Los Angeles, CA

(480) High Rates of Acute Rejection with a CNI Sparing Regimen of Everolimus and Mycophenolate in Long Term Lung Transplant Recipients; P.M. Hopkins, F. Kermeen, J. Dunning, K. McNeil, Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

(481) Is IL-17 Attenuated by Everolimus (ERL)?: A Longitudinal Airway Biopsy (EBB) Study Post Lung Transplant (LTx); G.L. Snell, B.J. Levvey, L. Zheng, B. Orsida, M. Bailey, T. Kotsimbos, T. Williams, Lung Transplant Service, The Alfred Hospital, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia; Epidemiology & Preventative Medicine, Monash University, Melbourne, Victoria, Australia

(482) Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Development of Cardiac Allograft Vasculopathy and Cardiac Adverse Events in Heart Transplant Patients; E.R. Raichlin, J.H. Bag, J.P. McConnell, W.R. Kremers, R.P. Frantz, A. Lerman, Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN; Laboratory Medicine, Mayo Clinic College of Medicine, Rochester, MN; Biostatistics, Mayo Clinic College of Medicine, Rochester, MN

(483) Calcineurin-Inhibitor Associated Nephrotoxicity after Orthotopic Heart Transplantation Associated with Single Nucleotide Polymorphisms (SNP); H. Milting, A. Wirth, B. Klauke, G. Tenderich, B. Bohms, A. Zittermann, R. Koerfer, Erich und Hanna Klessmann-Institut fuer Kardiovaskulaere Forschung und Entwicklung, Herz- und Diabetesszentrum NRW, Bad Oeynhausen, NRW

(484) Quinolone-Related Achilles Tendinopathy in Heart Transplant Recipients: Incidence and Risk Factors; E. Barge-Caballero, M.G. Crespo-Leiro, M.J. Paniagua-Martín, J. Muñiz, A. Bouzas-Mosquera, R. Marzoa-Rivas, P. Piñon-Esteban, P. Pazos, A. Juffé-Stein, A. Castro-Beiras, Heart Transplantation Unit, Hospital Juan Canalejo, La Coruña, Spain

(485) Influence of Levosimendan, a Ca2+-Sensitiser, on Acute Graft Failure after Heart Transplantation: A Pilot Study; A. Beiras-Fernandez, I. Kaczmarek, F. Weis, B.M. Meiser, M. Weis, B. Reichart, Department of Cardiac Surgery, University Hospital Grosshadern, LM-University, Munich, Germany; Department of Anesthesiology, University Hospital Grosshadern, LM-University, Munich, Germany

(486) Does the Presence of Adiposity or the Metabolic Syndrome in Transplant Donor or Recipient Increase the Progression of Cardiac Allograft Vasculopathy?; A.M. Wilson, S.A. Virani, H.A. Valantine, M.X. Pham, W.F. Fearon, J.P. Cooke, Cardiovascular Medicine, Stanford University, Stanford, CA

(487) Outcomes of Percutaneous Coronary interventions and Surgical Revascularization in the Treatment of Cardiac Allograft Vasculopathy; D.Q. Nguyen, J.K. Bhama, K. Sun, Y. Toyoda, S. Zomak, C. Yost, K.M. McCurry, R.L. Kormos, C. Bermudez, Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA

(488) Increased Infection Risk of Non-Cardiac Surgeries after Heart Transplantation; O. Aye, J.K. Patel, A. Seid, L. Chinkam, M.M. Kittleson, J.A. Kobashigawa, Medicine, University of California at Los Angeles, Los Angeles, CA

(489) Evolution of Endothelial-Dependent Forearm Vasodilatation after Heart Transplantation and Its Relationship with Early Graft Vasculopathy; E. Roig, A. Cuppoletti, R. Kiamco, M. Sitges, M. Masotti, C. Pare, I. Vallejos, F. Perez Villa, Cardiology - Thorax Institute, Hospital Clinic, Barcelona, Spain
*(490)* Pharmacologic Myocardial Perfusion Stress Testing to Detect Significant Cardiac Allograft Vasculopathy – Is It Worthwhile?; *J.K. Patel,¹ M.A. Kawano,¹ M.M. Kittleson,¹ J.A. Kobashigawa,¹ Medicine, University of California at Los Angeles, Los Angeles, CA

*(491)* The Use of ECMO/Intra-Aortic Balloon Pump to Support Hemodynamics in Patients with Cardiogenic Shock Due to Severe Rejection; *S.J. Miller,¹ J.A. Kobashigawa,¹ M.M. Kittleson,¹ J.K. Patel,¹ M.A. Kawano,¹ A. Ardehali,² Medicine, University of California at Los Angeles, Los Angeles, CA; ²Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, CA

*(492)* Short and Long-Term Survival after Surgery for Lung Cancer in Heart Transplant Recipients; *G. Bruschi,¹ T. Colombo,² S. Conforti,² A. Rinaldo,² S. Fieschi,² G. Pedrazzini,¹ S. Campisi,¹ F. Turazza,¹ F. Oliva,¹ M. Frigerio,¹ M. Ravini,² E. Vitali,¹ Cardiology & Cardiac Surgery “A. De Gasperis”, Niguarda Ca’ Granda Hospital, Milan, Italy; ²Division of Thoracic Surgery, Niguarda Ca’ Granda Hospital, Milan, Italy

*(493)* Re-Transplantation for Heart Failure with Preserved Systolic Function; *B.K. Itatani,¹ J.K. Kobashigawa,¹ G.W. Wu,¹ W. Brubaker,¹ M.A. Kawano, L. Gokanapudy,¹ M.M. Kittleson,¹ J.K. Patel,¹ Medicine, University of California at Los Angeles, Los Angeles, CA

*(494)* What Is the Prognostic Value of a Normal Adenosine Myocardial Perfusion Imaging in Cardiac Transplant Patients?; *M. Arita,¹ E. Garcia-Sayan,¹ M. Al-Mallah,² C. Assal,¹ G. Tapia Zegarra,¹ B. Czerska,¹ K. Ananthsubramaniam,¹ Cardiology, Henry Ford Hospital, Detroit, MI; ²Cardiology, Brigham and Women’s Hospital, Boston, MA

*(495)* Cardiac Allograft Vasculopathy Is Associated with Endothelial Dysfunction but Not Endothelial Progenitor Cell Numbers; *P.P. Chang,¹ R.V. Kelly,¹ M. Caughey,¹ K.R. Smith,¹ S.S. Smyth,² M.G. Cohen,² G.A. Stouffer,² W.A. Tan,¹ D. Tate,¹ S.C. Smith, Jr.,¹ S.L. Kowalczyk,¹ C. Patterson,¹ A.L. Hindeliter,¹ Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC; ²Medicine, University of Kentucky, Lexington, KY; ³Medicine, East Carolina University, Greenville, NC

*(496)* Negative Impact of Nesiritide in Combination with Inotropic Therapy among Patients Admitted with Acute Heart Failure; *D. Putney, L. Matura, K. Daniels, V. Thohan, Pharmacy, Methodist Hospital, Houston, TX; Nursing Education, Methodist Hospital, Houston, TX; Cardiology, Wake Forest University, Winston Salem, NC; ²Cardiology, Wake Forest University, Winston Salem, NC

*(497)* 2D Strain Echocardiography a Novel Non-Invasive Tool for Pre-Transplant Evaluation of Patients with Dilated Cardiomyopathy; *M. Dandel,¹ N. Suramalshilvili,¹ H.B. Lehmkuhl,¹ C. Knosalla,¹ O. Grauhan,¹ R. Hetzer,¹ Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

*(498)* The Chronicle² Implantable Hemodynamic Monitor in Patients on the Heart Transplant Waiting List: One Year Results; *M. Schmoockel,¹ P. Lamm,¹ M. Wolf,¹ I. Kaczmarek,² P. Reiters,² M.R. Hill,² B. Reichart,¹ Department of Cardiac Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany; ²Bakken Research Centre, Medtronic Inc., Maastricht, Netherlands

*(499)* Is Screening Computed Tomography of the Chest, Abdomen, and Pelvis in Potential Heart Transplant Recipients Necessary?; *M. Montpetit,¹ S. Pauwaa,¹ G. Macaluso,¹ B. Pavlovic-Surjancev,¹ J. Sinacore,¹ A. Heroux,¹ Heart Transplant/Heart Failure, Loyola University Medical Center, Maywood, IL

*(500)* Serial Changes in BNP Are Not Associated with Changes in Submaximal or Maximal Exercise or Quality of Life; *A.H. Wu,¹ L.C. Matthews,¹ D.B. Dyke,¹ S.M. Zick,² K.D. Aaronson,¹ Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI; ²Department of Family Medicine, University of Michigan, Ann Arbor, MI

*(501)* Weight of Age in the Selection of Candidates for Heart Transplantation; *L. Potena,¹ F. Grigioni, I.G. Bianchi, M. Masetti, F. Fabbri, G. Magnani, F. Cocco, F. Fallani, A. Russo, C. Magelli, G. Arpesella, A. Branzi, Cardiovascular Diseases, University of Bologna, Bologna, Italy

*(502)* Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-Chain Amyloidosis; *A.V. Kristen,¹ J.B. Perez,² S.O. Schonland,² F.U. Sack,² H.A. Katus,¹ T.J. Dengler,¹ Department of Cardiology, Medical University of Heidelberg, Heidelberg, Germany; ²Department of Haematology, Medical University of Heidelberg, Heidelberg, Germany; ³Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

*(503)* Mechanical Dyssynchrony in Pediatric Cardiomyopathy; *M.K. Friedberg,¹ N.H. Silverman,¹ A.M. Dubin,¹ D.N. Rosenthal,¹ Division of Pediatric Cardiology, Stanford University, Palo Alto, CA

*(504)* Left Ventricular Systolic Asynchrony in Pediatric and Adolescent Patients with Congestive Heart Failure; *G. Srinath,¹ A. Ali,² G. Rosenthal,¹ R. Grimm,¹ R. Sterba,¹ E. Saarel,¹ A. Younoszai,¹ G. Boyle,¹ Pediatric Cardiology, The Cleveland Clinic Foundation, Cleveland, OH; ²Adult Cardiology, The Cleveland Clinic Foundation, Cleveland, OH; ³Pediatric Cardiology, Children’s Hospital, Denver, CO; ⁴Pediatric Cardiology, Primary Childrens Medical Center, Salt Lake City, UT

*(505)* Perceptions of Transitional Care Needs and Experiences in Paediatric Heart Transplantation: An Exploratory Study; *S.J. Anthony,¹ K.A. Martin,¹ A. Drabble,¹ M. Seifert-Hansen,¹ A.I. Dipchand,² M. Kaufman,¹ Paediatric Academic Multi-Organ Transplant Program, The Hospital for Sick Children, Toronto, ON, Canada; ²Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

*(506)* Primary Graft Dysfunction Does Not Increase the Risk of Acute Rejection in Pediatric Lung Transplant Recipients; *M.G. Schecter,¹ J.M. Robertson,¹ M.L. Doan,¹ E.D. McKenzie,² J.S. Heintel,² G.B. Mallory,¹ O. Eledimer,¹ Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; ²Congenital Heart Surgery, Baylor College of Medicine, Houston, TX
**(507)** Effect of Body Mass Index on Outcome in Pediatric Heart Transplant Patients; J.W. Rossano,1 M.A. Grenier,1 W.J. Dreyer,1 J.J. Kim,1 J.F. Price,1 J.L. Jefferies,2 S.K. Clunie,1 M. Moulik,1 J.A. Decker,1 J.P. Breinholt,1 D.L. Morales,2 E.D. McKenzie,2 J.A. Towbin,1 S.W. Denfield,1 1Cardiology, Baylor College of Medicine/Texas Children’s Hospital, Houston, TX; 2Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX

**(508)** Cardiac Structure and Function in Long-Term Pediatric Heart Transplant Survivors; A. Kulikowska,1 S.E. Boslaugh,1 S. Foerster,1 C.H. Gumbiner,1 K.E. Ward,1 C. Ong Simon,4 M. Kimberling,5 S.K. Gandhi,6 C.E. Huddleston,6 C.E. Canter,1 1Department of Pediatrics, St Louis Children’s Hospital, St. Louis, MO; 2Department of Pediatrics, Children’s Hospital of Omaha, Omaha, NE; 3Department of Pediatrics, The Children’s Hospital at University of Oklahoma, Oklahoma City, OK; 4Department of Pediatrics, Children’s Mercy Hospitals and Clinics, Kansas City, MO; 5Department of Pediatrics, The Children’s Hospital at Saint Francis, Tulsa, OK; 6Department of Surgery, St Louis children’s Hospital, St. Louis, MO

**(509)** The Predictive Value of Donor Specific Antibody Responses in Pediatric Heart Recipients: A Pilot Study; R.J. Boucek, Jr.,1 D. Yung,1 K. Nelson,1 P. Hopkins,1 L. Permut,1 G. Cohen,1 1Pediatrics, U of Wash/Seattle Children’s Hospital, Seattle, WA; 2Puget Sound Blood Center, Seattle, WA; 3Surgery, U of Wash, Seattle, WA

**(510)** Quality of Life and Psychological Functioning in Paediatric Patients at 1 Year Post Lung Transplant – A Single Centre Experience; T. Lunnon-Wood,1 B.K. Field,1 J. Wray,1 P. Aurora,1 1Dept of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

**(511)** Associations between Markers of Inflammatory Activation and Heart Failure in Children; C. Ratnasamy,1 D.D. Kinnamon,1 S.E. Lipshultz,1 P.G. Rusconi,1 1Pediatrics, Miller School of Medicine University of Miami, Miami, FL

**(512)** Dobutamine Stress Echocardiography for the Assessment of Coronary Artery Disease in Paediatric Heart Transplant Recipients; A.L. Dipchand,1 W. Bharat,1 C. Manihit,1 M. Safi,1 N. Lobach,1 B.W. McCrindle,1 1Cardiology, Hospital for Sick Children, Toronto, ON, Canada

**(513)** Heart Rate Recovery from Maximal Exercise in Children One-Year after Heart Transplantation – Effect of Autonomic Denervation; T.P. Singh,1 J. Rhodes,1 H.J. Bastardi,1 E.D. Blume,1 1Cardiology, Children’s Hospital, Boston, MA

**(514)** Donor (+)/Recipient (-) EBV Mismatch Leads to a High Incidence of Post-Transplant Lymphoproliferative Disorder in Pediatric Lung Transplant Recipients; O. Eldemir,1 M.G. Schecter,1 E.D. McKenzie,2 J.S. Heinle,2 G.B. Mallory,1 1Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; 2Congenital Heart Surgery, Baylor College of Medicine, Houston, TX

**(515)** Outcomes of Fetal, Neonate and Infant Candidates for Heart Transplantation; S.M. Pollock-BarZiv,1 B.W. McCrindle,1 L.J. West,2 M. VanderVliet,1 A.J. Dipchand,1 1Cardiology, Hospital for Sick Children, Toronto, ON, Canada; 2Heart Transplantation Research, University of Alberta, Edmonton, AB, Canada

**(516)** Use of Endomyocardial Biopsy for Rejection Surveillance in Pediatric Heart Transplant Patients; D.A. Dodd,1 J. Burger,1 1Pediatric Cardiology, Vanderbilt University Medical Center, Nashville, TN

**(517)** Transplantation in Children with Idiopathic Pulmonary Arterial Hypertension; A.E. Lammers,1 M. Burch,1 S.G. Haworth,2 M.J. Elliott,3 P. Aurora,1 1Paediatric Cardiothoracic Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom; 2UK Pulmonary Hypertension Service for Children, Great Ormond Street Hospital for Children, London, United Kingdom; 3Paediatric Cardiothoracic Surgery, Great Ormond Street Hospital for Children, London, United Kingdom

**(518)** Medium Term Renal Function of Pediatric Heart Transplant Patients on Reduced Calcineurin Inhibitor and Rapamycin; M.S. Zahra,1 S.W. Srun,1 C.W. Belsha,2 D.L. Marshall,2 P.J. Haupman,3 K.O. Schowengerdt,3 J.C. Balfour,3 1Division of Critical Care, Dept of Pediatrics, University of Miami School of Medicine, Miami, FL; 2Division of Cardiology, Dept of Pediatrics, St Louis University Health Sciences Center, St. Louis, MO; 3Division of Nephrology, Dept of Pediatrics, St Louis University Health Sciences Center, St. Louis, MO

**(519)** Campath-1H Therapy for Resistant Rejection in Pediatric Heart Transplant Patients; S.D. Miyamoto,1 D. Gilbert,1 A. Ballard,1 S. Anderson,1 P.N. Le,1 M.B. Mitchell,2 D.N. Campbell,1 B.A. Pietra,1 1Pediatric Cardiology, The Children’s Hospital, Denver, CO; 2Pediatric Cardiovascular Surgery, The Children’s Hospital, Denver, CO

**(520)** Value of the Natriuretic Peptide proANP as a Prognostic Marker in Pediatric Heart Transplantation; G. Heise,1 H. Lehmkuhl,1 B. Stiller,1 J. Lemmer,1 S. Schubert,1 M. Redlin,1 C. Knoasalla,1 R. Hetzer,1 F. Berger,1 1Deutsches Herzzentrum, Berlin, Germany


**(522)** Single Institution Experience of Paediatric Heart Transplant Following Anthracycline Cardiomyopathy Including Early Use of Mechanical Support; S. Janakiraman,1 D.S. Crossland,1 A. Hasan,1 J.R.L. Hamilton,1 G. Parry,1 C.R. Kirk,1 1Paediatric Cardiothoracic Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(523)** Erythropoietin Reverses Pulmonary Vascular Remodelling in Experimental Flow-Associated Pulmonary Hypertension; M.E. van Albada,1 R.M. Berger,1 R.G. Schoemaker,1 1Dept of Pediatric Cardiology, Beatrix Children’s Hospital, University Medical Center Groningen, University of
(524) Serial NT-proBrain Natriuretic Peptide (NT-proBNP) Levels in Patients with Pulmonary Arterial Hypertension (PAH): L.S. Mackay, R. Hughes, R. Peaston, G. MacGowan, G. Parry, A.J. Fisher, J. Lordan, P.A. Corris, Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

(525) Novel Therapies for Pediatric Patients with Elevated Pulmonary Vascular Resistance Undergoing Heart Transplantation: B. Daftari, G.S. Perens, N.J. Halhon, J.C. Alejos, Pediatrics, UCLA Medical Center, Los Angeles, CA

(526) Resting Heart Rate Predicts Mortality in Patients with Isolated Right Ventricular Failure and Pulmonary Hypertension: A.K. Andreasen, S. Arora, E. Gude, S. Simonsen, O.R. Geiran, L. Gullstad, Cardioiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; Thoracic Surgery, Rikshospitalet-Radiumhosiptalet Medical Center, Oslo, Norway

(527) Transplantability and Bridge to Heart Transplant Using Intra-Aortic Balloon Pumping in High-Urgency Candidates with Pulmonary Hypertension: H. Guelmez, G. Tenderich, U. Schulz, A. Zittermann, S. Schulte-Eistrup, U. Fuchs, W. Deyerling, R. Koerfer, Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany

(528) Three Different Approaches for Non-Invasive Estimation of Pulmonary Artery Mean Pressure in Patients with Pulmonary Arterial Hypertension: N. Selimovic, B. Rundqvist, C.-H. Bergh, B. Andersson, S. Petersson, O. Bech-Hanssen, Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Clinical Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

(529) WITHDRAWN

(530) Correlation of NT-proBrain Natriuretic Peptide (NT-proBNP) and Haemodynamics in Patients with Pulmonary Arterial Hypertension (PAH): L.S. Mackay, R. Hughes, R. Peaston, G. MacGowan, G. Parry, A.J. Fisher, J. Lordan, P.A. Corris, Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

(531) Imatinib-Mesylate in Combination with RAD Reduces Significantly Chronic Rejection (CR) after Orthotopic Lung Transplantation (LTX) in an Experimental Rat Model: S. Hirt, T. Puehler, E. Lesser, C. Hass, M. Ernst, B. Bewig, U. Wottge, J. Cremer, Cardiovascular Surgery, University Hospital SH Campus Kiel, Kiel, SH, Germany; Pneumology, University Hospital SH Campus Kiel, Kiel, SH, Germany; Immunology, University Hospital SH Campus Kiel, Kiel, SH, Germany

(532) The Immunosuppressant Everolimus Significantly Prevents Atherosclerosis in LDLR-/- Mice Despite Severe Hypercholesterolemia: M.A. Mueller, F. Beutner, D. Teupser, U. Ceglarek, F. Jeromin, W. Wilfert, J. Thiery, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany

(533) Immunosuppressive Properties of Cordyceps: J.L. Jordan, B. Ross, G.M. Hirsch, T.D.G. Lee, Pathology, Dalhousie University, Halifax, NS, Canada; Surgery, Dalhousie University, Halifax, NS, Canada; Surgery, Dalhousie University, Halifax, NS, Canada; Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada


(535) Is the Malononitrilamide FK778 Better for Prevention of Acute or Chronic Rejection?: T. Deuse, S. Schrepfer, F. Koch-Nolte, M.P. Pelletier, M.P. Fischbein, R.C. Robbins, H. Reichenspunner, Cardiovascular Surgery, University Heart Center gGmbH, Hamburg, Germany; Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; Immunology, University Hospital Hamburg, Hamburg, Germany

(536) Suppression of De Novo Synthesis of MHC Class-II by Pravastatin Prolongs Graft Survival in a Congenic Rat Model of Orthotopic Single Lung Transplantation: Y. Li, F. Laenger, A. Koertner, A. Meyer, C. Moerike, A. Haverich, A.R. Simon, Hannover Thoracic Transplant Program (Division of Thoracic- and Cardiovascular Surgery), Hannover Medical School, Hannover, Germany; Division of Pathology, Hannover Medical School, Hannover, Germany

6:15 PM – 7:15 PM
Scientific Council Meeting on Cell Transplantation/Tissue Engineering (Union Square 15/16)
Scientific Council Meeting on Nursing and Social Sciences (Union Square 23/24)
Scientific Council Meeting on Pulmonary Transplantation (Plaza A)
Scientific Council Meeting on Heart Failure and Transplant Medicine (Plaza B)

6:45 PM – 7:15 PM
Joint Scientific Council Meeting: Pathology/Basic Science and Pulmonary Transplantation (Plaza A)

6:45 PM – 8:00 PM
General Poster Session 3 Removal (Continental Ballroom)
Mini Oral Sessions 1-4 Poster Removal (Yosemite Ballroom)

7:00 PM – MIDNIGHT
Exhibit Hall Strike

SATURDAY, APRIL 28, 2007

24 Hours - Noon
Internet Café Open (Continental Ballroom Foyer)

7:00 AM – 10:00 AM
Exhibit Hall Strike (Continental Ballroom)

7:00 AM – NOON
Slide Ready Room Open (Green Room)

7:00 AM – NOON
Press Office Open (Executive Boardroom)

7:30 AM – 10:00 AM
Registration Desk Open (West Foyer)

8:00 AM – 9:30 AM
CONCURRENT SESSION 40: Frontiers in MCS Therapy (Grand Ballroom B)
*Chairs: *Steven S. L. Tsui, MD, FRCS and *Bartley P. Griffith, MD

8:00 AM (537) Clinical Outcome of the European Multicenter Trial with the DuraHeart® Mag-Lev Centrifugal Left Ventricular Assist System; A. El-Banayosy,1 R. Koerfer,1 R. Hetzer,2 G. Wieselthaler,2 A. Pavie,4 1Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany; 2Thoracic and Cardiovascular Surgery, German Heart Center Berlin, Berlin, Germany; 3Thoracic and Cardiovascular Surgery, University of Vienna, Vienna, Austria; 4Thoracic and Cardiovascular Surgery, Pitie Salpetriere Hospital, Paris, France

8:15 AM (538) Bridge to Heart Transplantation with Second and Third Generation Continuous-Flow Left Ventricular Assist Devices; M.J. Jurmann,1 Y. Weng,1 T. Drews,1 M. Pasic,1 E. Hennig,1 F. Kaufmann,1 E. Potapov,1 R. Hetzer,1 Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

8:30 AM (539) Low Thromboembolic Risk with the Heartmate II Left Ventricular Assist Device; R. John,1 F. Kamdar,1 C. Toninato,1 A. Boyle,2 M. Colvin-Adams,2 K. Liao,1 L. Miller,2 L. Joyce,3 Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; 2Division of Cardiology, University of Minnesota, Minneapolis, MN

8:45 AM (540) Early Experience with Off Pump Placement of Implantable Mechanical Circulatory Support Devices (MCSD); B. Sun,1 L. Louis,1 A. Panza,1 C. Sai-Sudhakar,1 Cardiothoracic Surgery, The Ohio State University Medical Center, Columbus, OH

9:00 AM Invited Lecture: The Role of INTERMACS in Patient Selection for Longer Term Mechanical Circulatory Support, Lynne Warner Stevenson, MD, Brigham and Women’s Hospital, Boston, MA

9:15 AM (541) Pneumatic Paracorporeal Ventricular Assist Device in Infants and Children: Initial Stanford Experience; S.C. Malaisrie,1 M.P. Pelletier,1 J.J. Yun,1 K. Sharma,1 T.A. Timek,1 D.N. Rosenthal,2 G.E. Wright,2 R.C. Robbins,1 B.A. Reitz,1 1Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA; 2Division of Pediatric Cardiology, Stanford University Medical Center, Stanford, CA

9:30 AM – 10:30 AM
CONCURRENT SESSION 41
Pre-Transplant Matters on Post-Transplant Outcomes (Grand Ballroom A)
*Chairs: *Roberto R. Favaloro, MD and *Angeline S. Leet, MBBS, FRACP

8:00 AM (542) Naturally Occurring Leukopenia as a Marker for Good Outcome after Cardiac Transplantation; M.M. Kittleson,1 H. Song,1 M. Yajnik,2 G.W. Wu,1 B.I. Kobashigawa,1 J.K. Patel,1 J.A. Kobashigawa,1 Medicine, University of California at Los Angeles, Los Angeles, CA

8:15 AM (543) Negative Impact of Pre Transplant Blood Transfusions on Post Heart Transplant Outcomes – Analysis of the UNOS Database; L.U. Nwakama,1 E.S. Weiss,1 W.A. Baumgartner,1 S.B. Russell,2 J.V. Conte,1 Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; 2Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD

8:30 AM (544) Management and Outcomes of Heparin-Induced Thrombocytopenia in Ventricular Assist Device and Cardiac Transplant Patients; L. Wang,1 J.R. Smith,1 M. Cornell,1 T.J. Guthrie,1 M.K. Pasque,1 M.S. Avidan,1 C.J. de Wet,1 L.L. Hill,3 N. Mozamm,1 Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; 2Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO; 3Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO

8:45 AM (545) Impact of Pretransplant Statin Treatment on Sensitization and Crossmatch Results of Cardiac Allograft Recipients; S. Reverdin,1 E. Varughese,1 R. Radovancevic,1 A. Hoover,2 T. Tu,2 K. Hosek,2 B. Victor,2 S. Stepkowski,2 B. Radovancevic,1 O. Frazier,1 R. Kerman,2 Surgery, Texas Heart Institute, Houston, TX; 2Surgery, University of Texas Medical School, Houston, TX
9:00 AM (546) No Harm, No Foul? The Prospective Treatment of Sensitized Heart Transplant Recipients with Plasmapheresis and IVIG – Three Year Follow-Up; M.W. Weston,1 M. Lopez-Cepeda,2 L. DiChiara,3 Cardiology, LifeLink HealthCare Institute, Tampa, FL; 2Immunology, LifeLink Immunology Laboratory, Tampa, FL; 3Cardiology, Tampa General Hospital, Tampa, FL

9:15 AM (547) The Effect of Body Mass Index on Postoperative Length of Stay and Survival in Heart Transplant Recipients; J.C. Mullen,1 A. Oreopoulos,1 S. Becker,1 M.J. Bentley,1 D.L. Modry,1 S. Wang,1 R. MacArthur,1 D.B. Ross,1 E.T. Gelfand,1 Surgery, University of Alberta, Edmonton, AB, Canada

8:00 AM – 9:30 AM
CONCURRENT SESSION 42
Regulation of Bronchiolitis Obliterans (Imperial Ballroom A)
*Chairs: *Erik A.M. Verschuuren, MD and Mark R. Nicolls, MD

8:00 AM (548) Regression of Established Post-Transplant Allograft Airway Obliteration by Targeting Interaction of Fibrosis and Immune System; M. Sato,1 M. Anraku,1 M. Cypel,1 S. Hirayama,1 T.K. Waddell,1 M. Liu,1 S. Keshavjee,1 Thoracic Surgery Research Laboratory, Toronto General Research Institute, University Health Network, Toronto, ON, Canada

8:15 AM (549) Lipopolysaccharide Induced IL-8 Release from Alveolar Macrophages in Lung Transplant Recipients with Chronic Rejection Is Not Suppressed by Glucocorticoids; L.G. Spencer,1 D. Singh,2 C.T. Leonard,1 Transplant Unit, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom; 2North West Lung Centre, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom

8:30 AM (550) Airway Changes after Vascularized Aeralotrophic Mouse Lung Transplantation Differ Markedly from Those after Heterotopic Tracheal Transplantation; M. Okazaki,1 A.S. Krupnick,1 C.G. Kornfeld,1 S.B. Richardson,1 J. Lai,1 J.H. Ritter,1 G.A. Patterson,1 A.E. Gelman,1 D. Kreisel,1 Department of Surgery, Washington University in St. Louis, St. Louis, MO

8:45 AM (551) An MHC Class II Disparity Raises the Threshold for Tolerance Induction in Pulmonary Allografts in Miniature Swine; T. Shoji,1 H. Sahara,1 A. Munippan,1 D.A. Guenther,1 S.L. Houser,1 A.C. Pujara,1 M.A. Bravard,1 J.C. Wain,1 D.H. Sachs,1 J.C. Madsen,1 J.S. Allan,1 Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

9:00 AM (552) Natural Killer Lymphocytes Migrate to the Lung during Bronchiolitis Obliterans Syndrome; J.E. Fildes,1 K. Tunstall,1 L. Griffiths-Davies,1 A.H. Walker,1 M. Al-Aloul,1 N. Yonan,1 P. Bishop,2 C.T. Leonard,1 The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom; 2Department of Pathology, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

9:15 AM (553) Inhaled Immunosuppression with Tacrolimus after Airway Transplantation; S. Schreepfer,1 T. Deuse,2 J. Hoffmann,1 M.P. Pelletier,1 M.P. Fischbein,1 H. Reichenspurner,2 R.C. Robbins,1 Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; 2Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

8:00 AM – 9:30 AM
CONCURRENT SESSION 43
Mechanic Insights into Ischemia/Reperfusion (Imperial Ballroom B)
*Chairs: Stephen C. Clark, MD and Thomas M. Egan, MD, MSC

8:00 AM (554) Donor Myocardial Hypoxia Inducible Factor (HIF)-1α Expression Predicts Cardiac Allograft Dysfunction: Results of a 7-Year Prospective Study; S. Achiraje,1,2 K. Krenn,1,2 R. Schafer,1 E. Wolner,1 A. Aliabadi,1 A. Zuckermann,1 M. Grimm,1 Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; 2Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

8:15 AM (555) Delayed Pulmonary Graft Function: The Role of CD26/Dipeptidylpeptidase IV; W. Zhai,1,2 I. Inci,1 S. Arni,1 I.D. Meester,3 S. Hillinger,1 M. Cardell,1 W. Jungraithmayr,1 B. Oberreiter,1 W. Weder,1 S. Korom,1 Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; 2Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; 3Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium

8:30 AM (556) The Lectin-Like Domain of Thrombomodulin Suppresses Leukocyte Infiltration in a Murine Lung Ischemia-Reperfusion Injury Model; N. Geudens,1 M. Van de Wouwer,1 B.M. Vanaudenaerde,1 C. Van De Wauwer,2 T. Lerut,2 E. Verbeeken,2 G.M. Verleden,2 E. Conway,2 D.E.M. Van Raemdonck,1,4 Experimental Thoracic Surgery, Katholieke Universiteit, Leuven, Belgium; 2Center for Transgene Technology and Gene Therapy, Katholieke Universiteit, Leuven, Belgium; 2Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; 4Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

8:45 AM (557) FP15, a Novel Peroxynitrite Decomposition Catalyst Reduces Reperfusion Injury in a Rat Heart Transplantation Model; G. Szabó,1 T. Radovits,1 A. Koch,1 C. Szabó,2 Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 2Cellscreen Applied Research Center, Semmelweis University, Budapest, Hungary

9:00 AM (558) Human Atrial Natriuretic Peptide Ameliorates Warm Ischemia-Reperfusion Injury of the Lung; A. Aoyama,1 F. Chen,1 T. Nakamura,1 T. Fujinaga,2 J. Zhang,2 T. Okamoto,1 N. Satoda,1 A. Takahashi,1 H. Hamakawa,1 N. Kondo,1 T. Shoji,1 H. Sakai,1 H. Wada,1 T. Bando,1 Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 2Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

9:15 AM (559) Endothelin-1 Exacerbates Hypoxic Injury through eNOS Derived Free Radical Production: Implication for Primary Allograft Dysfunction; D. Ramzy,1 L.C. Tumiati,1 N. Xu,1 E. Tepperman, D.H. Delgado,1 J. Jackman,1 M. Badiwala,1 R. Sheshgiri,1 W. Rao,1,2 Cardiac Surgery, University of Toronto, Toronto, ON, Canada
8:00 AM – 9:30 AM
CONCURRENT SESSION 44
Innovative Alternatives to Allotransplantation (Plaza Ballroom A)
Chairs: Andre R. Simon, MD and Marc P. Pelletier, MD, MSc

8:00 AM (560) Stem Cell Transplantation and Migration: The Lung Barrier; S. Schrepefer,1 T. Deuse,¹ H. Reichenspurner,2 M.P. Fischheim,¹ R.C. Robbins,¹ M.P. Pelletier,¹ Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; 2Cardiovascular Surgery, University Heart Center Hamburg gGmbH, Hamburg, Germany

8:15 AM (561) Short Time In Vitro Electrostimulation Induces Cardiomyocyte Predifferentiation of Adult Fibroblasts; J.A. Genoves,¹ C. Spadaccio,¹ J. Langer,¹ A.N. Patel,¹ Cardiac Regeneration Laboratory, Heart, Lung and Esophageal Surgery Institute, UPMC & McGowan Institute for Regenerative Medicine, Pittsburgh University, Pittsburgh, PA

8:30 AM (562) Functional Vascular Network Development in Infarcted Rat Hearts by Selective Recruitment of Vessel Forming Macrophages; P. Paulus,¹ M. Gmeiner,¹ N. Sela,¹ R. Schaefer,¹ E. Wolner,² M. Grimm,² G. Weigel,² Bastian,² C. Plass,³ E. Rieder,² U. Losert,¹ ¹Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria; ²Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; ³Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria

8:45 AM (563) In Vivo Remodeling of Decellularized Xenogeneic Arteries: Impact of Heparin-Crosslinking on Graft Stability; H. Bergmeister,¹ F. Bastian,² C. Plass,³ E. Rieder,² U. Losert,¹ G. Weigel,² ¹Division Biomedical Research, Medical University of Vienna, Vienna, Austria; ²Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; ³Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria

9:00 AM (564) Appraisal of Inherent Myocardial Ability to Recoverate from Ischemia/Infarction; T. Pätilä,¹ T.S. Ikonen,² E. Kankuri,¹ J. Lommi,⁴ K. Virtanen,⁴ L. Krogerus,⁵ K. Lauerma,¹ A. Harjuha,¹ ¹Department of Cardiothoracic Surgery, Helsinki University Meilahti Hospital, Helsinki, Finland; ²Department of Vascular Surgery, Helsinki University Meilahti Hospital, Helsinki, Finland; ³Department of Clinical Pharmacology, Helsinki University, Helsinki, Finland; ⁴Department of Cardiology, Helsinki University Meilahti Hospital, Helsinki, Finland; ⁵Department of Radiology, Helsinki University Meilahti Hospital, Helsinki, Finland

9:15 AM (565) Are GT-KO Pigs Essential for Successful Cardiac Xenotransplantation?; C.G.A. McGregor,¹ H.D. Tazelaar,¹ V.P. Rao,¹ D. Ricci,¹ N. Miyagi,¹ M.H. Gazi,¹ S.L. Edgerton,¹ G.W. Byrne,¹ Mayo Clinic-Rochester William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

8:00 AM – 9:30 AM
CONCURRENT SESSION 45
The Impact of Antibodies on Pediatric Heart Transplant (Plaza Ballroom B)
*Chairs: W. Jeff Dreyer, MD and *Jacqueline R. Szmuszkovicz, MD

8:00 AM (566) Over Twenty Years of Pediatric Heart Transplantation; N.W. Hasaniya,¹ A.J. Razzouk,¹ L.L. Baily,¹ Cardiothoracic Surgery, Loma Linda University Children Hospital, Loma Linda, CA

*8:15 AM (567) ABO-Incompatible Paediatric Heart Transplantation: The First 10 Years; A.I. Dipchand,¹ L.J. West,² S.M. Pollock BarZiv,¹ C. Manhlhiot,¹ M. VanderVliet,¹ B.W. McCrindle,¹ ¹Cardiology, Hospital for Sick Children, Toronto, ON, Canada; ²Paediatrics, Stollery Children’s Hospital, Edmonton, AB, Canada

8:30 AM (568) Cardiac Transplant Outcomes in Pediatric Patients with Preformed Anti-HLA Antibodies and/or Positive Retrospective Crossmatch; E.J. Wright,¹ W.P. Fiser,¹ R.E. Edens,¹ M. Imamura,¹ R.D. Jaquiss,¹ Surgery, University of Arkansas for Medical Sciences, Little Rock, AR; ²Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR

8:45 AM (569) Outcomes in Pediatric Cardiac Transplantation with a Positive HLA Cross-Match; M.E. Richmond,¹ D.T. Hsu,¹ S.R. Mital,¹ R.S. Mosca,² J.M. Chen,² J.M. Quaegebeur,² E.M. Burke,² L.J. Addonizio,¹ J.M. Lamour,¹ ¹Division of Pediatric Cardiology, Morgan Stanley Children’s Hospital of New-York-Columbia University, New York, NY; ²Division of Cardiothoracic Surgery, Columbia University, New York, NY

9:00 AM (570) Heart Transplantation in Pediatric HLA-Sensitized Patients; S.M. Pollock-BarZiv,¹ N. den Hollander,² B.Y. Ngan,³ B.W. McCrindle,¹ P. Kantor,¹ A.I. Dipchand,¹ ¹Cardiology, Hospital for Sick Children, Toronto, ON, Canada; ²University Health Network; HLA Laboratory, Toronto, ON, Canada; ³Pathology, Hospital for Sick Children, Toronto, ON, Canada

9:15 AM (571) Elevated PRA Is a Risk Factor for Late Mortality among Pediatric Heart Transplant Recipients; T.A. Nasirov,¹ A.J. Razzouk,¹ L.L. Bailey,¹ N.W. Hasaniya,¹ R.E. Chinnock, Division of Cardiothoracic Surgery, Department of Surgery, Loma Linda University Medical Center, Loma Linda, CA; Department of Pediatrics, Loma Linda University Medical Center, Loma Linda, CA

9:30 AM – 9:45 AM
Coffee Break (West Foyer)

9:45 AM – NOON
CLOSING PLENARY SESSION (Grand Ballroom B)
*Chairs: *Lori West, MD, D.Phil. and *Paul Corris, MB, FRCP

9:45 AM Awards Presentations
10:00 AM Strategic Planning: The Future of the Society, Robert C. Robbins, MD, Stanford University Medical Center, Stanford, CA
10:15 AM Every Second Counts: The Race to Perform the First Human Heart Transplant, Donald McRae, London, UK
10:50 AM Using RNA Interference to Eliminate Unwanted Gene Expression, Mark A. Kay, MD, PhD, Stanford University, Palo Alto, CA
11:25 AM Science in Society, Lawrence M. Krauss, PhD, Case Western Reserve University, Cleveland, OH

12:30 PM – 4:30 PM
ISHLT Board of Directors Meeting (Union Square 19/20)
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abiomed</td>
<td>107</td>
</tr>
<tr>
<td>Actelion</td>
<td>510</td>
</tr>
<tr>
<td>Alsius Corporation</td>
<td>706</td>
</tr>
<tr>
<td>Astellas Pharma Europe LTD</td>
<td>202</td>
</tr>
<tr>
<td>Baptist Health</td>
<td>105</td>
</tr>
<tr>
<td>Berlin Heart</td>
<td>101</td>
</tr>
<tr>
<td>CardiacAssist, Inc.</td>
<td>703</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>606</td>
</tr>
<tr>
<td>Cylex, Inc.</td>
<td>108</td>
</tr>
<tr>
<td>Elsevier</td>
<td>103</td>
</tr>
<tr>
<td>Encysive Pharmaceuticals</td>
<td>210</td>
</tr>
<tr>
<td>F. Hoffmann-LaRoche Ltd</td>
<td>502</td>
</tr>
<tr>
<td>ISHLT Registry</td>
<td>705</td>
</tr>
<tr>
<td>Levitronix, LLC</td>
<td>205</td>
</tr>
<tr>
<td>Lippincott/Williams &amp; Wilkins</td>
<td>704</td>
</tr>
<tr>
<td>Micromed Cardiovascular, Inc.</td>
<td>702</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>302</td>
</tr>
<tr>
<td>Organ Recovery Systems</td>
<td>604</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>602</td>
</tr>
<tr>
<td>Syncardia Systems, Inc.</td>
<td>608</td>
</tr>
<tr>
<td>Terumo Heart, Inc.</td>
<td>710</td>
</tr>
<tr>
<td>Thoratec Corporation</td>
<td>201</td>
</tr>
<tr>
<td>TransMedics</td>
<td>310</td>
</tr>
<tr>
<td>USCOM, Inc.</td>
<td>708</td>
</tr>
<tr>
<td>Ventracor Inc</td>
<td>207</td>
</tr>
<tr>
<td>ViraCor Laboratories</td>
<td>701</td>
</tr>
<tr>
<td>Vital Engineering</td>
<td>709</td>
</tr>
<tr>
<td>Vitrolife</td>
<td>102</td>
</tr>
<tr>
<td>World Heart Corporation</td>
<td>104</td>
</tr>
<tr>
<td>XDx</td>
<td>410</td>
</tr>
</tbody>
</table>
EXHIBITORS AND PRODUCT DESCRIPTIONS

**Abiomed**
22 Cherry Hill Drive  
Danvers, MA 01923  
Website: [www.abiomed.com](http://www.abiomed.com)  
Booth Number: 107 & 109

ABIOMED develops, manufactures and markets cardiac assist and recovery devices. Products include: the BVS®5000, the AB5000™, Impella® Circulatory Support Systems and the AbioCor®, the world’s first fully implantable artificial heart.

**Actelion**
5000 Shoreline Court  
Suite 200  
South San Francisco, CA 94080  
Website: [www.actelion.com](http://www.actelion.com)  
Booth Number: 510

Actelion Pharmaceuticals is a research leader in Pulmonary Arterial Hypertension. Tracleer® (bosentan) is the first oral endothelin receptor antagonist and Ventavis® (iloprost) is the first non-invasive prostacyclin for the treatment of pulmonary arterial hypertension (WHO Class III or IV).

**ALSIUS Corporation**
15770 Laguna Canyon Road  
Suite 150  
Irvine, CA 92618  
Website: [www.alsius.com](http://www.alsius.com)  
Booth Number: 706

ALSIUS is the worldwide leader in providing catheter-based intravascular patient temperature management. The THERMOGARD™ system and catheters deliver precise core patient warming/cooling in an easy-to-use and cost-effective system to achieve and maintain normothermia.

**Astellas Pharma US, Inc.**
3 Parkway North  
Deerfield, Illinois 60015  
Website: [www.us.astellas.com](http://www.us.astellas.com)  
Email: Booth Number: 202

Astellas Pharma, Inc. manufactures and markets proprietary pharmaceutical products in specialty therapeutic areas where there is an unmet medical need. Astellas Pharma’s global mission to explore the frontiers of human health underscores the company’s commitment to the field of immunology, where aggressive research and development initiatives have helped to put Astellas at the forefront of transplantation.

**Baptist Health**
904 Autumn Road  
Suite 300  
Little Rock, AR 72211  
Website: [www.baptist-health.org](http://www.baptist-health.org)  
Booth Number: 105

Heart Clinic Arkansas, in Little Rock, is seeking to recruit a Board Certified Cardiologist with heart transplant or heart failure training to join the largest, most comprehensive group of cardiologists in the state of Arkansas. In addition, Heart Clinic Arkansas currently has opportunities for invasive cardiologist and interventionalists with carotid stenting and peripheral training.

Heart Clinic Arkansas is a partnership of 27 doctors. There were two doctors in this group that were experts in heart failure and they started a transplant program over 15 years ago. The practice is located next to the campus of Baptist Medical Center, a 787-bed facility.
Berlin Heart
Wiesenweg 10
Berlin 12247 Germany
Website: www.berlinheart.com
Booth Number: 101

As the only company worldwide we cover all areas of ventricular assist device application and CHF patients of every size and age with the partly implantable INCOR®.

Excor® is a paracorporeal pulsatile blood pump for uni- or biventricular support in newborns, children, adolescents and adults. Longest time on device: 5 years.

INCOR® is an implantable axial flow blood pump for left ventricular support in adults. INCOR® is the only 3rd generation axial flow pump with CE-mark approval. Longest time on device: 3.5 years

INCOR® and EXCOR® are not FDA approved.

CardiacAssist, Inc.
240 Alpha Dr.
Pittsburgh, PA 15238
Website: www.tandemheart.com
Booth Number: 703

The TandemHeart System provides up to five liters per minute (lpm) of blood flow through a cardiac catheterization procedure in as little as 30 minutes. The System is used in 17 of the top 20 heart and heart surgery hospitals in the U.S. and 11 of the top 14 hospitals overall. It is FDA approved for extracorporeal circulatory support for up to six hours for procedures not requiring full cardiopulmonary bypass. To date, more than 800 uses of the device in 28 countries at 90 different facilities by 120 different physicians have been performed.

CSL Behring
1020 First Ave
King of Prussia, PA 19406
Website: www.cslbehring.com
Booth Number: 606

CSL Behring is a leader in the plasma biotherapeutics industry. Dedicated to improving the quality of life for patients worldwide, CSL Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. CSL Behring is a subsidiary of CSL Limited.

Cylex, Inc.
8980-I Old Annapolis Road
Columbia, MD 21045
Website: www.cylex.net
Booth Number: 108

Cylex develops and manufactures the only FDA-cleared assay measuring the vitality of patients’ immune systems from a single drop of blood. ImmuKnow® enables physicians to better manage and individualize treatments for life-threatening diseases, such as HIV, HCV, cancer and autoimmune disorders, as well as solid organ and bone marrow transplantation.

Elsevier, Inc.
1600 JFK Blvd
Suite 1800
Philadelphia, PA 19103
Website: www.elsevierhealth.com
Booth Number: 103

Elsevier is proud to publish the Journal of Heart and Lung Transplantation, the official journal of the International Society for Heart and Lung Transplantation. Be sure to stop by our booth to view the latest issue of the journal and browse our other books, journals and software in the field of Heart & Lung Transplantation.
Encysive Pharmaceuticals
4848 Loop Central Dr.
Suite 700
Houston, TX  77027
Website:  www.encysive.com
Booth Number:  210

Encysive Pharmaceuticals, a biopharmaceutical company focused on the discovery, development and commercialization of novel
drugs, is recognized for our expertise in small molecule drug development and vascular biology.  A selective endothelin receptor
antagonist is currently in development to treat pulmonary arterial hypertension.

F. Hoffmann-LaRoche Ltd
Grenzacher Str 177
Bldg 074/302
CH-4070 Basel  Switzerland
Website:  www.roche.us
www.rocheusa.com
Booth Number:   502

Roche is a leading, global innovator of pharmaceuticals and diagnostics dedicated to enhancing people’s health and quality of life.
Our people are engaged in the discovery, development, manufacturing and marketing of prescription medicine in a wide variety of
therapeutic areas, including cancer, HIV/AIDS, hepatitis C, transplantation, influenza and osteoporosis.  We invite you to visit out
booth #502 to learn more about CellCept and Valcyte

ISHLT Registry
700 North 4th St
Richmond, VA  23219
Website:  www.help@ishlt.org
Booth Number:  705

The International Registry for Heart and Lung Transplantation provides ongoing, current information on the worldwide thoracic organ
transplantation experience.  The data, utilized for scientific study, contributes to the body of knowledge regarding both heart and lung
transplantation efforts throughout the world.  Our goal is to identify overall best practices for improving cardiothoracic patient care.

This year the exhibit will make your center-specific information available for your review.  In addition, members can view data
screens from the ISHLT Registry and receive guidance on enrollment, training on submission of data and instructions for submitting
data requests.

Levitronix, LLC
45 First Ave
Waltham, MA  02451
Website:  www.levitronix.com
Booth Number:   205

The Levitronix CentriMag Ventricular Assist System (VAS) is designed to provide temporary mechanical circulatory support to one
or both sides of the heart with a maximal flow capability of 9.9 l/min.  In the United States, the Levitronix CentriMag VAS is
undergoing clinical trials to assess its safety and effectiveness for the treatment of cardiogenic shock following acute myocardial
infarction or postcardiomyotomy cardiogenic shock, and also as an investigational RVAS for temporary right ventricular support in
patients who have had a commercial LVAS implanted.  The CentriMag Blood Pumping System is FDA 510 (k) cleared for use for up
to six hours to provide cardiopulmonary support during cardiopulmonary surgical procedures.  The CentriMag VAS is approved and
commercially available throughout Europe and countries that recognize the CE Mark as a VAD or for ECMO.

Lippincott/Williams & Wilkins
187 Ridgecrest Dr.
Napa, CA  94558
Website:  www.lww.com
Booth Number:   704
Lippincott/Williams & Wilkins publishes the very latest titles covering all specialties in medical and nursing books, journals and multimedia products.

**MicroMed Cardiovascular, Inc.**  
8965 Interchange Dr.  
Houston, TX 77054  
Website: [www.micromedtech.com](http://www.micromedtech.com)  
Booth Number: 702

The DeBakey VAD® is a miniaturized ventricular assist device (VAD) which was jointly developed by the famed heart surgeon Dr. Michael E. DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). The DeBakey VAD® is an implantable axial flow device designed to provide long term, improved quality of life for patients who suffer from severe heart failure. It is the only device that provides accurate, real-time flow measurement improving the clinicians’ patient care. It’s CE-mark approved in Europe, undergoing an IDE BTT clinical study in the U.S. and is the only FDA approved pediatric ventricular assist device.

**Novartis Pharma AG**  
Lichtstrasse 35  
CH-4056 Basel Switzerland  
Website: [www.novartis.com](http://www.novartis.com)  
Booth Number: 302

Novartis is a world leader in transplantation and immunology. With the discovery and introduction of cyclosporine more than 20 years ago, Novartis revolutionized the field of transplantation and now has the broadest portfolio of immunosuppressants on the market, including Noetal, Simulect, Myfortic and Certican, and a very innovative pipeline with new mechanisms of action. This allows for effective personalized care in a field where individualized therapy is most needed.

**Organ Recovery Systems**  
2570 E. Devon Ave  
Des Plaines, IL 60018  
Website: [www.organ-recovery.com](http://www.organ-recovery.com)  
Booth Number: 604

Organ Recovery Systems develops technologies to improve the quality and quantity of organs for transplantation. The company markets LifePort® Kidney Transporter, now in routine use worldwide and recognized for excellence in design by Popular Science (Best of What's News 2003), the Industrial Designers Society of America (Silver Award IDEA2004), the Medical Design Excellence Awards (Gold Winner 2004), the Museum of Modern Art (SAFE2005, Permanent Collection), BusinessWeek (Ten Devices Changing Medicine 2006), the Smithsonian Cooper-Hewitt National Design Museum (Design Life Now 2006, and the Art Institute of Chicago (Young Chicago 2007). LifePorts for heart and lung are in preclinical development.

**Scanlan International, Inc.**  
One Scanlan Plaza  
Saint Paul, MN 55107  
Website: [www.scanlangroup.com](http://www.scanlangroup.com)  
Booth Number: 602

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 designs in stainless steel and titanium instrumentation featuring Needle Holders, forceps, and clamps, including Scanlan SUPER CUT™ and ULTRA SHARP® scissors, Heifetz™ temporary occlusion clips, and DIAMOND DUST™ instrumentation. Offering a wide variety of custom modifications to accommodate surgeons’ specific needs. Single-use products include Surg-I-Loop® PLUS, single-use Aorta/Vein Punch, A/C LOCATOR® and RADIOMARK® graft markers, Vascu-Stat® single-use bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers. Exclusive worldwide distributor for Surgical Acuity HiRes™ class II Magnifying Loupes.

**SynCardia Systems, Inc.**  
3940 East Silverlake  
Tucson, AZ 85713  
Website: [www.syncardia.com](http://www.syncardia.com)
The CardioWest™ temporary Total Artificial Heart (TAH-T) is the only FDA, Health Canada and CE approved device that provides circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, providing a life-saving bridge until a donor human heart becomes available. Recently, the EXCOR® TAH-t mobile driver was granted a CE mark, enabling European hospitals to discharge stable patients on the TAH-t to return home while they are awaiting a transplant. At ISHLT, we will be recruiting investigators for our upcoming clinical trial of the Companion driver designed for use in the operating room, hospital room and at home.

Terumo Heart, Inc.
6180 Jackson Road
Ann Arbor, MI  48103
Website:  www.terumoheart.com
Booth Number:  710

Terumo Heart, Inc is dedicated to the innovation, introduction and advancement of products to improve the quality of healthcare of heart failure patients. Our principal focus is the development of the DuraHeart™ Left Ventricular Assist System (LVAS). The system is designed to provide long-term circulatory support and address the shortage of donor hearts for cardiac transplantation. Combining patented magnetic-levitation and centrifugal pump technologies, the DuraHeart LVAS is expected to decrease complications and improve the lives of patients with severe heart failure. The DuraHeart LVAS is not currently for sale in the Untied States pending clinical investigation.

Thoratec Corporation
6035 Stoneride Dr.
Pleasanton, CA  94588
Website:  www.thoratec.com
Booth Number:  201

Thoratec® Corporation innovates and delivers technologies that enable a full range of therapies to save, support and restore failing hearts, allowing patients to reclaim their lives.
Brand Names:
Thoratec® PVAD™
Thoratec® IVAD™ (Implantable Ventricular Assist Device)
Thoratec® CentriMag®
Thoratec®HeartMate® XVE

TransMedics
200 Minuteman, Suite 302
Andover, MA  01810
Website:  www.transmedics.com
Booth Number:  310

The TransMedics Organ Care System is a novel medical device that maintains organs in their functioning state outside the body to minimize ischemic injury and to allow ex-vivo visual, functional and metabolic assessment. The Organ Care System perfuses organs with warm, oxygenated nutrient-rich blood from time of removal until implantation. The system is designed with the goals of providing patients with the healthiest possible organs: increasing the number of organs available and improving post transplant outcomes. TransMedics completed PROTECT I: Heart and is expanding clinical activity to the US as well as to the lungs and other solid organs.

USCOM, Inc.
1060 Grant St, Suite 1-D
Benicia, CA  94510
Website:  www.uscom.com
Booth Number:  708

USCOM is a CW Doppler-based hemodynamic monitor that provides real-time information from either the right or left heart. The USCOM technique is entirely noninvasive, with no patient risk and no proprietary disposables. USCOM has been validated against bench flow models, flow-probes, echo, PAC and artificial hearts in animals, pediatrics and adults.
The USCOM system provides information regarding preload, contractility and afterload and has numerous applications in the PICU, ED, MICU, burn and trauma units. Reliable hemodynamic information will be obtained where other monitoring methods fail. On-site training is provided.

**Ventricor Inc**
101 Lincoln Centre
Suite 420
Foster City, CA  94404
Website:  [www.ventracor.com](http://www.ventracor.com)
Booth Number:  207

Ventricor is a global medical device company which has developed a blood pump, the VentrAssist left ventricular assist device (LVAD) for patients in heart failure. Ventricor plans to bring the VentrAssist to the global market.

**ViraCor Laboratories**
1210 NE Windsor Dr.
Lee's Summit, MO  64086
Website:  [www.viracor.com](http://www.viracor.com)
Booth Number:  701

ViraCor Laboratories specializes in bringing innovative Molecular Diagnostic services for immunocompromised patients. ViraCor provides quantitative Real-Time PCR results within 24 hours for CMV, EBV, Adenovirus, HHV-6, and other relevant viral and fungal pathogens.

**Vital Engineering**
330 Scaife Hall
200 Lothrop St
Pittsburgh, PA  15213
Website:  [www.vitalengineering.com](http://www.vitalengineering.com)
Booth Number:  709

Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnership benefits to patients, clinicians, hospital, and industry.

**Vitrolife**
113 Buttercup Road
Lake Ozark, MO  65049
Website:  [www.vitrolife.com](http://www.vitrolife.com)
Booth Number:  102

Vitrolife, develops and markets solutions and equipment to preserve organs and tissue prior to transplantation. Two of the products are Perfadex, an organ flush solution, and Steen Solution which along with machine perfusion methodology permits a more refined functional ex-vivo evaluation of the organ prior to transplantation.

**World Heart Corporation**
4750 Wiley Post Way
Suite 120
Salt Lake City, UT  84116
Website:  [www.worldheart.com](http://www.worldheart.com)
Booth Number:  104

World Heart Corporation is a developer of mechanical circulatory support systems. Its Novacor® LVAS is approved for bridge-for transplantation in the US and has an unrestricted indication for use in the EU. It Levacor™ rotary VAD is the only bearingless, fully magnetically levitated implantable centrifugal heart pump in clinical trials. A next-generation pulsatile pump (Novacor II) is being developed, as is a miniature rotary VAD based on proprietary MagLev™ technology for use in neonates.

**XDx**
Founded in 2000, XDx is a molecular diagnostics company with a focus on gene expression testing in immune-mediated conditions such as organ transplant rejection and inflammatory diseases. Its first offering, AlloMap® molecular expression testing, is a breakthrough in heart transplant patient management. Available for patients as early as two months post transplant, AlloMap testing uses a blood sample to determine if a heart transplant patient’s immune system is quiet or if the patient is at an increased risk of acute cellular rejection. AlloMap testing is a service provided by XDx through its CLIA-certified laboratory in Brisbane, California.
FUTURE ISHLT MEETINGS

28th ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS, APRIL 9 – 12, 2008
Boston, MA
Boston Marriott and Hynes Convention Center

29th ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS, APRIL 22 – 25, 2009
Paris, France
Meridien Etoile, Concorde LaFayette, and Palais des Congress

30th ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS, APRIL 21 – 24, 2010
Chicago, IL
Hilton Chicago